{"title":"All Supplements, Cosmetics and Medical Devices Subject to Collecting Points","description":"\u003cp\u003eThe discounts activated by the \" \u003cstrong\u003eActivate Discount!\u003c\/strong\u003e \" button at the bottom center of the screen \u003cstrong\u003eapply to ALL Supplements, Cosmetics and Medical Devices available in this list.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e \u003cstrong\u003eNever use association or partner discounts\u003c\/strong\u003e if you intend to collect points. Points and VIP offer spend totals acquired through orders with association or partner codes will be reset to zero within 48 business hours of the order.\u003c\/p\u003e","products":[{"product_id":"pelvilen-dual-act-20-bustine","title":"Pelvilen Dual Act 20 Sachets","description":"\u003cp style=\"margin: 0px; font-size: 15px; line-height: 25px; color: #666666; font-family: Roboto, sans-serif;\"\u003e \u003cspan style=\"font-weight: bold;\"\u003ePelvilen Dual Act\u003c\/span\u003e is a \u003cspan style=\"font-weight: bold;\"\u003efood supplement\u003c\/span\u003e with antioxidant properties that can be taken\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003ein case of pain and inflammation in the pelvic area\u003c\/strong\u003e supported by induced mast cell tissue hyperreactivity. The action of this supplement\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003esupports and strengthens the walls of the uterus and pelvic muscles\u003c\/strong\u003e , proving very useful in cases of endometriosis, interstitial and recurrent cystitis, chronic prostatitis, irritable bowel syndrome. Pelvilen Dual Act intervenes effectively against inflammation and pain thanks to the action of the active ingredient included, Palmitoylethanolamide. \u003c\/p\u003e\n\u003cp style=\"margin: 0px; font-size: 15px; line-height: 25px; color: #666666; font-family: Roboto, sans-serif;\"\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp style=\"margin: 0px; font-size: 15px; line-height: 25px; color: #666666; font-family: Roboto, sans-serif;\"\u003e \u003cstrong\u003eHOW TO USE\u003c\/strong\u003e\u003cbr data-mce-fragment=\"1\"\u003e The recommended dose of Pelvilen Dual Act is one sachet per day, to be applied under the tongue for rapid absorption. \u003c\/p\u003e\n\u003cp style=\"margin: 0px; font-size: 15px; line-height: 25px; color: #666666; font-family: Roboto, sans-serif;\"\u003e\u003c\/p\u003e\n\u003cp style=\"margin: 0px; font-size: 15px; line-height: 25px; color: #666666; font-family: Roboto, sans-serif;\"\u003e \u003cstrong\u003eCOMPOSITION\u003c\/strong\u003e\u003cbr data-mce-fragment=\"1\"\u003e Ultramicronized palmitoylethanolamide 200 mg., Palmitoylethanolamide 160 mg. in co-micronized form with trans-Polydatin 40 mg., mixture of excipients 415 mg. (Sorbitol, Palmitic esters of sucrose, Vegetable polysorbate, Colorant E127). \u003c\/p\u003e\n\u003cp style=\"margin: 0px; font-size: 15px; line-height: 25px; color: #666666; font-family: Roboto, sans-serif;\"\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp style=\"margin: 0px; font-size: 15px; line-height: 25px; color: #666666; font-family: Roboto, sans-serif;\"\u003e \u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003cbr\u003e Always consult your doctor before taking this supplement. Keep out of reach of children. Do not exceed the recommended dose. The use of Pelvilen Dual Act during pregnancy or breastfeeding is not recommended. Keep the product in a dry and cool place, away from humidity and heat sources.\u003c\/p\u003e","brand":"EPITECH GROUP SpA","offers":[{"title":"Default Title","offer_id":40093366943859,"sku":"925646794","price":31.83,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/epitech-group-spa-pelvilen-dual-act-20-bustine-farmacia-dottor-tili-1213792942.jpg?v=1767132270"},{"product_id":"vitagyn-c-crema-vaginale-30g","title":"Vitagyn C Vaginal Cream 30g","description":"\u003cp\u003eVITAGYN C vaginal cream is indicated as an adjuvant treatment and in the prevention of bacterial vaginosis and recurrent urinary infections. Its use is especially useful in relapsing subjects and after antibiotic drug therapies. VITAGYN C vaginal cream restores and maintains the physiological vaginal pH and promotes the growth of the natural lactobacillary flora. In this way it prevents the establishment of favorable conditions for the development of bacterial vaginosis, even during pregnancy.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cp style=\"font-weight: 400;\"\u003e\u003cstrong\u003eDOSING SCHEMES\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp style=\"font-weight: 400;\"\u003eThe non-profit association Cistite.info in collaboration with numerous professionals in the sector has put together some schemes that help to take this product in the correct dosages and timing. Download them now from the links below!\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 12pt;\" data-mce-style=\"margin-bottom: 12pt;\"\u003e\u003cspan style=\"color: #2b00ff;\"\u003e- \u003ca href=\"https:\/\/www.dottortili.it\/img\/cms\/Schema_Protocollo_Dada.pdf\" style=\"color: #2b00ff;\" data-mce-href=\"https:\/\/www.dottortili.it\/img\/cms\/Schema_Protocollo_Dada.pdf\"\u003eS\u003c\/a\u003e \u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Schema_Protocollo_Dada.pdf?v=1666792371\" title=\"Cure to prevent cystitis in menopause\" style=\"color: #2b00ff;\" target=\"_blank\" data-mce-href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Schema_Protocollo_Dada.pdf?v=1666792371\"\u003eloads the Dada Cystitis in Menopause diagram\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"FARMA-DERMA SRL","offers":[{"title":"Default Title","offer_id":40093367009395,"sku":"904556711","price":17.58,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/farma-derma-srl-vitagyn-c-crema-vaginale-30g-farmacia-dottor-tili-1213792953.jpg?v=1767132251"},{"product_id":"femelle-fermenti-lattici-30-capsule","title":"Femelle Lactic Ferments 30 Capsules","description":"\u003cp\u003eFemelle is a food supplement based on \u003cstrong\u003elactic ferments with probiotic action\u003c\/strong\u003e useful for \u003cstrong\u003ere-establishing the balance of the intestinal bacterial flora\u003c\/strong\u003e compromised by incorrect diet, antibiotic therapy and intestinal disorders such as diarrhea or constipation. \u003cspan data-mce-fragment=\"1\"\u003eThe lactic ferments contained in \u003cstrong\u003eFemelle\u003c\/strong\u003e\u003c\/span\u003e \u003cstrong\u003ealso act on the intimate bacterial flora\u003c\/strong\u003e , protecting and supporting the urogenital system in cases of \u003cstrong\u003ecystitis, candida, various bacterial and fungal infections.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e Its rebalancing function is due to the presence of probiotic lactic ferments capable of producing \u003cstrong\u003ebacteriocins,\u003c\/strong\u003e small peptides that prevent the growth of pathogenic bacteria thus preventing \u003cstrong\u003eintestinal infections\u003c\/strong\u003e and \u003cstrong\u003eurogenital infections\u003c\/strong\u003e .\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cdiv align=\"justify\"\u003e\n\n \u003cstrong\u003eMEDIA ANALYSIS\u003c\/strong\u003e\u003cbr\u003e Lactobacillus jensenii 121.1 less than 1 x 109\u003cbr\u003e Lactobacillus plantarum LP 115 less than 1 x 109\u003cbr\u003e Lactobacillus rhamnosus LR 32 less than 1 x 109\u003cbr\u003e Lactobacillus acidophilus LA 14 equal to 1 x 109 (1 billion) \u003c\/div\u003e\n\u003cdiv align=\"justify\"\u003e\u003c\/div\u003e\n\u003cdiv align=\"justify\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv align=\"justify\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv align=\"justify\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv align=\"justify\"\u003e\n\n \u003cstrong\u003eINGREDIENTS\u003c\/strong\u003e\u003cbr\u003e Corn maltodextrin, corn starch, gelatin (capsule ingredient), mixture of lactic ferments (Lactobacillus plantarum LP 115, Lactobacillus acidophilus LA 14, Lactobacillus jensenii KS 121.1, Lactobacillus rhamnosus LR 32); anti-caking agents: magnesium salts of fatty acids, silicon dioxide. The raw materials are produced and the packaging is made in factories that also process milk and soy derivatives. \u003c\/div\u003e\n\u003cdiv align=\"justify\"\u003e\u003c\/div\u003e\n\u003cdiv align=\"justify\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv align=\"justify\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv align=\"justify\"\u003e \u003cstrong\u003eHOW TO USE\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv align=\"justify\"\u003e We recommend 2 capsules per day, after meals, with a glass of water. \u003c\/div\u003e\n\u003cdiv align=\"justify\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv align=\"justify\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv align=\"justify\"\u003e\n\n\u003cbr\u003e \u003cstrong\u003eWARNINGS\u003c\/strong\u003e\n\n\u003c\/div\u003e\n\u003cdiv align=\"justify\"\u003e Do not exceed the recommended dose. Keep out of reach of children under 3 years of age. Supplements are not intended as a substitute for a varied and balanced diet and a healthy lifestyle. Store in a cool, dry place away from light and heat, keep at a temperature below 25°C. Validity for unopened package: 20 months.\u003c\/div\u003e","brand":"BROMATECH Srl","offers":[{"title":"Default Title","offer_id":40093367271539,"sku":"912033673","price":20.46,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/bromatech-srl-femelle-fermenti-lattici-30-capsule-farmacia-dottor-tili-1213792929.jpg?v=1767122589"},{"product_id":"enterelle-plus-24-capsule","title":"Enterelle Plus 24 Capsules","description":"\u003cp\u003e \u003cstrong\u003eEnterelle Plus\u003c\/strong\u003e is a food supplement based on probiotics, designed to promote the balance of intestinal flora and support the well-being of the digestive system. The formulation of Enterelle Plus is enriched with selected bacterial strains that help restore the intestinal microflora compromised by antibiotics, poor diet or intestinal disorders such as diarrhea and constipation. Thanks to its balanced and delicate action, Enterelle Plus is suitable for daily use and to improve intestinal functionality.\u003c\/p\u003e\n\n\u003ch2\u003e Dosage and method of use\u003c\/h2\u003e\n\n\u003ch3\u003e How to take Enterelle Plus?\u003c\/h3\u003e\n\n\u003cp\u003e The recommended dose is \u003cstrong\u003e1 or 2 capsules\u003c\/strong\u003e per day, preferably taken away from meals. The capsules should be swallowed whole with plenty of water. For prolonged action, it is possible to continue the treatment for 15-30 days, according to the instructions of the doctor or pharmacist.\u003c\/p\u003e\n\n\u003ch2\u003e Ingredients\u003c\/h2\u003e\n\n         \u003ch3\u003eWhat ingredients does Enterelle Plus contain?\u003c\/h3\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eSaccharomyces boulardii\u003c\/strong\u003e : probiotic yeast that promotes the rebalancing of intestinal flora.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eLactobacillus rhamnosus\u003c\/strong\u003e : probiotic bacterium that helps protect the gut from pathogens and support the immune system.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eEnterococcus faecium\u003c\/strong\u003e : aids digestion and supports intestinal health.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eExcipients\u003c\/strong\u003e : gelatin (capsule), silica, magnesium stearate.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003ch2\u003e Warnings\u003c\/h2\u003e\n\n\u003ch3\u003e What are the warnings of Enterelle Plus?\u003c\/h3\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e Do not exceed the recommended daily dose.\u003c\/li\u003e\n\n\u003cli\u003e Keep out of reach of children under 3 years.\u003c\/li\u003e\n\n\u003cli\u003e Food supplements should not be considered as a substitute for a varied and balanced diet and a healthy lifestyle.\u003c\/li\u003e\n\n\u003cli\u003e Consult a doctor before use if you are pregnant or breastfeeding or are taking any medications.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n         \u003ch2\u003eExpiry and storage\u003c\/h2\u003e\n\n\u003ch3\u003e What are the expiration dates and storage of Enterelle Plus?\u003c\/h3\u003e\n\n\u003cp\u003e Store \u003cstrong\u003eEnterelle Plus\u003c\/strong\u003e in a cool, dry place, away from heat and direct light. Check the expiry date on the package before use.\u003c\/p\u003e\n\n\n\u003ch2\u003e Format\u003c\/h2\u003e\n\n\u003cp\u003e Enterelle Plus is available in a pack of \u003cstrong\u003e24 capsules\u003c\/strong\u003e , practical and convenient for prolonged treatment.\u003c\/p\u003e\n\n","brand":"BROMATECH Srl","offers":[{"title":"Default Title","offer_id":40093367369843,"sku":"974373159","price":19.53,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/bromatech-srl-enterelle-plus-24-capsule-farmacia-dottor-tili-1213792941.jpg?v=1767122670"},{"product_id":"dafneben-8-capsule-vaginali","title":"Dafneben 8 Vaginal Capsules","description":"\u003cp\u003eDafneben is a food supplement specifically created to restore the \u003cstrong\u003enormal physiological condition of the vaginal microenvironment\u003c\/strong\u003e . Dafneben promotes the \u003cstrong\u003erestoration of the normal physiological endovaginal condition\u003c\/strong\u003e .\u003c\/p\u003e\n\u003cp align=\"justify\"\u003e The internal application of the Guar Gomma gelling agent forms a \u003cstrong\u003ehydrogel\u003c\/strong\u003e on the vaginal mucosa a few minutes after the capsules dissolve.\u003cbr\u003e This hydrogel adheres to the vaginal wall and, producing a \u003cstrong\u003ephysical barrier against potentially pathogenic microorganisms\u003c\/strong\u003e , \u003cstrong\u003elubricates and humidifies the vagina\u003c\/strong\u003e .\u003c\/p\u003e\n\u003cp align=\"justify\"\u003e The \u003cstrong\u003eprobiotic Lactobacilli microorganisms\u003c\/strong\u003e ( \u003ci\u003eLactobacillus Crispatus, Lactobacillus Jensenii, Lactobacillus Rhamnosus, Lactobacillus Reuteri\u003c\/i\u003e ) which are disseminated in the vagina rebalance the internal microflora (Doderlein complex), enhancing the barrier effect of the hydrogel and promoting the restoration of the physiological pH (4, 0-4.5), which is in itself a protective factor.\u003c\/p\u003e\n\u003cp align=\"justify\"\u003e The prebiotic \u003cstrong\u003einulin\u003c\/strong\u003e is a substance that \u003cstrong\u003eis not absorbed by the body\u003c\/strong\u003e , but represents a \u003cstrong\u003eselective nourishment for the microorganisms of the vaginal flora\u003c\/strong\u003e present in Dafneben. It therefore favors their ability to colonize the vaginal ecosystem, reducing the time needed to restore the normal microflora.\u003cbr\u003e\u003c\/p\u003e\n\u003cp align=\"justify\"\u003e Lactobacilli are regular non-pathogenic guests of the vagina, therefore Dafneben \u003cstrong\u003ecan also be used during pregnancy and during breastfeeding.\u003c\/strong\u003e\u003cbr\u003e The guar gum gelling agent is considered safe as it is widely used as a food additive (E 412).\u003cbr\u003e Dafneben is not absorbed, leaves no residue and is eliminated with the physiological exudates normally produced by the vaginal mucosa.\u003cbr\u003e\u003cbr\u003e \u003cb\u003eIngredients\u003c\/b\u003e\u003cbr\u003e Each hard vegetable gelatin capsule contains: Guar gum, methyl-sulfonyl-methane (MSM), Lactobacillus Crispatus, Lactobacillus Jensenii, Lactobacillus Rhamnosus, Lactobacillus Reuteri, Inulin, Vegetable magnesium stearate.\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp align=\"justify\"\u003e \u003cstrong\u003eAverage analysis 1 capsule\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp align=\"justify\"\u003e Lactobacillus crispatus 1011 CFU\/g 52.5 mg\u003cbr\u003e Lactobacillus jensenii 1011 CFU\/g 52.5 mg\u003cbr\u003e Lactobacillus rhamnosus 1011 CFU\/g 52.5 mg\u003cbr\u003e Lactobacillus reuteri 1011 CFU\/g 52.5 mg\u003cbr\u003e Inulin 30.0 mg\u003c\/p\u003e\n\u003cp align=\"justify\"\u003e\u003cbr\u003e \u003cb\u003eHow to use\u003c\/b\u003e\u003cbr\u003e Before use, wash your hands thoroughly, remove the capsule from the housing and insert it delicately and as deeply as possible into the vaginal canal to facilitate rapid dissolution, preferably in a lying position, at bedtime. The recommended dose is 1 capsule per day for 8 days, unless otherwise prescribed by a doctor.\u003c\/p\u003e\n\u003cp align=\"justify\"\u003e \u003cb\u003e\u003cbr\u003eWarnings\u003c\/b\u003e\u003cbr\u003e Keep the product out of the sight and reach of children. Do not take the product orally. Do not exceed the recommended dose. Do not use the product after the expiration date printed on the package, or if the package is damaged or torn.\u003cbr\u003e During pregnancy or breastfeeding, use the product only after consulting your doctor.\u003cbr\u003e If irritation or adverse reactions of any kind occur, consult your doctor or pharmacist. Do not use together with other medical devices or drugs for vaginal use without first consulting your doctor. Prolonged use of topical products applied to body surfaces can give rise to allergic sensitization phenomena. If these phenomena occur it is advisable to suspend treatment and consult your doctor.\u003cbr\u003e\u003cbr\u003e \u003cb\u003e\u003cbr\u003eContraindications\u003c\/b\u003e\u003cbr\u003e Hypersensitivity confirmed towards one or more components of the product.\u003cbr\u003e\u003cbr\u003e \u003cb\u003e\u003cbr\u003estorage\u003c\/b\u003e\u003cbr\u003e Store in a dry place away from direct light, at a temperature not exceeding 25°C. The expiry date indicated refers to the product in intact packaging and correctly stored.\u003cbr\u003e\u003c\/p\u003e","brand":"S\u0026R FARMACEUTICI SpA","offers":[{"title":"Default Title","offer_id":40093367763059,"sku":"927287060","price":18.91,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/s-r-farmaceutici-spa-dafneben-8-capsule-vaginali-farmacia-dottor-tili-1213792920.jpg?v=1767122929"},{"product_id":"santes-14-ovuli-vaginali","title":"Santes 14 Vaginal Ovules","description":"\u003cp\u003e\u003cstrong\u003eSantes 14 Vaginal Ovules\u003c\/strong\u003e is a medical device indicated as an adjuvant in the treatment of \u003cstrong\u003evulvovaginitis and cervicovaginitis of any origin and nature\u003c\/strong\u003e. It is particularly useful too \u003cstrong\u003eafter local physical treatments\u003c\/strong\u003e (such as DTC, laser therapy and cryotherapy), in association with healing therapies.\u003c\/p\u003e\n\u003cp\u003eThanks to the presence of \u003cstrong\u003ehyaluronic acid\u003c\/strong\u003e, creates optimal conditions for \u003cstrong\u003ecell migration and proliferation\u003c\/strong\u003e, favoring the processes of \u003cstrong\u003erepair and regeneration of the vaginal mucosa\u003c\/strong\u003e. Its hygroscopic properties help maintain a \u003cstrong\u003ehumid environment\u003c\/strong\u003e, supporting the physiological process of tissue regeneration.\u003c\/p\u003e\n\u003cp\u003eThe formulation is enriched with \u003cstrong\u003evitamins A and E\u003c\/strong\u003e, which perform an action \u003cstrong\u003eantioxidant and protective\u003c\/strong\u003e on the mucous membranes, supporting intimate well-being and the physiological functionality of the vaginal epithelium.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003eInstructions for use\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eHow to use Santes 14 Vaginal Ovules?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAs an adjuvant for vaginal diseases: insert \u003cstrong\u003e1 egg in the evening for 7 consecutive days\u003c\/strong\u003e;\u003c\/li\u003e\n\u003cli\u003eAs an adjuvant after physical treatments: insert \u003cstrong\u003e1 egg in the evening for 14 consecutive days\u003c\/strong\u003e, starting from the first day of treatment;\u003c\/li\u003e\n\u003cli\u003eAs a soothing and lubricating treatment: insert \u003cstrong\u003e1 egg in the evening for 14 consecutive days\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIt is advisable to insert the egg deeply, preferably in the evening before going to bed.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003eIngredients\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eWhat ingredients does Santes 14 Vaginal Ovules contain?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eHyaluronic acid sodium salt (5 mg per ovule)\u003c\/li\u003e\n\u003cli\u003eTocopheryl acetate (Vitamin E)\u003c\/li\u003e\n\u003cli\u003eRetinyl palmitate (Vitamin A)\u003c\/li\u003e\n\u003cli\u003eSemi-synthetic glycerides to taste\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003eWarnings\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eWhat are the warnings of Santes 14 Vaginal Ovules?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDo not use in case of hypersensitivity to one of the components;\u003c\/li\u003e\n\u003cli\u003eFor vaginal use only;\u003c\/li\u003e\n\u003cli\u003eKeep out of reach of children;\u003c\/li\u003e\n\u003cli\u003eIf symptoms persist, consult your doctor.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003eExpiration and conservation\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eWhat are the expiration and storage times of Santes 14 Vaginal Ovules?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore in a cool, dry place, away from heat sources and direct light. Do not use beyond the expiry date indicated on the package.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003eFormat\u003c\/h3\u003e\n\u003cp\u003ePack of \u003cstrong\u003e14 vaginal ovules\u003c\/strong\u003e.\u003c\/p\u003e","brand":"LO.LI.PHARMA Srl","offers":[{"title":"Default Title","offer_id":40093368221811,"sku":"900125269","price":21.85,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/lo-li-pharma-srl-santes-14-ovuli-vaginali-farmacia-dottor-tili-1236660881.webp?v=1778086929"},{"product_id":"monurelle-plus-af-15-capsule","title":"Monurelle Plus AF 15 Capsules","description":"\u003cp\u003e\u003cstrong\u003eMonurelle Plus AF\u003c\/strong\u003e is a food supplement based on \u003cstrong\u003ecranberry extract\u003c\/strong\u003e and \u003cstrong\u003eD-mannose\u003c\/strong\u003e , formulated to promote urinary tract health and prevent recurrent urinary infections. Cranberry extract is rich in proanthocyanidins, which help prevent bacteria from adhering to the walls of the bladder, while D-mannose is a natural sugar that is eliminated through urine, helping to eliminate the bacteria responsible for infections.\u003c\/p\u003e\n\n\n\u003ch2\u003e Dosage and method of use\u003c\/h2\u003e\n\n\u003ch3\u003e How to take Monurelle Plus AF?\u003c\/h3\u003e\n\n\u003cp\u003e It is recommended to take \u003cstrong\u003e1 capsule per day\u003c\/strong\u003e with a glass of water, preferably between meals or before bedtime. For effective prevention, a treatment cycle of at least 15 days is recommended, unless otherwise indicated by your doctor. The capsules are easy to swallow and can be taken at any time of the day.\u003c\/p\u003e\n\n\n\u003ch2\u003e Ingredients\u003c\/h2\u003e \n\u003ch3\u003eWhat ingredients does Monurelle Plus AF contain?\u003c\/h3\u003e\n\n\u003cp\u003e Monurelle Plus AF contains:\n\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eCranberry Extract\u003c\/strong\u003e : 120 mg, rich in proanthocyanidins (PAC), which help protect the urinary tract from bacteria.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eD-mannose\u003c\/strong\u003e : 500 mg, a natural sugar that helps fight urinary tract infections.\u003c\/li\u003e\n\n\u003cli\u003e Excipients: gelatin (for the capsule), magnesium stearate, silica.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Warnings\u003c\/h2\u003e\n\n\u003ch3\u003e What are the warnings for Monurelle Plus AF?\u003c\/h3\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e Do not exceed the recommended daily dose.\u003c\/li\u003e\n\n\u003cli\u003e Keep out of reach of children under 3 years.\u003c\/li\u003e\n\n\u003cli\u003e Supplements should not replace a varied and balanced diet and a healthy lifestyle.\u003c\/li\u003e\n\n\u003cli\u003e Consult a doctor if pregnant or breastfeeding before use.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Expiry and storage\u003c\/h2\u003e\n\n\u003ch3\u003e What are the expiration dates and storage of Monurelle Plus AF?\u003c\/h3\u003e\n\n         \u003cp\u003eStore \u003cstrong\u003eMonurelle Plus AF\u003c\/strong\u003e in a cool, dry place, below 25°C, away from heat and humidity. Check the expiry date on the package and do not use the product beyond that date.\u003c\/p\u003e\n\n\n\u003ch2\u003e Format\u003c\/h2\u003e\n\n\u003cp\u003e Monurelle Plus AF is available in a pack of \u003cstrong\u003e15 capsules\u003c\/strong\u003e , ideal for a complete treatment cycle.\u003c\/p\u003e\n\n","brand":"ZAMBON ITALIA Srl","offers":[{"title":"Default Title","offer_id":40093368254579,"sku":"984733562","price":20.45,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/zambon-italia-srl-monurelle-plus-af-15-capsule-farmacia-dottor-tili-1213792912.jpg?v=1767123089"},{"product_id":"nutriflor-60-cps","title":"Nutriflor 60 caps","description":"\u003cp\u003e Food supplement based on probiotics with plant extracts, useful for promoting the balance of intestinal bacterial flora, thanks also to the contribution of probiotic fibers contained in Helianthus tuberosus. Bamboo extract favors the elimination of intestinal gas\u003c\/p\u003e\n\u003cbr\u003e --\u003cbr\u003e \u003cp\u003eRecommended: - in case of reduced or compromised intestinal flora and as probiotic support during or after antibiotic therapy; - defecation of the immune system. It can be useful in vaginitis and urinary infections, Candida, skin infections and inflammations (Herpes, acne), post-flu recovery and respiratory problems. The supplementation of quality bifidobacteria can also be important in osteoporosis and in case of excess cholesterol.\u003c\/p\u003e","brand":"NUTRIGEA","offers":[{"title":"Default Title","offer_id":40207821832307,"sku":"924784933","price":24.18,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/nutrigea-nutriflor-60-cps-farmacia-dottor-tili-1213792795.jpg?v=1767111990"},{"product_id":"etinerv-smp-30-compresse","title":"Etinerv SMP 30 tablets","description":"\u003cp\u003e Etinerv SMP tablets is a food supplement of α-lipoic acid, acetyl L-Carnitine, Zinc, Nervonic acid, Vaccinium myrtillus, Vitamins B3, B6, B12 and Selenium useful for assisting the good functionality of the central, peripheral and ocular nervous tissue, facilitating their protective and reparative processes. Adjuvant of the good functionality of the nervous tissue, in the presence of chronic neuropathic pain, it helps to improve neurological functionality. Useful in case of chronic cystitis, \u003cstrong\u003evulvodynia\u003c\/strong\u003e , \u003cstrong\u003epelvic neuropathy\u003c\/strong\u003e .\u003cbr\u003e \u003cbr\u003e\u003cstrong\u003eAlpha-lipodic acid\u003c\/strong\u003e prevents damage from oxidative stress at the level of the central and peripheral nervous system. It helps to increase the synthesis of neurotransmitters.\u003cbr\u003e\u003cbr\u003e \u003cstrong\u003eAcetyl L-Carnitine\u003c\/strong\u003e helps stimulate neuronal growth and repair factors (NGF) protecting the nervous system from oxidative damage.\u003cbr\u003e\u003cbr\u003e \u003cstrong\u003eZinc\u003c\/strong\u003e is an essential mineral that aids in the absorption and action of the B vitamins.\u003cbr\u003e\u003cbr\u003e \u003cstrong\u003eNervonic acid\u003c\/strong\u003e is able to regenerate the myelin sheath and improve brain function. Excellent aid in the treatment of neuromuscular pathologies (also muscular dystrophy) and skin pathologies of autoimmune origin.\u003cbr\u003e\u003cbr\u003e \u003cstrong\u003eBlueberry\u003c\/strong\u003e (Vaccinium myrtillus) protects the peripheral venous microcirculation.\u003cbr\u003e\u003cbr\u003e \u003cstrong\u003eVitamins B3 - B6 - B12\u003c\/strong\u003e are essential for the prevention and repair of tissue damage.\u003cbr\u003e \u003cbr\u003e\u003cstrong\u003eSelenium\u003c\/strong\u003e fights the formation of free radicals and is essential to prevent the phenomena of senescence.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eINGREDIENTS\u003c\/strong\u003e\u003cbr\u003e α-lipodic acid; Acetyl L-carnitine; Zinc; Nervonic acid; Vaccinium myrtillus; vitamins B3, B6 and B12; Selenium.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eMEDIA ANALYSIS\u003c\/strong\u003e\u003cbr\u003e α-lipodic acid 300 mg\u003cbr\u003e Acetyl L-Carnitine 250 mg\u003cbr\u003e zinc gluconate 7.5 mg\u003cbr\u003e nervonic acid 50 mg\u003cbr\u003e blueberry tit 2.5% in anthocyanosides 50 mg\u003cbr\u003e vitamins B3 9 mg\u003cbr\u003e vitamins B6 1 mg\u003cbr\u003e vitamins B12 1 mcg\u003cbr\u003e selenium 25 mcg\u003cbr\u003e Excipients: E171 (colour), hydroxypropyl methylcellulose, food talc and shellac (glazing agents), silicon dioxide and magnesium stearate (anti-caking agents)\u003c\/p\u003e\n\n\u003cp\u003e\u003cbr\u003e\u003cstrong\u003eHOW TO USE\u003c\/strong\u003e\u003cbr\u003e 1-2 tablets a day are recommended to be swallowed without chewing. It can be taken regardless of meals.\u003cbr\u003e \u003c\/p\u003e\n\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eKeep out of reach of children. Do not take during pregnancy. Food supplements are not intended as a substitute for a varied diet, do not exceed the recommended daily dose. Do not consume after the deadline for conservation. The expiry date refers to the product unopened and correctly stored. Store in a cool (maximum 25°C) and dry place.\u003c\/p\u003e","brand":"SPM PHARMA SAS","offers":[{"title":"Default Title","offer_id":40207821930611,"sku":"935343994","price":26.13,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/spm-pharma-sas-etinerv-smp-30-compresse-farmacia-dottor-tili-1213792791.jpg?v=1767112067"},{"product_id":"normast-600mg-30-bustine-orosolubili","title":"Normast 600mg 30 Orodispersible Sachets","description":"\u003cp\u003e Normast® 600 mg 30 orodispersible sachets is a food for special medical purposes, based on Palmitoylethanolamide (PEA) in ultra-micronized form (particle size between 0.8 and 6.0 microns). Normast 600mg acts in the body by\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003ebiological modulator\u003c\/strong\u003e , capable of\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003epromote at different levels\u003c\/strong\u003e (sensory endings, end-neural compartment, spinal synaptic junction between the 1st and 2nd neuron)\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003ethe control of the physiological reactivity of nervous tissue\u003c\/strong\u003e , thereby controlling the\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003einflammatory pain and\/or neuropathic pain.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cbr\u003e Taking Normast 600 mg 30 sachets replenishes the\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eendogenous reserves of Palmitoyl ethanolamide\u003c\/strong\u003e , known to decrease in conditions of peripheral nerve damage, supported by mast cell-induced tissue hyperreactivity.\u003c\/p\u003e\n\n\u003cp\u003e \u003cbr\u003eThe\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003enervous tissue\u003c\/strong\u003e , both peripheral and spinal, subjected to recurrent and\/or chronic neuroinflammatory conditions of different origins,\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003etends to exhaust its natural capacity for synthesizing endogenous Palmitoylethanolamide\u003c\/strong\u003e , thereby increasing the risk of\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eonset of inflammatory pain\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eand, in the case of injury and\/or dysfunction of the somatosensory system, the progressive transformation of inflammatory pain into neuropathic pain.\u003c\/p\u003e\n\n\u003cp\u003e\u003cbr\u003e In such cases it is of great importance\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003ecounteract the activation process of non-neuronal cells\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003e(mast cells at the level of the sensory endings and\/or in the endoneurial compartment and microglia at the spinal level) normally responsible for ensuring the homeodynamic balance of the nervous tissue and its correct trophism.\u003c\/p\u003e\n\n\u003cp\u003e \u003cbr\u003eNormast 600mg 30 Sachets helps support peripheral nerve function in cases of pain and discomfort. This product:\u003cbr\u003e • relieves \u003cstrong\u003epain caused by endoneurial edema\u003c\/strong\u003e ;\u003cbr\u003e • contains Palmitoylethanolamide, a powerful analgesic and anti-inflammatory;\u003cbr\u003e • it is indicated in case of \u003cstrong\u003eperipheral nerve disorders\u003c\/strong\u003e associated with end-neural edema;\u003cbr\u003e • stimulates peripheral nerve function.\u003cbr\u003e\u003c\/p\u003e\n\n\u003cp\u003e Normast 600mg 30 Sachets must be used under medical supervision for the dietary regime of subjects with disorders supported by neuroinflammatory processes.\u003cbr\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cbr\u003e \u003cstrong\u003eINGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e Ultra-micronized palmitoylethanolamide; sweetener: sorbitol; emulsifier: sucrose esters of fatty acids; stabilizers: cross-linked sodium carboxymethylcellulose, polyvinylpyrrolidone; emulsifier: polysorbate 80. \u003c\/p\u003e\n\n\u003cp style=\"margin: 0px 0px 10px; line-height: 22px; color: #444444; font-family: 'HelveticaNeueW02-55Roma', 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px;\"\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003cp style=\"margin: 0px 0px 10px; line-height: 22px; color: #444444; font-family: 'HelveticaNeueW02-55Roma', 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px;\"\u003e \u003cstrong\u003eHOW TO USE:\u003c\/strong\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003cp style=\"margin: 0px 0px 10px; line-height: 22px; color: #444444; font-family: 'HelveticaNeueW02-55Roma', 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px;\"\u003e It is recommended to take Normast 600mg 30 sachets directly on the tongue or dissolved in a little water as directed by a doctor, for possibly repeated cycles:\u003cbr\u003e - Acute phase: 2 sachets per day for 21 days,\u003cbr\u003e - Maintenance phase: 1 sachet per day for 30 days. \u003c\/p\u003e\n\n\u003cp style=\"margin: 0px 0px 10px; line-height: 22px; color: #444444; font-family: 'HelveticaNeueW02-55Roma', 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px;\"\u003e\u003c\/p\u003e\n\n\u003cp style=\"margin: 0px 0px 10px; line-height: 22px; color: #444444; font-family: 'HelveticaNeueW02-55Roma', 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px;\"\u003e \u003cstrong\u003eWARNINGS:\u003c\/strong\u003e \u003c\/p\u003e\n\n\u003cp style=\"margin: 0px 0px 10px; line-height: 22px; color: #444444; font-family: 'HelveticaNeueW02-55Roma', 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px;\"\u003e Use under medical supervision. This product should not be used as a sole source of nutrition. Keep out of reach of children under 3 years of age. Use during pregnancy is not recommended. Store in a cool, dry place. \u003c\/p\u003e\n\n\u003cp style=\"margin: 0px 0px 10px; line-height: 22px; color: #444444; font-family: 'HelveticaNeueW02-55Roma', 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px;\"\u003e \u003cb\u003eConservation\u003c\/b\u003e\u003cbr\u003e Store in a cool, dry place. Avoid exposure to localized heat, sunlight, and contact with water.\u003cbr\u003e The expiry date refers to the product when stored correctly and in its intact packaging.\u003cbr\u003e Shelf life of intact packaging: 36 months.\u003c\/p\u003e","brand":"EPITECH GROUP SpA","offers":[{"title":"Default Title","offer_id":40207822028915,"sku":"951387873","price":32.3,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/epitech-group-spa-normast-600mg-30-bustine-orosolubili-farmacia-dottor-tili-1213792790.jpg?v=1767112050"},{"product_id":"gynocanesbalance-gel-vaginale-vaginosi-batterica-7-flaconcini-applicatori","title":"Gynocanesbalance Vaginal Gel Bacterial Vaginosis 7 Applicator Vials","description":"\u003cp\u003eGynocanesbalance Vaginal Gel Bacterial Vaginosis is a specific product for \u003cstrong\u003etreating and preventing bacterial vaginosis, vaginitis and candida\u003c\/strong\u003e . It contains lactic acid, effective in \u003cstrong\u003eneutralizing bad odors\u003c\/strong\u003e and \u003cstrong\u003erestoring the normal pH of the vagina\u003c\/strong\u003e , and glycogen, which provides \u003cstrong\u003enourishment to the lactobacilli,\u003c\/strong\u003e supporting their growth. By normalizing the pH and nourishing the protective vaginal bacterial flora, Gyno-Canesbalance Gel \u003cstrong\u003erestores the natural vaginal defenses\u003c\/strong\u003e .\u003cbr\u003e Gynocanesbalance is administered with pre-filled, easy-to-use disposable applicator vials. It can be used during pregnancy and menstruation.\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cp\u003e \u003cstrong\u003eHOW TO USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e Use 1 applicator bottle per day for 7 days. Remove the tab, sit or lie down in a comfortable position and gently insert the applicator neck into the vagina as deeply as possible. Gently squeeze the applicator to release the contents. Remove the tube while continuing to squeeze. It is best to use Gyno-Canesbalance before bedtime. It is advisable to wear a panty liner as it is common to see some leakage. This does not mean that the treatment has not worked.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e \u003cstrong\u003eDOSAGE SCHEMES\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e The Cistite.info association in collaboration with numerous professionals in the sector has developed schemes that help to use this product in the correct ways and timing. Download them now from the links below!\u003c\/p\u003e\n\u003cp\u003e \u003cstrong\u003eSchemes that include the product:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e \u003cspan style=\"color: #2b00ff;\"\u003e- \u003ca style=\"color: #2b00ff;\" href=\"https:\/\/www.dottortili.it\/img\/cms\/Schema_Protocollo_Dada.pdf\"\u003eDownload\u003c\/a\u003e \u003ca style=\"color: #2b00ff;\" title=\"Treat Prevent Cystitis in Menopause\" href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Schema_Protocollo_Dada.pdf?v=1666792371\" target=\"_blank\"\u003ethe Dada Cystitis in Menopause diagram\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e \u003cspan\u003e\u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Schema_Protocollo_Miriam.pdf?v=1666792371\"\u003e\u003cspan\u003e\u003cspan\u003e\u003cbr\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e \u003cstrong\u003eDiagrams that do not include the product:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 12pt;\"\u003e \u003cspan style=\"color: #2b00ff;\"\u003e- \u003ca style=\"color: #2b00ff;\" title=\"Treating acute bacterial cystitis\" href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Schema-Cura-Cistite-Acuta.pdf?v=1666792371\" target=\"_blank\"\u003eDownload the Acute Cystitis diagram\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 12pt;\"\u003e \u003cspan style=\"color: #2b00ff;\"\u003e- \u003ca style=\"color: #2b00ff;\" title=\"Cure Prevent Honeymoon Post Coital Cystitis\" href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Schema-Cura-Cistite-Postcoitale.pdf?v=1666792371\" target=\"_blank\"\u003eDownload the Post-coital Cystitis diagram\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 12pt;\"\u003e \u003cspan style=\"color: #2b00ff;\"\u003e- \u003ca data-mce-fragment=\"1\" style=\"color: #2b00ff;\" title=\"Treat Prevent Chronic Cystitis\" href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Schema-Cura-Cistite-Cronica.pdf?v=1666792371\" target=\"_blank\"\u003eDownload the Chronic Cystitis diagram\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cp\u003e \u003cstrong\u003eINGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e Lactic acid, glycogen, propylene glycol, hydroxypropyl methylcellulose, sodium lactate, water, pH 3.8.\u003c\/p\u003e","brand":"BAYER SpA","offers":[{"title":"Default Title","offer_id":40207822094451,"sku":"971089192","price":18.34,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/bayer-spa-gynocanesbalance-gel-vaginale-vaginosi-batterica-7-flaconcini-applicatori-farmacia-dottor-tili-1213792781.jpg?v=1767112031"},{"product_id":"saginil-gel-vaginale-vaginosi-e-vaginite-40-ml","title":"Saginil Vaginal Gel Vaginosis and Vaginitis 40 ml","description":"\u003cp\u003e Saginil Gel is a vaginal gel indicated for the \u003cstrong\u003esymptomatic treatment of discomforts of the female intimate sphere, such as itching, burning, irritation, tenderness and dyspareunia\u003c\/strong\u003e (pain during sexual intercourse). These disorders can occur in isolation or in the course of \u003cstrong\u003evulvodynia, vulvovaginitis, bacterial vaginosis, contact vulvitis and vulvar vestibulitis.\u003c\/strong\u003e\u003c\/p\u003e\n\n \u003cp\u003e\u003cstrong\u003eGlycerin\u003c\/strong\u003e is a well-known cosmetic ingredient with \u003cstrong\u003emoisturising, lubricating and emollient properties\u003c\/strong\u003e . Combined with hyaluronic acid, it deeply hydrates and soothes itching and intimate burning. Hyaluronic acid helps accelerate the \u003cstrong\u003eprocess of epithelialization and tissue repair\u003c\/strong\u003e .\u003cbr data-mce-fragment=\"1\"\u003e\u003cbr data-mce-fragment=\"1\"\u003e \u003cstrong\u003ePhytosphingosine\u003c\/strong\u003e has \u003cstrong\u003eantibacterial and anti-inflammatory properties\u003c\/strong\u003e , useful for \u003cstrong\u003emaintaining and restoring the balance of vaginal bacterial flora\u003c\/strong\u003e .\u003cbr data-mce-fragment=\"1\"\u003e\u003cbr data-mce-fragment=\"1\"\u003e \u003cstrong\u003eTocopherol Acetate\u003c\/strong\u003e and \u003cstrong\u003eQuercetin\u003c\/strong\u003e have a marked \u003cstrong\u003eantioxidant action\u003c\/strong\u003e and help keep the vaginal mucous membranes hydrated.\u003c\/p\u003e\n\n \u003cp\u003e\u003cstrong data-mce-fragment=\"1\"\u003eAdelmidrol\u003c\/strong\u003e is an active ingredient derived from azelaic acid whose \u003cstrong data-mce-fragment=\"1\"\u003eanti-inflammatory and analgesic action\u003c\/strong\u003e is known. Thanks to these properties, adelmidrol is used for \u003cstrong data-mce-fragment=\"1\"\u003etopical treatments characterized by irritation and inflammation of the skin and mucous membranes\u003c\/strong\u003e . Acts on symptoms such as \u003cstrong data-mce-fragment=\"1\"\u003eitching, burning, irritation, tenderness and dyspareunia (pain during sexual intercourse)\u003c\/strong\u003e . These disorders may occur in isolation or in the presence of vulvodynia, vulvovaginitis, bacterial vaginosis, contact vulvitis, and vulvar vestibulitis.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eINGREDIENTS SAGINIL GEL\u003c\/strong\u003e\u003c\/p\u003e\n\n \u003cp\u003eaqua, adelmidrol (inn), peg-40 hydrogenated castor oil, noveon AA-1 polycarbophil, tocopheryl acetate, sodium hydroxide, polyvinyl aclohol, phenethyl alcohol, sodium hylorunate, methylparaben, phytosphingosine, quercitin\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e \u003cstrong\u003eHOW TO USE SAGINIL GEL\u003c\/strong\u003e\u003cbr\u003e Apply Saginil Gel 2 times a day by dispensing 1-2 doses and distributing the gel evenly over the affected area until symptoms are remitted or otherwise according to medical opinion. The product, in consideration of the peculiar bioadhesive characteristics, is able to remain for a long time in the areas of application thus guaranteeing an optimal long-acting effect.\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e \u003cstrong\u003eWARNINGS SAGINIL GEL\u003c\/strong\u003e \u003cbr\u003eUse only as specifically directed in the directions for use. Do not use in case of ulcers or potentially infected wounds. Keep out of the reach of children under 3 years of age. Do not use if the package is not intact or has been damaged. If vaginal dryness, itching and local pain persist or worsen despite using the product, contact your doctor.\u003cbr\u003e\u003cbr\u003e Do not dispose of empty containers in the environment. Do not use the product after the expiry date indicated on the package. Do not swallow. Avoid contact with eyes. In case of contact with eyes, rinse with plenty of water. Keep out of the reach of children. Store the product in a dry place away from sources of light and heat.\u003cbr\u003e\u003c\/p\u003e","brand":"EPITECH GROUP SpA","offers":[{"title":"Default Title","offer_id":40207822159987,"sku":"989874589","price":20.43,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/epitech-group-spa-saginil-gel-vaginale-vaginosi-e-vaginite-40-ml-farmacia-dottor-tili-1213792786.jpg?v=1767112128"},{"product_id":"arnica-compositum-heel-50-compresse","title":"Arnica Compositum Heel 50 Tablets","description":"\u003cp\u003eArnica Compositum Heel is a homeopathic medicine in tablet form indicated in all \u003cstrong\u003einflammatory pathologies\u003c\/strong\u003e , \u003cstrong\u003epains from inflammation, neuralgia\u003c\/strong\u003e and \u003cstrong\u003einflammatory pathologies\u003c\/strong\u003e of \u003cstrong\u003emuscular, tendon and skeletal origin\u003c\/strong\u003e , in injuries and \u003cstrong\u003ewounds\u003c\/strong\u003e . \u003cspan data-mce-fragment=\"1\"\u003eAlso useful in the presence of pelvic inflammatory diseases such as\u003c\/span\u003e \u003cstrong data-mce-fragment=\"1\"\u003eVulvodynia and Pelvic Neuropathy\u003c\/strong\u003e \u003cspan data-mce-fragment=\"1\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eArnica Compositum Heel tablets are \u003cstrong\u003eindicated in sports\u003c\/strong\u003e as they are \u003cstrong\u003enot included in the list of medicines banned by the Wada (World Anti-Doping Agency).\u003c\/strong\u003e Arnica Compositum Heel tablets can be taken in case of \u003cstrong\u003ebruises\u003c\/strong\u003e , \u003cstrong\u003ehematomas\u003c\/strong\u003e , \u003cstrong\u003esprains\u003c\/strong\u003e , muscle strains, non-traumatic inflammations of tissues of mesenchymal derivation (muscles, bones, tendons, ligaments, muscle bands).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003c\/strong\u003eArnica Compositum Heel contains Arnica, Calendula, Hamamelis, Millefolium and Belladonna and extracts of 9 other plants. These substances have the following properties:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eArnica montana\u003c\/strong\u003e : stimulates wound healing; it is useful in case of fractures, dislocations, contusions, hematomas, weakness of the heart muscle, neuralgia, myalgia, analgesic and haemostatic.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCalendula\u003c\/strong\u003e : it is used in homeopathy for difficult healing wounds; favors granulations; has analgesic effect.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHamamelis\u003c\/strong\u003e : active on venous stasis, varicose veins, crural ulcer, haemorrhoids, venous haemorrhages; prevents inflammation; has analgesic effect.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMillefolium\u003c\/strong\u003e : used in case of haemorrhages, especially oozing, precapillary, arteriovenous haemorrhages.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBelladonna\u003c\/strong\u003e : active on localized reaction phases; states of cerebral irritation with spasms and delusions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAconitum\u003c\/strong\u003e : action on the neurogenic phase of inflammation and the phases of generalized inflammation; analgesic and haemostatic through increased capillary tone.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMercurius solubilis Hannemani\u003c\/strong\u003e : modulates suppurations, action on abscesses and edema.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHepar sulfuris carbonicum\u003c\/strong\u003e : antiseptic action, in case of: tendency to suppurations, tonsillar and lymphatic abscesses, pain like pins and needles.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eChamomile\u003c\/strong\u003e : natural analgesic and anti-inflammatory properties. Stimulates the healing of difficult wounds.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSymphytum\u003c\/strong\u003e : accelerates the formation of bone callus and tissues of mesenchymal origin (tendons, ligaments), bruises.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBellis perennis\u003c\/strong\u003e : used in case of dislocations, bruises and edema.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEchinacea Angustifolia\u003c\/strong\u003e : antiseptic action. It helps to modulate the vascular phase of inflammation, making it useful in the presence of localized inflammation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEchinacea purpurea\u003c\/strong\u003e : stimulates fibroblasts, activates macrophages, dendrocytes and monocytes.\u003c\/li\u003e\n\u003cli\u003e\nSt. John's \u003cstrong\u003eWort\u003c\/strong\u003e : healing action on nerve tissue and skin.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul\u003e\u003c\/ul\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eHOW TO USE\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003eTake 1 tablet of Arnica Compositum, letting it dissolve in the mouth, 3 times a day.\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCOMPOSITION 1 TABLET\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eArnica D2, Calendula D2, Hamamelis D2, Millefolium D3 ana 15 mg; Belladonna D4 75mg; Aconitum D3, Mercurius solubiIis Hahnemanni D8, Hepar sulfuris D8 ana 30 mg; Chamomilla D3, Symphytum D8 ana 24 mg; Bellis perennis D2, Echinacea D2, Echinacea purpurea D2 ana 6 mg; Hypericum D2 3 mg.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn some cases it is possible to experience side effects such as headache, tachycardia, abdominal and respiratory pain. Do not take in case of hypersensitivity to any of the components of the product. Do not exceed the recommended daily dose. In case of bandaging, use materials that allow the skin to breathe. For use during pregnancy and while breastfeeding, seek medical advice. Spicy foods, mint and stimulants can reduce the effectiveness of homeopathic medicines. Keep out of the reach of children under 3 years of age.\u003c\/p\u003e","brand":"GUNA SpA","offers":[{"title":"Default Title","offer_id":40207822192755,"sku":"909474912","price":11.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/guna-spa-arnica-compositum-heel-50-compresse-farmacia-dottor-tili-1213792779.jpg?v=1767112109"},{"product_id":"lubrigyn-vaginale-crema-20-bustine-monodose","title":"Lubrigyn Vaginal Cream 20 Single-Dose Sachets","description":"\u003cp data-start=\"263\" data-end=\"611\" class=\"\"\u003e Lubrigyn® Vaginal Cream is a topical treatment specifically formulated to \u003cstrong\u003ecombat vaginal dryness and irritation\u003c\/strong\u003e . Thanks to its creamy and highly tolerated texture, Lubrigyn® helps \u003cstrong\u003erestore hydration and elasticity to the mucous membranes\u003c\/strong\u003e , providing rapid relief from discomfort such as itching, burning and dryness.\u003c\/p\u003e\n\n\u003cp data-start=\"613\" data-end=\"730\" class=\"\"\u003e The formula is indicated in all situations in which there is a \u003cstrong\u003ereduction in physiological lubrication\u003c\/strong\u003e , such as: \u003c\/p\u003e\n\n\u003cul data-start=\"732\" data-end=\"1021\"\u003e\n\n\u003cli data-start=\"732\" data-end=\"811\" class=\"\"\u003e\n\n\u003cp data-start=\"734\" data-end=\"811\" class=\"\"\u003e systemic or local hormonal treatments (including the contraceptive pill) \u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli data-start=\"812\" data-end=\"841\" class=\"\"\u003e\n\n\u003cp data-start=\"814\" data-end=\"841\" class=\"\"\u003e pre-menopause and menopause \u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli data-start=\"842\" data-end=\"857\" class=\"\"\u003e\n\n\u003cp data-start=\"844\" data-end=\"857\" class=\"\"\u003e postpartum \u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli data-start=\"858\" data-end=\"869\" class=\"\"\u003e\n\n\u003cp data-start=\"860\" data-end=\"869\" class=\"\"\u003e diabetes \u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli data-start=\"870\" data-end=\"922\" class=\"\"\u003e\n\n\u003cp data-start=\"872\" data-end=\"922\" class=\"\"\u003e intimate hygiene with aggressive or soapy products \u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli data-start=\"923\" data-end=\"974\" class=\"\"\u003e\n\n\u003cp data-start=\"925\" data-end=\"974\" class=\"\"\u003e hormonal changes during the menstrual cycle \u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli data-start=\"975\" data-end=\"1021\" class=\"\"\u003e\n\n\u003cp data-start=\"977\" data-end=\"1021\" class=\"\"\u003elocal or systemic pharmacological treatments\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp data-start=\"1023\" data-end=\"1191\" class=\"\"\u003e The single-dose sachets guarantee hygiene, practicality and precise dosing, ideal for daily or cyclical use, even in conjunction with other gynecological treatments.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n \u003cp style=\"margin-bottom: 12pt;\"\u003e\u003cstrong\u003eDOSAGE SCHEMES\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp style=\"margin-bottom: 12pt;\"\u003e The Cistite.info association in collaboration with numerous professionals in the sector has developed schemes that help to use this product in the correct ways and timing. Download them now from the links below!\u003c\/p\u003e\n\n\u003cp style=\"margin-bottom: 12pt;\"\u003e \u003cstrong\u003eSchemes that include the product:\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp style=\"margin-bottom: 12pt;\"\u003e \u003cspan style=\"color: #2b00ff;\"\u003e- \u003ca title=\"Treat and prevent cystitis during pregnancy and breastfeeding\" href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Schema_gravidanza_allattamento.pdf?v=1666792371\" style=\"color: #2b00ff;\" target=\"_blank\"\u003eDownload the Cystitis in Pregnancy and Breastfeeding chart\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp style=\"margin-bottom: 12pt;\"\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003cp style=\"margin-bottom: 12pt;\"\u003e \u003cstrong\u003eDiagrams that do not include the product:\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp style=\"margin-bottom: 12pt;\"\u003e \u003cspan style=\"color: #2b00ff;\"\u003e- \u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Assunzione-Mannosio-Schema.pdf?v=1666792371\" title=\"How to take D-mannose\" style=\"color: #2b00ff;\" target=\"_blank\"\u003eDownload the generic D-mannose intake chart\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp style=\"margin-bottom: 12pt;\"\u003e\u003cspan style=\"color: #2b00ff;\"\u003e- \u003ca href=\"https:\/\/www.dottortili.it\/img\/cms\/Schema_Protocollo_Dada.pdf\" style=\"color: #2b00ff;\"\u003eDownload\u003c\/a\u003e \u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Schema_Protocollo_Dada.pdf?v=1666792371\" title=\"Treat Prevent Cystitis in Menopause\" style=\"color: #2b00ff;\" target=\"_blank\"\u003ethe Dada Cystitis in Menopause diagram\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp style=\"margin-bottom: 12pt;\"\u003e \u003cspan style=\"color: #2b00ff;\"\u003e- \u003ca title=\"Cure Prevent Honeymoon Post Coital Cystitis\" href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Schema-Cura-Cistite-Postcoitale.pdf?v=1666792371\" style=\"color: #2b00ff;\" target=\"_blank\"\u003eDownload the Post-coital Cystitis diagram\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp style=\"margin-bottom: 12pt;\"\u003e \u003cspan style=\"color: #2b00ff;\"\u003e- \u003ca title=\"Treat Prevent Vaginal Candida Infections\" href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Schema_Protocollo_Miriam.pdf?v=1666792371\" style=\"color: #2b00ff;\" target=\"_blank\"\u003eDownload the Miriam Candida and Vaginal Infections chart\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp style=\"margin-bottom: 12pt;\"\u003e\u003cspan style=\"color: #2b00ff;\"\u003e- \u003ca title=\"Treat Prevent Chronic Cystitis\" href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Schema-Cura-Cistite-Cronica.pdf?v=1666792371\" style=\"color: #2b00ff;\" target=\"_blank\"\u003eDownload the Chronic Cystitis diagram\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp style=\"margin-bottom: 12pt;\"\u003e\u003c\/p\u003e\n\n\u003cp\u003e \u003cstrong\u003eINGREDIENTS\u003c\/strong\u003e\u003cbr\u003e Aqua, Prunus Amygdalus Dulcis Oil, Propylene Glycol, Cetearyl Alcohol, Cetyl Alcohol, Stearyl Alcohol, Ceteareth-12, Isopropyl Myristate, Retinyl Palmitate, Calendula Officinalis Flower Extract, Glucose, Lecithin, Hydrolyzed Elastin, Lactic Acid, Sodium Hyaluronate, Isopropyl Palmitate, Phenoxyethanol, Dimethicone, Potassium Sorbate, Imidazolidinyl Urea, PEG-32, PEG-6, Cocamidopropyl Betaine, Tocopherol, Ascorbyl Palmitate, Citric Acid, Ethylhexylglycerin.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003cp\u003e \u003cstrong\u003eHOW TO USE\u003c\/strong\u003e\u003cbr\u003e \u003cspan\u003eApply the contents of one sachet with a gentle massage on the external female genitals, even several times a day if necessary.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003cp\u003e \u003cspan\u003eFormat 20 single-use sachets\u003c\/span\u003e\u003c\/p\u003e","brand":"UNIDERM FARMACEUTICI Srl","offers":[{"title":"Default Title","offer_id":40207822225523,"sku":"900760240","price":15.01,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/uniderm-farmaceutici-srl-lubrigyn-vaginale-crema-20-bustine-monodose-farmacia-dottor-tili-1213792782.jpg?v=1767112090"},{"product_id":"tachipirina-antidolorifico-500-mg-20-compresse","title":"Tachipirina Painkiller 500 mg 20 Tablets","description":"\u003cp\u003eTachipirina 500 mg is an over-the-counter drug based on \u003cstrong\u003eparacetamol with analgesic, antipyretic and anti-inflammatory action\u003c\/strong\u003e . Tachipirina 20 Tablets is an antipyretic indicated in the symptomatic treatment of febrile conditions such as \u003cstrong\u003einfluenza, exanthematous diseases, acute respiratory tract conditions\u003c\/strong\u003e or.\u003c\/p\u003e\n\n\u003cp\u003e Paracetamol is an antipyretic \u003cstrong\u003esuitable for treating fever in children\u003c\/strong\u003e , lowering temperature and controlling flu symptoms.\u003c\/p\u003e\n\n\u003cp\u003e Paracetamol is a painkiller and analgesic useful in cases of \u003cstrong\u003eheadaches, neuralgia, myalgia\u003c\/strong\u003e and other painful conditions of medium severity and of various origins.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Tachipirina Antidolorifico 500 mg 20 Tablets - What is the active ingredient of Tachipirina Antidolorifico 500 mg 20 Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThis medicine 500 mg tablets. Each tablet contains: paracetamol 500 mg. This medicine 500 mg effervescent granules. Each sachet contains: paracetamol 500 mg. This medicine 125 mg effervescent granules. Each sachet contains: paracetamol 125 mg. This medicine - newborns 62.5 mg suppositories. Each suppository contains: paracetamol 62.5 mg. This medicine - early childhood 125 mg suppositories. Each suppository contains: paracetamol 125 mg. This medicine - children 250 mg suppositories. Each suppository contains: paracetamol 250 mg. This medicine - children 500 mg suppositories. Each suppository contains: paracetamol 500 mg. This medicine - adults 1000 mg suppositories. Each suppository contains: paracetamol 1000 mg.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Tachipirina Antidolorifico 500 mg 20 Tablets - What does Tachipirina Antidolorifico 500 mg 20 Tablets contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eTablets: microcrystalline cellulose, povidone, pregelatinized starch, stearic acid, croscarmellose sodium. Effervescent granules: maltitol, mannitol, sodium bicarbonate, anhydrous citric acid, citrus flavouring, aspartame, sodium docusate. Suppositories: solid semi-synthetic glycerides.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Tachipirina Antidolorifico 500 mg 20 Tablets - Why is Tachipirina Antidolorifico 500mg 20 Tablets used? What is it used for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eAs an antipyretic: symptomatic treatment of febrile conditions such as influenza, exanthematous diseases, acute respiratory tract conditions, etc. As an analgesic: headaches, neuralgia, myalgia and other moderately severe painful conditions of various origins.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Tachipirina Antidolorifico 500 mg 20 Tablets - When should Tachipirina Antidolorifico 500 mg 20 Tablets not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eHypersensitivity to paracetamol or to any of the excipients. Patients with severe haemolytic anaemia (this contraindication does not apply to the 500 mg oral formulations). Severe hepatocellular insufficiency (this contraindication does not apply to the 500 mg oral formulations).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Tachipirina Antidolorifico 500 mg 20 Tablets - How do you take Tachipirina Antidolorifico 500 mg 20 Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eFor children, it is essential to respect the dosage defined according to their body weight, and therefore choose the appropriate formulation. The approximate ages according to body weight are given for information purposes only. In adults, the maximum oral dosage is 3000 mg and rectal dosage is 4000 mg of paracetamol per day. The doctor must evaluate the need for treatments for more than 3 consecutive days. The dosage schedule of this medicine in relation to body weight and administration route is as follows. 500 mg tablets. Children weighing between 21 and 25 kg (approximately between 6.5 and less than 8 years): 1\/2 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day (3 tablets). Children weighing between 26 and 40 kg (approximately 8 to 11 years): 1 tablet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 41 and 50 kg (approximately 12 to 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Children weighing more than 50 kg (approximately over 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Adults: 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. In the case of severe pain or high fever, 2 tablets of 500 mg to be repeated if necessary after not less than 4 hours. Effervescent granules of 500 mg in sachets. Dissolve the effervescent granules in a glass of water. Children weighing between 26 and 40 kg (approximately 8 to 11 years): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 41 and 50 kg (approximately 12 to 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Children weighing more than 50 kg (approximately over 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Adults: 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. In the case of severe pain or high fever, 2 sachets of 500 mg to be repeated if necessary after not less than 4 hours. Effervescent granules of 125 mg in sachets. Dissolve the effervescent granules in a glass of water. Children weighing between 7 and 10 kg (approximately between 6 and 19 months): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 11 and 12 kg (approximately between 20 and 29 months): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Children weighing between 13 and 20 kg (approximately between 30 months and less than 6.5 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 21 and 25 kg (approximately between 6.5 and less than 8 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Suppositories Neonates 62.5 mg. Children weighing between 3.2 and 5 kg (approximately between birth and 2 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Suppositories Early Childhood 125 mg. Children weighing between 6 and 7 kg (approximately between 3 and 5 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 7 and 10 kg (approximately between 6 and 19 months): 1 suppository at a time, to be repeated if necessary after 4 - 6 hours, without exceeding 5 administrations per day. Children weighing between 11 and 12 kg (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Suppositories Children 250 mg. Children weighing between 11 and 12 kg (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. Children weighing between 13 and 20 kg (approximately between 30 months and less than 6.5 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Suppositories Children 500 mg. Children weighing between 21 and 25 kg (approximately between 6.5 and less than 8 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. Children weighing between 26 and 40 kg (approximately between 8 and 11 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Suppositories Adults 1000 mg. Children weighing between 41 and 50 kg (approximately between 12 and 15 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. Children weighing more than 50 kg (approximately over 15 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Adults: 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Renal insufficiency. In case of severe renal insufficiency (creatinine clearance less than 10 ml\/min), the interval between administrations must be at least 8 hours.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Tachipirina Antidolorifico 500 mg 20 Tablets - How is Tachipirina Antidolorifico 500 mg 20 Tablets stored?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eTablets and effervescent granules: no special precautions for storage. Suppositories: store at a temperature not exceeding 25 degrees C.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Tachipirina Antidolorifico 500 mg 20 Tablets - About Tachipirina Antidolorifico 500 mg 20 Tablets it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIn rare cases of allergic reactions, administration should be suspended and appropriate treatment should be instituted. Use with caution in cases of chronic alcoholism, excessive alcohol intake (3 or more alcoholic drinks per day), anorexia, bulimia or cachexia, chronic malnutrition (low reserves of hepatic glutathione), dehydration, hypovolemia. Paracetamol should be administered with caution to patients with mild to moderate hepatocellular insufficiency (including Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh\u0026gt;9), acute hepatitis, in concomitant treatment with drugs that alter liver function, glucose-6-phosphate dehydrogenase deficiency, hemolytic anemia. High or prolonged doses of the product can cause alterations to the kidney and blood, even serious, therefore administration to subjects with renal insufficiency should be carried out only if really necessary and under direct medical supervision. In case of prolonged use it is advisable to monitor liver and renal function and blood count. During treatment with paracetamol, before taking any other medicine, check that it does not contain the same active ingredient, since if paracetamol is taken in high doses, serious adverse reactions may occur. Invite the patient to contact the doctor before combining any other medicine. Important information about some of the excipients. This 125 mg effervescent granules medicine contains: aspartame, which is a source of phenylalanine. It may be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk associated with the accumulation of the amino acid phenylalanine. Maltitol: use with caution in patients with rare hereditary problems of fructose intolerance. 70.6 mg of sodium per sachet equivalent to 3.53% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult: to be taken into consideration by people with reduced kidney function or who follow a low-sodium diet. This 500 mg effervescent granules medicinal product contains: aspartame, a source of phenylalanine. It may be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk associated with the accumulation of the amino acid phenylalanine. Maltitol: use with caution in patients with rare hereditary problems of fructose intolerance. 283 mg of sodium per sachet is equivalent to 14.1% of the WHO recommended maximum daily intake of 2 g of sodium for an adult. The maximum dose for this product is equivalent to 84.6% of the WHO recommended maximum daily intake of sodium: to be taken into consideration by patients with reduced kidney function or who follow a low-sodium diet.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Tachipirina Antidolorifico 500 mg 20 Tablets - Which medicines or foods can modify the effect of Tachipirina Antidolorifico 500 mg 20 Tablets?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe oral absorption of paracetamol depends on the rate of gastric emptying. Therefore, the concomitant administration of drugs that slow (e.g. anticholinergics, opioids) or increase (e.g. prokinetics) the rate of gastric emptying may determine a decrease or increase respectively in the bioavailability of the product. The concomitant administration of cholestyramine reduces the absorption of paracetamol. The simultaneous intake of paracetamol and chloramphenicol may induce an increase in the half-life of chloramphenicol, with the risk of increasing toxicity. Concomitant use of paracetamol (4 g daily for at least 4 days) with oral anticoagulants may cause slight variations in INR values. In these cases, more frequent monitoring of INR values ​​should be performed during concomitant use and after its interruption. Use with extreme caution and under close supervision during chronic treatment with drugs that can determine the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutethimide, phenobarbital, carbamazepine). The same applies in cases of alcoholism and in patients treated with zidovudine. The administration of paracetamol may interfere with the determination of uricemia (by the phosphotungstic acid method) and with that of glycemia (by the glucose-oxidase-peroxidase method).\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Tachipirina Antidolorifico 500 mg 20 Tablets can cause side effects - What are the side effects of Tachipirina Antidolorifico 500 mg 20 Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe following are the adverse reactions of paracetamol organised according to the MedDRA system organ classification. There are insufficient data to establish the frequency of the individual effects listed. Blood and lymphatic system disorders: thrombocytopenia, leukopenia, anaemia, agranulocytosis. Immune system disorders: hypersensitivity reactions (urticaria, laryngeal edema, angioedema, anaphylactic shock). Nervous system disorders: dizziness. Gastrointestinal disorders: gastrointestinal reaction. Hepatobiliary disorders: abnormal liver function, hepatitis. Skin and subcutaneous tissue disorders: erythema multiforme, Stevens Johnson syndrome, epidermal necrolysis, rash. Renal and urinary disorders: acute renal failure, interstitial nephritis, haematuria, anuria. Very rare cases of serious skin reactions have been reported. Reporting of suspected adverse reactions. Reporting of suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tachipirina Antidolorifico 500 mg 20 Tablets.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003ePregnancy: A large amount of data on pregnant women indicate neither malformative nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. Breastfeeding: It is recommended to administer the product only in cases of real need and under the direct supervision of a doctor.\u003c\/span\u003e\u003c\/p\u003e","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":40207822356595,"sku":"012745093","price":5.89,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-spa-tachipirina-antidolorifico-500-mg-20-compresse-farmacia-dottor-tili-1213792780.jpg?v=1767112250"},{"product_id":"buscofen-12-capsule-molli-200mg","title":"Buscofen 12 Soft Capsules 200mg","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBuscofen 12 Soft Capsules is a drug based on\u003c\/span\u003e \u003cspan\u003eibuprofen\u003c\/span\u003e \u003cspan\u003e(200 mg per capsule), an active ingredient belonging to the category of nonsteroidal anti-inflammatory drugs (NSAIDs), indicated for the treatment of\u003c\/span\u003e \u003cspan\u003epain of various origins\u003c\/span\u003e \u003cspan\u003e. It is particularly effective for relieving pain related to conditions such as\u003c\/span\u003e \u003cspan\u003emenstrual pain\u003c\/span\u003e \u003cspan\u003e,\u003c\/span\u003e \u003cspan\u003eheadache\u003c\/span\u003e \u003cspan\u003e,\u003c\/span\u003e \u003cspan\u003etoothache\u003c\/span\u003e \u003cspan\u003e,\u003c\/span\u003e \u003cspan\u003eneuralgia\u003c\/span\u003e \u003cspan\u003e, and\u003c\/span\u003e \u003cspan\u003eosteoarticular\u003c\/span\u003e \u003cspan\u003eand\u003c\/span\u003e \u003cspan\u003emuscular\u003c\/span\u003e pain \u003cspan\u003e. Thanks to its formulation in\u003c\/span\u003e \u003cspan\u003esoft capsules\u003c\/span\u003e \u003cspan\u003e, it is rapidly absorbed by the body, offering faster relief than other solid formulations.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eBuscofen 12 Soft Capsules is indicated for the symptomatic treatment of mild to moderate pain, including:\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e \u003cspan\u003eMenstrual cramps\u003c\/span\u003e \u003cspan\u003e(dysmenorrhea);\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n \u003cp role=\"presentation\" dir=\"ltr\"\u003e\u003cspan\u003eHeachache\u003c\/span\u003e \u003cspan\u003e;\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e \u003cspan\u003eToothache\u003c\/span\u003e \u003cspan\u003e;\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e \u003cspan\u003eNeuralgia\u003c\/span\u003e \u003cspan\u003e;\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e \u003cspan\u003eMuscle and joint pain\u003c\/span\u003e \u003cspan\u003e(such as lumbago, back pain and arthralgia);\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e \u003cspan\u003eRheumatic\u003c\/span\u003e \u003cspan\u003eand inflammatory pain of musculoskeletal origin.\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Buscofen 12 Soft Capsules 200mg - What is the active ingredient of Buscofen 12 Soft Capsules 200mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eCoated tablets, 1 tablet contains: ibuprofen 200 mg. Soft gelatin capsules: 1 soft capsule contains: ibuprofen 200 mg. For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Buscofen 12 Soft Capsules 200mg - What does Buscofen 12 Soft Capsules 200mg contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eCoated tablets - blister pack of 20 tablets: corn starch, sodium carboxymethyl starch, magnesium stearate, hydroxypropyl methylcellulose, polyethylene glycol 6000, talc, titanium dioxide, antifoam emulsion. Soft capsules - blister pack of 12 or 24 capsules: macrogol 600, potassium hydroxide, purified water, gelatin, partially dehydrated liquid sorbitol.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eDIRECTIONS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Buscofen 12 Soft Capsules 200mg - Why is Buscofen 12 Soft Capsules 200mg used? What is it used for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003ePain of various origins and natures (menstrual pain, headache, toothache, neuralgia, osteoarticular and muscular pain).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Buscofen 12 Soft Capsules 200mg - When should Buscofen 12 Soft Capsules 200mg not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eHypersensitivity to the active substance or to any of the excipients. Subjects with hypersensitivity to acetylsalicylic acid or other analgesics, antipyretics, nonsteroidal anti-inflammatory drugs (NSAIDs), in particular when hypersensitivity is associated with nasal polyposis, angioedema and\/or asthma. Severe hepatic insufficiency. Severe renal insufficiency (glomerular filtration rate less than 30 ml\/min). Severe cardiac insufficiency (NYHA class IV). Subjects with blood dyscrasias of unknown origin, porphyria, hypertension, severe uncontrolled coronary insufficiency. Severe or active peptic ulcer. History of gastrointestinal bleeding or perforation related to previous active treatments or history of recurrent peptic ulcer\/haemorrhage (two or more distinct episodes of proven ulceration or bleeding). Subjects with clinical conditions that determine an increased tendency to bleeding. In conjunction with surgical procedures (including dental operations). Subjects who have undergone significant fluid loss (through vomiting, diarrhoea or insufficient fluid intake). During the third trimester of pregnancy (see section 4.6). Children under 12 years of age.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Buscofen 12 Soft Capsules 200mg - How to take Buscofen 12 Soft Capsules 200mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eDo not administer to children under 12 years of age. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration of treatment necessary to control symptoms (see section 4.4). Coated tablets. Adults and adolescents over 12 years: 1-2 tablets, two - three times a day, preferably on a full stomach. However, do not exceed the dose of 1200 mg (6 tablets) per day. Do not exceed the recommended doses. If the use of the medicine is necessary for more than 3 days in adolescents, or in the event of worsening of symptoms, a doctor should be consulted. Elderly: elderly patients should stick to the minimum doses indicated. Patients with renal insufficiency: in the presence of renal insufficiency, elimination may be reduced and the dosage should be adjusted accordingly. Soft capsules. Adults and adolescents over 12 years: 1-2 soft capsules, two - three times a day, preferably on a full stomach. Do not exceed the dose of 1200 mg (6 soft capsules) per day. Do not exceed the recommended doses. If the use of the medicine is necessary for more than 3 days in adolescents, or in case of worsening of the symptoms, a doctor must be consulted. Elderly: elderly patients must stick to the minimum doses indicated. Patients with renal insufficiency: in the presence of renal insufficiency, elimination may be reduced and the dosage must be adjusted accordingly. Buscofen must not be used for more than 7 days. If higher doses are necessary or if a more prolonged treatment is required, then it is necessary to contact your doctor. The coated tablets and soft capsules must be swallowed without chewing, preferably with a little water. It is recommended to take them during or after meals, especially for people with gastric disorders.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Buscofen 12 Soft Capsules 200mg - How to store Buscofen 12 Soft Capsules 200mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eCoated tablets - blister pack of 20 tablets: store at room temperature. Soft capsules - blister pack of 12 or 24 capsules: no storage conditions.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eWARNINGS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Buscofen 12 Soft Capsules 200mg - About Buscofen 12 Soft Capsules 200mg it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe use of Buscofen with concomitant NSAIDs, including cyclooxygenase-2 (COX-2) selective inhibitors, should be avoided due to an increased risk of ulceration or bleeding (see section 4.5). Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see sections below on gastrointestinal and cardiovascular risks). Paediatric population: There is a risk of impaired renal function in dehydrated adolescents. Elderly: Elderly patients have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal (see section 4.2). Gastrointestinal bleeding, ulceration and perforation: Gastrointestinal bleeding, ulceration and perforation, which can be fatal, have been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious GI events. The risk of gastrointestinal bleeding, ulceration or perforation is higher with increasing NSAID doses, in the elderly and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3). These patients should start treatment on the lowest dose available. The concomitant use of protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients and also for patients who are taking low dose acetylsalicylic acid or other drugs likely to increase gastrointestinal risk (see below and section 4.5). Patients with a history of gastrointestinal toxicity, particularly when elderly, should report any unusual gastrointestinal symptoms (especially gastrointestinal bleeding), particularly in the initial stages of treatment. Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors (SSRIs) or anti-platelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients receiving Buscofen, the treatment should be withdrawn. NSAIDs should be given with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Use with caution in patients with coagulation defects. Cardiovascular and cerebrovascular effects: Appropriate monitoring and advice are necessary in patients with a history of hypertension and\/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy. Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day), may be associated with a small increased risk of arterial thrombotic events (e.g. myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low doses of ibuprofen (e.g. \u0026lt;= 1200 mg\/day) are associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III), established ischaemic heart disease, peripheral arterial disease, and\/or cerebrovascular disease should only be treated with ibuprofen after careful consideration and high doses (2400 mg\/day) should be avoided. Careful consideration should also be exercised before initiating long-term treatment of patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking), particularly if high doses (2400 mg\/day) of ibuprofen are required. Severe skin reactions: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at highest risk early in the course of therapy, with the onset of the reaction occurring in the majority of cases within the first month of treatment. Acute generalised exanthematous pustulosis (AGEP) has been reported in connection with medicinal products containing ibuprofen. Treatment with Buscofen should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity. Masking of symptoms of underlying infections: Buscofen may mask the symptoms of infection, which may delay the initiation of adequate treatment and therefore worsen the outcome of the infection. This has been observed in community-acquired bacterial pneumonia and bacterial complications of varicella. When Buscofen is administered for the relief of infection-related fever or pain, monitoring for infection is advised. In non-hospital settings, the patient should seek medical attention if symptoms persist or worsen. Renal effects: Caution should be exercised in patients with considerable dehydration when initiating treatment with ibuprofen.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Buscofen 12 Soft Capsules 200mg - Which medicines or foods can modify the effect of Buscofen 12 Soft Capsules 200mg?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIbuprofen (like other NSAIDs) should be used with caution in association with: corticosteroids: increased risk of gastrointestinal ulceration or bleeding (see section 4.4); anticoagulants: NSAIDs may increase the effects of anticoagulants such as warfarin (see section 4.4). It is advisable to monitor patients treated with coumarins; acetylsalicylic acid and other NSAIDs: these substances may increase the risk of adverse reactions affecting the gastrointestinal tract (see section 4.4). The concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased undesirable effects. Experimental data suggest that ibuprofen may competitively inhibit low dose acetylsalicylic acid on platelet aggregation when the two drugs are administered concomitantly. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No clinically relevant effect is considered likely following occasional use of ibuprofen (see section 5.1). It is however advisable not to combine ibuprofen with aspirin or other NSAIDs; antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding (see section 4.4); diuretics, ACE inhibitors and angiotensin II antagonists: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. Diuretics may also increase the risk of nephrotoxicity associated with NSAIDs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients) the co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking Buscofen concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, this combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and periodically thereafter; lithium: concomitant administration of lithium and NSAIDs causes an increase in lithium levels in the blood due to reduced elimination, with the possibility of reaching the toxic threshold. If this combination is necessary, monitor lithium levels in order to adapt the lithium dosage during concomitant treatment with ibuprofen; methotrexate: NSAIDs may inhibit the tubular secretion of methotrexate and reduce its clearance, resulting in an increased risk of toxicity; aminoglycosides: NSAIDs may decrease the excretion of aminoglycosides; cardiac glycosides: NSAIDs may exacerbate cardiac failure, reduce the glomerular filtration rate and increase plasma levels of cardiac glycosides; phenytoin: NSAIDs may lead to an increase in plasma concentrations of phenytoin; cholestyramine: concomitant administration of ibuprofen and cholestyramine may reduce the absorption of ibuprofen from the gastrointestinal tract. However, the clinical relevance of this interaction is unknown; ciclosporin: increased risk of nephrotoxicity with NSAIDs; COX-2 inhibitors and other NSAIDs: concomitant use with other NSAIDs, including cyclooxygenase-2 selective inhibitors, should be avoided due to the potential additive effect (see section 4.4); herbal extracts: Ginkgo Biloba may increase the risk of bleeding in association with NSAIDs; mifepristone: due to the antiprostaglandin properties of NSAIDs, a decrease in the efficacy of the medicinal product may theoretically occur. Limited evidence suggests that co-administration of NSAIDs on the day of prostaglandin administration does not adversely influence the effects of mifepristone or the prostaglandin on cervical ripening or uterine contractility and does not reduce the clinical efficacy of the medicinal product on pregnancy termination; quinolone antibiotics: animal data indicate that NSAIDs may increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions; sulfonylureas: NSAIDs may increase sulfonylureas. Rare cases of hypoglycaemia have been reported in patients treated with sulfonylureas who were taking ibuprofen; tacrolimus: possible increased risk of nephrotoxicity when NSAIDs are administered with tacrolimus; zidovudine: increased risk of haematotoxicity in case of co-administration with NSAIDs. There is evidence of an increased risk of haemarthrosis and haematoma in HIV-infected haemophiliac patients receiving concomitant treatment with zidovudine and other NSAIDs; ritonavir: possible increase in the concentration of NSAIDs; probenecid: slows the excretion of NSAIDs with possible increase in their plasma concentrations; sulfinpyrazone: may delay the excretion of ibuprofen; CYP2C9 inhibitors: concomitant administration of ibuprofen and CYP2C9 inhibitors may increase exposure to ibuprofen (CYP2C9 substrate). In a study with voriconazole and fluconazole (CYP2C9 inhibitors), an increased exposure to S(+)-ibuprofen by approximately 80% to 100% was observed. A reduction of the ibuprofen dose should be considered when strong CYP2C9 inhibitors are co-administered, particularly when high doses of ibuprofen are administered with voriconazole and fluconazole.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Buscofen 12 Soft Capsules 200 mg can cause side effects - What are the side effects of Buscofen 12 Soft Capsules 200mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe undesirable effects observed with ibuprofen are generally common to other analgesics, antipyretics, non-steroidal anti-inflammatory drugs. Gastrointestinal disorders: the most commonly observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or gastrointestinal haemorrhage, sometimes fatal, particularly in the elderly, may occur (see section 4.4). Gastrointestinal perforation with the use of ibuprofen has been observed rarely. After administration of Buscofen the following have been reported: nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, epigastric pain, heartburn, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4). Less frequently, gastritis has been observed. Pancreatitis has also been observed very rarely. Immune system disorders: hypersensitivity reactions have been reported following treatment with NSAIDs. These may consist of a) non-specific allergic reaction and anaphylaxis, b) respiratory tract reactions including asthma, including severe asthma, bronchospasm or dyspnoea or c) skin disorders including rashes of various types, pruritus, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatitis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme). Cardiac and vascular disorders: Oedema and fatigue, hypertension and cardiac failure have been reported in association with NSAID treatment. Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day), may be associated with a modest increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). Other adverse events reported less frequently and for which causality has not necessarily been established include: Blood and lymphatic system disorders: leukopenia, thrombocytopenia, neutropenia, agranulocytosis, aplastic anaemia and haemolytic anaemia. Psychiatric disorders: insomnia, anxiety, depression, confusional state, hallucinations. Nervous system disorders: headache, paraesthesia, dizziness, somnolence, optic neuritis. Infections and infestations: aseptic rhinitis and meningitis (especially in patients with pre-existing autoimmune disorders, such as systemic lupus erythematosus and mixed connective tissue disease) with symptoms of stiff neck, headache, nausea, vomiting, fever or disorientation (see section 4.4). Respiratory, thoracic and mediastinal disorders: bronchospasm, dyspnoea, apnoea. Eye disorders: rare cases of ocular alteration resulting in visual disturbances, toxic optic neuropathy. Ear and labyrinth disorders: impaired hearing, tinnitus, vertigo. Hepatobiliary disorders: impaired liver function, liver failure, hepatitis and jaundice. Skin and subcutaneous tissue disorders: bullous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis (very rare), photosensitivity reactions and drug reaction with eosinophilia and systemic symptoms (DRESS syndrome) (frequency not known), acute generalized exanthematous pustulosis (AGEP) (frequency not known). Renal and urinary disorders: impaired renal function and toxic nephropathy in various forms, including interstitial nephritis, nephrotic syndrome and renal failure. General disorders and administration site conditions: malaise, fatigue. Reporting of suspected adverse reactions Reporting of suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Buscofen 12 Soft Capsules 200mg.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003ePregnancy: Inhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or embryo\/fetal development. Data from epidemiological studies suggest an increased risk of miscarriage, cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor during early pregnancy. The absolute risk of cardiac malformations increases from less than 1%, up to approximately 1.5%. The risk is believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo-fetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy, ibuprofen should not be given unless clearly necessary. If used by women attempting to conceive or during the first and second trimester of pregnancy, the dose and duration of treatment should be as low and as short as possible, respectively. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction, which may progress to renal failure with oligo-hydroamniosis; the mother and the neonate, at the end of pregnancy, to: possible prolongation of bleeding time and antiaggregant effect which may occur even at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, ibuprofen is contraindicated during the third trimester of pregnancy. Breastfeeding: in the few studies available to date, NSAIDs may be found in breast milk in very low concentrations. NSAIDs should, if possible, be avoided during breastfeeding. Fertility: The use of ibuprofen may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of fertility, discontinuation of ibuprofen should be considered.\u003c\/span\u003e\u003c\/p\u003e","brand":"SANOFI SpA","offers":[{"title":"Default Title","offer_id":40207822389363,"sku":"029396037","price":7.91,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sanofi-spa-buscofen-12-capsule-molli-200mg-farmacia-dottor-tili-1213792773.jpg?v=1767112233"},{"product_id":"okitask-20-bustine-granulato-40-mg","title":"Okitask 20 granulated sachets 40 mg.","description":"\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eOkitask 20 orosoluble sachets 40 mg is an over-the-counter anti-inflammatory medicine based on Ketoprofen Lysine salt. Okitask 20 granulated sachets 40 mg belongs to a group of medicines called “Non-Steroidal Anti-Inflammatory Drugs” (NSAIDs), which can be sold without a prescription. The active ingredient in Okitask 20 granulated sachets 40 mg, ketoprofen,\u003c\/span\u003e \u003cb\u003eworks by blocking the chemicals that normally cause inflammation in our body\u003c\/b\u003e \u003cspan style=\"font-weight: 400;\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp\u003e \u003cspan style=\"font-weight: 400;\"\u003eOkitask 20 orosoluble sachets 40 mg can be used for\u003c\/span\u003e \u003cb\u003epain of different origins and\u003c\/b\u003e \u003cstrong\u003enatures\u003c\/strong\u003e \u003cspan style=\"font-weight: 400;\"\u003e\u003cstrong\u003e,\u003c\/strong\u003e in particular: headache, toothache, neuralgia (nerve pain), menstrual pain, muscle pain and osteoarticular pain (bone pain and joint inflammation).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eActive ingredients contained in Okitask 20 sachets granules 40 mg. - What is the active ingredient in Okitask 20 sachets granules 40 mg.?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eEach sachet contains. Active ingredient: ketoprofen lysine salt 40 mg (corresponding to 25 mg of ketoprofen) Excipients with known effect: aspartame, sodium dodecyl sulphate. For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Okitask 20 sachets granules 40 mg. - What does Okitask 20 sachets granules 40 mg contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003ePovidone, colloidal silica, hydroxypropyl methylcellulose, eudragit EPO, sodium dodecyl sulfate, stearic acid, magnesium stearate, aspartame, mannitol, xylitol, talc, lime flavouring, lemon flavouring, frescofort flavouring.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Okitask 20 sachets granules 40 mg. - Why is Okitask 20 sachets granules 40 mg used? What is it used for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003ePain of various origins and natures, and in particular: headache, toothache, neuralgia, menstrual pain, muscular and osteoarticular pain.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Okitask 20 sachets granules 40 mg. - When should Okitask 20 sachets granules 40 mg not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eOkitask 40 mg granules must not be administered in the following cases: hypersensitivity to the active substance, to other nonsteroidal anti-inflammatory drugs (NSAIDs) or to any of the excipients listed in section 6.1; asthma, bronchospasm, acute rhinitis, urticaria, skin rashes, nasal polyps, angioneurotic oedema or other allergic-type reactions caused by ketoprofen, or by medicinal products with a similar mechanism of action (for example acetylsalicylic acid, other NSAIDs and selective cyclooxygenase 2 inhibitors), see section 4.8; previous bronchial asthma; severe cardiac insufficiency; gastritis; active peptic ulcer\/haemorrhage or history of recurrent peptic ulcer\/haemorrhage (two or more distinct episodes of proven ulceration or haemorrhage); previous history of gastrointestinal bleeding, ulceration or perforation or chronic dyspepsia; history of gastrointestinal bleeding or perforation following previous NSAID therapy; Crohn's disease or ulcerative colitis; severe hepatic insufficiency (liver cirrhosis, severe hepatitis); severe renal insufficiency; leukopenia and thrombocytopenia; haemorrhagic diathesis and other coagulation disorders, haemostatic disorders; use of high doses of diuretics; third trimester of pregnancy; children under 15 years of age.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Okitask 20 sachets granules 40 mg. - How to take Okitask 20 sachets granules 40 mg.?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eDosage. Adults and over 15 years: the recommended dose is 40 mg (corresponding to 1 sachet), in a single dose, or repeated 2-3 times a day, in the most intense painful forms. Do not exceed the recommended doses. Special populations. Elderly. The dosage must be carefully established, taking into account a possible reduction of the dosages indicated above. Patients with hepatic or renal insufficiency. Therapy at the minimum daily dosage and careful monitoring are recommended (see section 4.4). In case of renal insufficiency, it is recommended to check the volume of diuresis and renal function (see section 4.4). Okitask 40 mg granules must not be used in patients with severe hepatic or renal dysfunction (see section 4.3). Paediatric population. The safety and efficacy of Okitask 40 mg granules in children have not yet been established. Method of administration: the contents of the sachet can be placed directly on the tongue. It dissolves with saliva: this allows its use without water. It is preferable to take the product on a full stomach. Duration of treatment: The duration of therapy should be limited to overcoming the painful episode. The lowest effective dose should be used for the shortest period necessary to relieve symptoms (see paragraph 4.4).\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Okitask 20 sachets granules 40 mg. - How do you store Okitask 20 sachets granules 40 mg.?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThis medicinal product does not require any special storage conditions.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Okitask 20 sachets granules 40 mg. - About Okitask 20 sachets granules 40 mg. it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eWarnings. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.2 and sections below on gastrointestinal and cardiovascular risks). The concomitant use of Okitask 40 mg granules with other NSAIDs, including cyclooxygenase-2 selective inhibitors, should be avoided. Gastrointestinal reactions. Gastrointestinal bleeding, ulceration and perforation: gastrointestinal bleeding, ulceration and perforation, which can be fatal, have been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious gastrointestinal events. The risk of gastrointestinal bleeding, ulceration or perforation is higher with increasing NSAID doses in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3). These patients should start treatment on the lowest possible dose. Concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients receiving concomitant low dose acetylsalicylic acid or other drugs likely to increase the risk of gastrointestinal events (see below and section 4.5). Patients with a history of gastrointestinal toxicity, especially the elderly, should report any abdominal symptoms and\/or signs (including gastrointestinal bleeding) also at the beginning of treatment. Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or anti-platelet agents such as acetylsalicylic acid (see section 4.5). Elderly. The elderly have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal (see section 4.2). Patients with active or previous gastrointestinal disease should be carefully observed for digestive disturbances, especially gastrointestinal bleeding. When gastrointestinal bleeding or ulceration occurs in patients receiving Okitask 40 mg granules, the treatment should be withdrawn. Patients with active or previous peptic ulcer. Some epidemiological evidence suggests that ketoprofen may be associated with a higher risk of serious gastrointestinal toxicity than other NSAIDs, particularly at high doses (see sections 4.2 and 4.3). Skin reactions. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at higher risk at the beginning of treatment. Okitask 40 mg granules should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. Precautions. Cardiovascular, renal and hepatic dysfunction: in patients with impaired renal function, the administration of ketoprofen should be carried out with particular caution in view of the essentially renal elimination of the drug. Renal function should be carefully monitored in patients with heart failure, cirrhosis and nephrosis, in patients receiving diuretic therapy, in patients with chronic renal impairment, particularly if the patients are elderly. In these patients, the administration of ketoprofen may cause a decrease in renal blood flow caused by prostaglandin inhibition and lead to renal failure (see section 4.3). Caution is also required in patients subject to diuretic therapy or likely to be hypovolemic because the risk of nephrotoxicity is increased. As with all NSAIDs, Okitask 40 mg granules may increase plasma urea nitrogen and creatinine. As with other inhibitors of prostaglandin synthesis, Okitask 40 mg granules may be associated with adverse events on the renal system that can lead to glomerular nephritis, renal papillary necrosis, nephrotic syndrome and acute renal failure (see section 4.8). In patients with abnormal liver function values ​​or with a history of liver disease, transaminase levels should be periodically evaluated. As with other NSAIDs, Okitask 40 mg granules may cause increases in some liver parameters and also significant increases in SGOT and SGPT (see section 4.8). In case of significant increases in these parameters, therapy should be discontinued. With the use of ketoprofen, cases of jaundice and hepatitis have been reported (see section 4.8). Elderly patients are more predisposed to reduction of renal, cardiovascular or hepatic function. Cardiovascular and cerebrovascular effects. As with other NSAIDs, patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should only be treated with ketoprofen after careful consideration. Similar consideration should be made before initiating treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking). Caution is required before initiating treatment in patients with a history of hypertension and\/or mild to moderate congestive heart failure since fluid retention and oedema have been reported in association with NSAID treatment. Clinical trial and epidemiological data suggest that the use of some NSAIDs may be associated with an increased risk of arterial thrombotic events (e.g. myocardial infarction or stroke). There are insufficient data to exclude such a risk for Okitask 40 mg granules. An increased risk of atrial fibrillation associated with the use of NSAIDs has been reported. Hyperkalaemia may occur, especially in patients with underlying diabetes, renal insufficiency, and\/or concomitant treatment with agents promoting hyperkalaemia (see section 4.5). In these circumstances, potassium levels should be periodically assessed. Infections. Masking of symptoms of underlying infections. Okitask 40 mg granules may mask the symptoms of infection, which may delay initiation of adequate treatment and therefore worsen the outcome of the infection. This has been observed in community-acquired bacterial pneumonia and in bacterial complications of varicella.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Okitask 20 sachets granules 40 mg. - What medicines or foods can modify the effect of Okitask 20 sachets granules 40 mg.?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eCombinations not recommended. Other NSAIDs (including selective inhibitors of cyclooxygenase 2) and high doses of salicylates (\u0026gt; 3 g\/day): the simultaneous administration of several NSAIDs may increase the risk of gastrointestinal ulcers and bleeding, due to a synergistic effect. Anticoagulants (heparin and warfarin): NSAIDs may amplify the effects of anticoagulants. If administration cannot be avoided, the patient must be closely monitored. Platelet aggregation inhibitors (ticlopidine and clopidogrel): the concomitant administration of an NSAID may increase the risk of bleeding by inhibition of platelet function and damage to the gastrointestinal mucosa (see section 4.4). If administration cannot be avoided, the patient must be closely monitored. Lithium: the simultaneous administration of several NSAIDs may increase plasma lithium levels, which may reach toxic values, due to reduced renal excretion. Plasma lithium levels should be carefully monitored and the lithium dosage should be adjusted during and after discontinuation of treatment with ketoprofen and other NSAIDs. Methotrexate, at doses greater than 15 mg\/week: concomitant administration of an NSAID may increase the risk of haematological toxicity of methotrexate, especially if administered at high doses, probably due to a displacement of binding to plasma proteins and a decrease in renal clearance. The intake of the two medicinal products should be separated by at least 12 hours. Hydantoins and sulphonamides: the toxic effects of these substances may be increased; since the protein binding of ketoprofen is high, it may be necessary to reduce the dosage of diphenylhydantoin or sulphonamides, in case of concomitant administration. Combinations requiring precaution. Drugs or therapeutic categories that may promote hyperkalaemia: potassium salts, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor blockers, NSAIDs, heparins (low molecular weight or unfractionated), ciclosporin, tacrolimus and trimethoprim. The occurrence of hyperkalaemia may depend on the presence of cofactors. The risk is increased in case of concomitant administration of the above mentioned drugs. Tenofovir: concomitant administration of tenofovir disoproxil fumarate and NSAIDs may increase the risk of renal failure. Diuretics: subjects treated with diuretics, especially if dehydrated, are at increased risk of developing renal failure secondary to the reduction in renal blood flow caused by prostaglandin inhibition. Hydration before initiating concomitant therapy and close monitoring of renal function after initiation of treatment are recommended (see section 4.4). NSAIDs may reduce diuretics. ACE inhibitors and angiotensin II antagonists: co-administration with cyclooxygenase inhibitors may lead to further deterioration of renal function and possible acute renal failure, especially in dehydrated and elderly subjects. Caution, hydration and monitoring of renal function are recommended in case of concomitant therapy. Methotrexate at doses lower than 15 mg\/week: anti-inflammatory drugs cause a decrease in renal clearance of methotrexate with consequent increase in haematological toxicity. In case of impaired renal function or advanced age, monitoring must be more frequent. Corticosteroids: concomitant administration of NSAIDs may increase the risk of gastrointestinal ulceration or bleeding (see section 4.4). Pentoxifylline: co-administration may increase the risk of bleeding: monitoring of bleeding time is recommended. Zidovudine: the combination with NSAIDs increases the risk of toxicity on reticulocytes, with severe anaemia occurring one week after the start of treatment with NSAIDs. Complete blood count and reticulocyte count should be checked one week after starting treatment with the NSAID. Sulfonylureas: NSAIDs may increase the hypoglycaemic effect of sulfonylureas by displacing them from plasma protein binding sites. Possible interactions with other oral hypoglycaemic agents should also be taken into account. Cardiac glycosides: NSAIDs may exacerbate cardiac failure, reduce the glomerular filtration rate and increase cardiac glycoside levels; however, the pharmacokinetic interaction between ketoprofen and active glycosides has not been demonstrated. Associations that need to be taken into account. Antihypertensive agents (Beta-blockers, ACE inhibitors, diuretics): treatment with an NSAID may reduce the hypoglycaemic effect of antihypertensive drugs by inhibiting the synthesis of vasodilatory prostaglandins. Mifepristone: The efficacy of the contraceptive method may theoretically be reduced due to the antiprostaglandin properties of NSAIDs including acetylsalicylic acid. There is some evidence to suggest that concomitant administration of NSAIDs on the day of administration of the prostaglandin dose does not adversely affect the effects of mifepristone or the prostaglandin on cervical ripening or uterine contractility and does not reduce the clinical efficacy of medical termination of pregnancy. Intrauterine contraceptive devices (IUDs): The efficacy of the device may be reduced resulting in pregnancy. Ciclosporin and tacrolimus: Concomitant treatment with NSAIDs may involve an increased risk of nephrotoxicity especially in the elderly. Thrombolytics: Concomitant administration with NSAIDs may increase the risk of bleeding. Anti-platelet agents (ticlopidine and clopidogrel) and Selective serotonin reuptake inhibitors (SSRIs): NSAIDs may increase the risk of gastrointestinal bleeding (see section 4.4). Probenecid: Concomitant administration of probenecid may markedly reduce the plasma clearance of ketoprofen by inhibiting tubular secretion and glucuronide conjugation, therefore an adjustment of the ketoprofen dose is necessary. Quinolone antibiotics: Animal data indicate that NSAIDs may increase the risk of convulsions related to the use of quinolones. Patients treated with NSAIDs and quinolones may have an increased risk of developing convulsions.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Okitask 20 sachets granules 40 mg. can cause side effects - What are the side effects of Okitask 20 sachets granules 40 mg.?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe most commonly observed adverse events are gastrointestinal in nature. Classification of expected frequencies: very common (1\/10), common (from 1\/100 to \u0026lt;=1\/10), uncommon (from 1\/1000 to \u0026lt;=1\/100), rare (from 1\/10000 to \u0026lt;=1\/1000), very rare (\u0026lt;=1\/10000), not known (frequency cannot be estimated from the available data). The following adverse reactions have been observed with the use of ketoprofen in adults. Blood and lymphatic system disorders. Rare (\u0026gt;=1\/10,000, \u0026lt;1\/1,000): haemorrhagic anaemia; frequency not known: thrombocytopenia, agranulocytosis, bone marrow failure, haemolytic anaemia, leukopenia, neutropenia, aplastic anaemia, leukocytosis, thrombocytopenic purpura. Immune system disorders. Frequency not known: anaphylactic reaction (including shock), hypersensitivity. Gastrointestinal disorders. Common (\u0026gt;=1\/100, \u0026lt;1\/10): dyspepsia, nausea, abdominal pain, vomiting; uncommon (\u0026gt;=1\/1,000, \u0026lt;1\/100): constipation, diarrhoea, flatulence, gastritis; rare (\u0026gt;=1\/10,000, \u0026lt;1\/1,000): stomatitis, peptic ulcer; frequency not known: exacerbation of colitis and Crohn's disease, gastrointestinal haemorrhage, gastrointestinal perforation (sometimes fatal, particularly in the elderly - see section 4.4), gastric ulcer, mouth ulceration, duodenal ulcer, duodenal perforation, melaena, haematemesis, abdominal discomfort, colitis, heartburn, mouth oedema, pancreatitis, hyperchlorhydria, gastric pain, erosive gastritis, tongue oedema. Skin and subcutaneous tissue disorders: Uncommon (\u0026gt;=1\/1,000, \u0026lt;1\/100): rash, pruritus; very rare (\u0026lt;1\/10,000): erythema; frequency not known: photosensitivity reaction, alopecia, urticaria, angioedema, bullous dermatitis including Stevens-Johnson syndrome and toxic epidermal necrolysis, oedema, exanthema, Lyell syndrome, maculo-papular rash, purpura, acute generalized exanthematous pustulosis, dermatitis. General disorders and administration site conditions. Uncommon (\u0026gt;=1\/1,000, \u0026lt;1\/100): fatigue; very rare (\u0026lt;1\/10,000): facial oedema; frequency not known: peripheral oedema, chills, asthenia. Nervous system disorders. Uncommon (\u0026gt;=1\/1,000, \u0026lt;1\/100): headache, dizziness, somnolence; rare (\u0026gt;=1\/10,000, \u0026lt;1\/1,000): paraesthesia; frequency not known: seizure, dysgeusia, dizziness, dyskinesia, syncope, tremor, hyperkinesia. Eye disorders. Rare (\u0026gt;=1\/10,000, \u0026lt;1\/1,000): blurred vision (see section 4.4); frequency not known: periorbital oedema. Ear and labyrinth disorders. Rare (\u0026gt;=1\/10,000, \u0026lt;1\/1,000): tinnitus. Hepatobiliary disorders. Rare (\u0026gt;=1\/10,000, \u0026lt;1\/1,000): hepatitis, increased transaminases, increased blood bilirubin; frequency not known: jaundice. Respiratory, thoracic and mediastinal disorders. Rare (\u0026gt;=1\/10,000, \u0026lt;1\/1,000): asthma; frequency not known: bronchospasm (especially in patients with known hypersensitivity to acetylsalicylic acid and other NSAIDs), rhinitis, dyspnoea, laryngeal oedema, laryngospasm, acute respiratory failure (one case, with fatal outcome, has been reported in an asthmatic patient sensitive to acetylsalicylic acid). Renal and urinary disorders. Frequency not known: acute renal failure, tubulointerstitial nephritis, nephritic syndrome, abnormal renal function test, haematuria, nephritis, nephrotic syndrome, glomerulonephritis, fluid\/sodium retention with possible oedema, acute tubular necrosis, renal papillary necrosis, oliguria. Psychiatric disorders. Frequency not known: altered mood, depression, hallucination, confusional state, agitation, insomnia. Cardiac disorders. Frequency not known: cardiac failure, atrial fibrillation, palpitations, tachycardia. Vascular disorders. Frequency not known: hypertension, vasodilation, hypotension, vasculitis (including leukocytoclastic vasculitis). Metabolism and nutrition disorders. Frequency not known: hyperkalaemia, hyponatraemia. Infections and infestations. Frequency not known: aseptic meningitis, lymphangitis. Investigations. Rare (\u0026gt;=1\/10,000, \u0026lt;1\/1,000): weight increased. Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long-term treatment) may be associated with an increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Okitask 20 sachets granules 40 mg.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003ePregnancy: The use of ketoprofen during the first and second trimester of pregnancy should be avoided, the administration of ketoprofen should be considered only if the expected benefit for the mother outweighs the risk to the embryo or fetus. Inhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or embryo\/fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased from less than 1%, up to approximately 1.5%. The risk was considered to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-fetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. From the twentieth week of pregnancy onwards, the use of ketoprofen may cause oligohydramnios resulting from fetal renal dysfunction. This may be seen soon after initiation of treatment and is usually reversible upon discontinuation of treatment. In addition, cases of constriction of the ductus arteriosus have been reported following treatment in the second trimester, most of which resolved after discontinuation of treatment. Therefore, during the first and second trimesters of pregnancy, ketoprofen should not be administered unless clearly necessary. If ketoprofen is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dosage should be kept as low as possible for the shortest duration possible. Following exposure to ketoprofen for several days from the 20th week of gestation onwards, antenatal monitoring for oligohydramnios and constriction of the ductus arteriosus should be considered. If oligohydramnios or constriction of the ductus arteriosus occurs, treatment with ketoprofen should be discontinued. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: cardiopulmonary toxicity (premature constriction\/closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction, which may progress to renal failure with oligohydramnios (see above). The mother and the neonate, at the end of pregnancy, to: possible prolongation of bleeding time and antiaggregant effect which may occur even at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labor. Use of the medicinal product close to delivery may cause alterations in the haemodynamics of the small circulation of the newborn with serious consequences for respiration. Consequently, ketoprofen is contraindicated during the third trimester of pregnancy (see sections 4.3 and 5.3). Breastfeeding: there is no information available on the excretion of ketoprofen in breast milk. Ketoprofen is not recommended during breastfeeding. Fertility: the use of NSAIDs may reduce female fertility and is therefore not recommended in women intending to become pregnant. The administration of NSAIDs, as well as Okitask 40 mg granules, must be suspended in women who have fertility problems or who are undergoing investigation of fertility.\u003c\/span\u003e\u003c\/p\u003e","brand":"DOMPE' FARMACEUTICI SpA","offers":[{"title":"Default Title","offer_id":40207822422131,"sku":"042028023","price":10.23,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/dompe-farmaceutici-spa-okitask-20-bustine-granulato-40-mg-farmacia-dottor-tili-1213792778.jpg?v=1767112213"},{"product_id":"buscopan-40-compresse-rivestite-10-mg","title":"Buscopan 40 Coated Tablets 10 mg","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBuscopan\u003c\/span\u003e \u003cspan\u003eis a drug used to treat abdominal cramps and pain, especially those related to gastrointestinal and urinary tract disorders. The active ingredient,\u003c\/span\u003e \u003cspan\u003ebutylscopolamine bromide\u003c\/span\u003e \u003cspan\u003e, acts as an antispasmodic, relaxing the smooth muscles of the gastrointestinal and urinary tract, thus reducing pain and discomfort. Thanks to its localized action, Buscopan is effective in the treatment of intestinal spasms, colic and similar disorders\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eBuscopan is indicated for:\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e \u003cspan\u003eSymptomatic treatment of abdominal cramps\u003c\/span\u003e \u003cspan\u003eand pain caused by gastrointestinal spasms.\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e \u003cspan\u003eRelief of pain from renal and biliary colic\u003c\/span\u003e \u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e \u003cspan\u003eTreatment of spasms and pain related to urinary tract disorders\u003c\/span\u003e \u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eActive ingredients contained in Buscopan 40 Coated Tablets 10 mg - What is the active ingredient of Buscopan 40 Coated Tablets 10 mg?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eCoated tablets, one coated tablet contains: N-butyl hyoscine bromide 10 mg. Excipients: sucrose. Suppositories, one suppository contains: N-butyl hyoscine bromide 10 mg. For a full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Buscopan 40 Coated Tablets 10 mg - What does Buscopan 40 Coated Tablets 10 mg contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eCoated tablets; core: calcium hydrogen phosphate, maize starch, soluble starch, colloidal anhydrous silica, tartaric acid, stearic acid. Coating: povidone, sucrose, talc, gum arabic, titanium dioxide (E171), macrogol 6000, carnauba wax, white wax. Suppositories: solid semi-synthetic glycerides.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eTherapeutic indications Buscopan 40 Coated Tablets 10 mg - Why is Buscopan 40 Coated Tablets 10 mg used? What is it used for?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eSymptomatic treatment of spastic-painful manifestations of the gastrointestinal tract.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Buscopan 40 Coated Tablets 10 mg - When should Buscopan 40 Coated Tablets 10 mg not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eHypersensitivity to the active substance or to any of the excipients. Acute angle glaucoma. Prostatic hypertrophy or other causes of urinary retention. Pyloric stenosis and other conditions stenosing the gastrointestinal tract. Mechanical stenosis of the gastrointestinal tract. Paralytic or obstructive ileus. Megacolon. Ulcerative colitis. Reflux esophagitis. Intestinal atony in the elderly and debilitated subjects. Myasthenia gravis. Children under 6 years of age. In case of rare hereditary conditions of incompatibility with one of the excipients (see section 4.4 \"Special warnings and precautions for use\"), the use of the medicinal product is contraindicated.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Buscopan 40 Coated Tablets 10 mg - How to take Buscopan 40 Coated Tablets 10 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eDosage: The following dosages are recommended for adults and children over 14 years of age. Coated tablets: 1-2 coated tablets 3 times a day. Suppositories: 1 suppository 3 times a day. Single doses can be increased according to the doctor's judgment. In pediatrics, in children aged between 6 and 14 years, the doctor's prescription must be followed exactly. Method of administration: The tablets must be swallowed whole with an adequate amount of water. Buscopan must not be taken daily on a regular basis or for prolonged periods without looking for the cause of the abdominal pain.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Buscopan 40 Coated Tablets 10 mg - How to store Buscopan 40 Coated Tablets 10 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eCoated tablets: This medicine does not require any special storage conditions. Suppositories: Do not store above 30 degrees C.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eWarnings Buscopan 40 Coated Tablets 10 mg - About Buscopan 40 Coated Tablets 10 mg it is important to know that:\u003c\/span\u003e\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIf severe abdominal pain of unknown cause persists or worsens, or occurs with other symptoms such as fever, nausea, vomiting, changes in bowel movement, abdominal tenderness, decreased blood pressure, fainting, or blood in the stool, seek medical attention immediately. Anticholinergics should be used with caution in the elderly, in patients with autonomic nervous system disorders, cardiac tachyarrhythmias, arterial hypertension, congestive heart failure, hyperthyroidism, and in patients with liver and kidney disease. Because of the potential risk of complications related to excessive anticholinergic effect, caution should be exercised in patients subject to narrow-angle glaucoma as well as in patients susceptible to intestinal and urinary stasis and in those prone to tachyarrhythmias. Anticholinergics may prolong gastric emptying time and cause antral stasis. Due to the possibility that anticholinergics may reduce sweating, Buscopan should be administered with caution in patients with pyrexia. Treatment with high doses should not be stopped abruptly. Minor side effects can be controlled by appropriately reducing the dose; the appearance of important secondary manifestations requires the interruption of therapy. One 10 mg coated tablet contains 41.2 mg of sucrose equivalent to 247.2 mg per maximum recommended daily dose. Therefore, patients with rare hereditary problems of fructose intolerance should not take this medicine.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Buscopan 40 Coated Tablets 10 mg - Which medicines or foods can modify the effect of Buscopan 40 Coated Tablets 10 mg?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eanticholinergic drugs such as tri- and tetracyclic antidepressants, phenothiazines, butyrophenones, antihistamines, antipsychotics, quinidine, amantadine, diisopyramide and other anticholinergics (e.g. tiotropium, ipratropium and atropine-like compounds) may be accentuated by Buscopan. Concomitant treatment with dopamine antagonists, such as metoclopramide, may cause a reduction in the effect of both drugs on the gastrointestinal tract. Tachycardia induced by beta-adrenergic drugs may be accentuated by Buscopan. Do not consume alcohol during therapy. Since antacids may reduce the intestinal absorption of anticholinergics, these drugs should not be administered concomitantly.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eLike all medicines, Buscopan 40 Coated Tablets 10 mg can cause side effects - What are the side effects of Buscopan 40 Coated Tablets 10 mg?\u003c\/span\u003e\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eMany of the listed adverse reactions can be attributed to the anticholinergic properties of Buscopan. The anticholinergic side effects of Buscopan are generally mild and self-limiting. Immune system disorders. Uncommon frequency: skin reactions, urticaria, pruritus; unknown frequency*: anaphylactic shock, anaphylactic reactions, dyspnoea, skin rash, erythema and other manifestations of hypersensitivity. * These adverse reactions have been observed in post-marketing experience. With a 95% probability, the frequency category is not greater than uncommon (3\/1368), but could be lower. A precise estimate of the frequency is not possible since these adverse reactions did not occur in 1368 patients in clinical trials. Cardiac disorders. Uncommon frequency: tachycardia. Gastrointestinal disorders. Uncommon frequency: dry mouth. Constipation has also been observed. Skin and subcutaneous tissue disorders. Uncommon: sweating disorders. Renal and urinary disorders. Rare: urinary retention. The following undesirable effects have also been observed. Eye disorders: mydriasis, accommodation disorders, increased ocular tone. Nervous system disorders: drowsiness. High doses may cause signs of central stimulation and more serious signs of interference with the nervous system, the state of consciousness and cardiorespiratory function. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Buscopan 40 Coated Tablets 10 mg.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThere are limited data from the use of hyoscine N-butylbromide in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). There is insufficient information on the excretion of Buscopan and its metabolites in human milk. As a precautionary measure, it is preferable to avoid the use of Buscopan during pregnancy and breastfeeding. No studies on the effects on human fertility have been performed (see section 5.3).\u003c\/span\u003e\u003c\/p\u003e","brand":"SANOFI SpA","offers":[{"title":"Default Title","offer_id":40207822454899,"sku":"006979088","price":17.01,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sanofi-spa-buscopan-40-compresse-rivestite-10-mg-farmacia-dottor-tili-1213792764.jpg?v=1767125423"},{"product_id":"oti-prodeg-gel-75-ml","title":"OTI Prodeg Gel 75ml","description":"\u003cp\u003eOti Prodeg Gel is a phytotherapeutic remedy with a \u003cstrong\u003eprogestin-like action\u003c\/strong\u003e that \u003cstrong\u003enormalizes the progestin phase and combats the symptoms of menopause and alterations in the menstrual cycle\u003c\/strong\u003e .\u003c\/p\u003e\n\n\u003cp\u003e \u003cstrong\u003eDioscorea Villosa\u003c\/strong\u003e contained in Oti Prodeg Gel (6%) is recognized as a natural progestin due to didiogenin. Useful for \u003cstrong\u003efighting the symptoms of menopause and alterations of the menstrual cycle\u003c\/strong\u003e . Excellent anti-aging effect on the skin\u003cbr\u003e\u003c\/p\u003e\n\n\u003cp\u003e Aloe vera and wheat germ oil ensure \u003cstrong\u003ebetter permeability through the skin\u003c\/strong\u003e of Oti Prodeg Gel. This facilitates the \u003cstrong\u003etransdermal\u003c\/strong\u003e \u003cstrong\u003eintake\u003c\/strong\u003e of Dioscorea villosa and ensures maximum availability to the body, avoiding intestinal transit which largely inactivates it.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003cp\u003e \u003cstrong\u003eHOW TO USE\u003c\/strong\u003e\u003c\/p\u003e\n\n \u003cp\u003eSpread 1 cm of Oti Prodeg Gel in the periumbilical area or in the elbow crease once a day. Massage until completely absorbed. The therapy can be continued, due to the total absence of contraindications, without suspension, for a prolonged period, as an estrogen-progestin replacement therapy.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003cp style=\"margin-bottom: 12pt;\"\u003e \u003cstrong\u003eDOSAGE SCHEMES\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp style=\"margin-bottom: 12pt;\"\u003e The non-profit association Cistite.info in collaboration with numerous professionals in the sector has developed schemes that help to use this product in the correct ways and times. Download them now from the links below!\u003c\/p\u003e\n\n\u003cp style=\"margin-bottom: 12pt;\"\u003e \u003cstrong\u003eSchemes that include the product:\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp style=\"margin-bottom: 12pt;\"\u003e \u003cspan style=\"color: #2b00ff;\"\u003e- \u003ca style=\"color: #2b00ff;\" href=\"https:\/\/www.dottortili.it\/img\/cms\/Schema_Protocollo_Dada.pdf\"\u003eDownload\u003c\/a\u003e \u003ca style=\"color: #2b00ff;\" href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Schema_Protocollo_Dada.pdf?v=1666792371\" title=\"Treat Prevent Cystitis in Menopause\" target=\"_blank\"\u003ethe Dada Cystitis in Menopause diagram\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n \u003cp\u003e\u003cstrong\u003eINGREDIENTS\u003c\/strong\u003e\u003cbr\u003e Aqua, Alcohol, Triticum Vulgare Germ Oil, Aloe Barbadensis Leaf Juice, Dioscorea Villosa Root Extract, Maltodextrin, Carbomer, Propylene Glycol, Polysorbate 20, Phenethyl Alcohol, Caprylyl Glycol, Disodium EDTA, Sodium Hydroxide.\u003cbr\u003e\u003cstrong\u003e\u003c\/strong\u003e\u003c\/p\u003e","brand":"OTI srl","offers":[{"title":"Default Title","offer_id":40207822553203,"sku":"903017236","price":21.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/oti-srl-oti-prodeg-gel-75-ml-farmacia-dottor-tili-1213792774.jpg?v=1767125452"},{"product_id":"codex-30-capsule-5-miliardi-250-mg-blister","title":"Codex 30 Capsules 5 Billion 250 mg Blister","description":"\u003cp\u003e \u003cstrong\u003eCodex\u003c\/strong\u003e is a food supplement based on \u003cstrong\u003eSaccharomyces boulardii\u003c\/strong\u003e , a natural probiotic that helps restore the balance of the intestinal flora, especially in situations of imbalance caused by diarrhea, antibiotics or an unbalanced diet. Each Codex capsule contains \u003cstrong\u003e5 billion live cells\u003c\/strong\u003e of Saccharomyces boulardii, for a targeted and rapid action. The capsule format is convenient to take and ideal for adults and children.\u003c\/p\u003e\n\n \n\u003ch2\u003eDosage and method of use\u003c\/h2\u003e\n\n\u003ch3\u003e How to take Codex?\u003c\/h3\u003e\n\n\u003cp\u003e It is recommended to take \u003cstrong\u003e1 or 2 capsules\u003c\/strong\u003e per day, as needed and as directed by your doctor. The capsules should be swallowed whole, preferably away from meals, with plenty of water. In case of treatment with antibiotics, it is preferable to take Codex at least 2 hours after the antibiotic to ensure the effectiveness of the product.\u003c\/p\u003e\n\n\n\u003ch2\u003e Ingredients\u003c\/h2\u003e\n\n\u003ch3\u003e What ingredients does Codex contain?\u003c\/h3\u003e\n\n\u003cp\u003e Codex contains:\n\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eSaccharomyces boulardii\u003c\/strong\u003e : 5 billion live cells per capsule, for targeted support of the intestinal flora.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eExcipients\u003c\/strong\u003e : gelatin (for the capsule), silicon dioxide, magnesium stearate.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Warnings\u003c\/h2\u003e\n\n\u003ch3\u003e What are the Codex warnings?\u003c\/h3\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e Do not exceed the recommended daily dose.\u003c\/li\u003e\n\n\u003cli\u003e Keep out of reach of children under 3 years.\u003c\/li\u003e\n\n         \u003cli\u003eFood supplements should not be considered a substitute for a varied and balanced diet and a healthy lifestyle.\u003c\/li\u003e\n\n\u003cli\u003e Consult your doctor if you are pregnant or breastfeeding before using this product.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Expiry and storage\u003c\/h2\u003e\n\n\u003ch3\u003e What are the expiration and storage of Codex?\u003c\/h3\u003e\n\n\u003cp\u003e Store \u003cstrong\u003eCodex\u003c\/strong\u003e in a cool, dry place, away from heat and direct light. Check the expiry date on the package before use.\u003c\/p\u003e\n\n\n\u003ch2\u003e Format\u003c\/h2\u003e\n\n\u003cp\u003e Codex is available in \u003cstrong\u003eblister packs of 30 capsules\u003c\/strong\u003e of 250 mg, with 5 billion live cells per capsule.\u003c\/p\u003e\n\n","brand":"ZAMBON ITALIA Srl","offers":[{"title":"Default Title","offer_id":40207822585971,"sku":"029032087","price":24.18,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/zambon-italia-srl-codex-30-capsule-5-miliardi-250-mg-blister-farmacia-dottor-tili-1213792770.jpg?v=1767125410"},{"product_id":"lady-presteril-cotton-power-pocket-assorbenti-giorno-con-ali-ripiegati-promo-10-pezzi","title":"Lady Presteril Cotton Power Pocket Day Sanitary Pads With Folded Wings Promo 10 Pieces","description":"\u003cp\u003e\u003cstrong\u003eLady Presteril Cotton Power Day Pads\u003c\/strong\u003e are designed to offer protection and comfort during the day. Made with \u003cstrong\u003e100% natural cotton\u003c\/strong\u003e , these pads are particularly suitable for sensitive skin, offering optimal protection against irritation and discomfort. Thanks to the anatomical shape and side wings, Lady Presteril Cotton Power guarantees a secure hold, while the \u003cstrong\u003efolded Pocket\u003c\/strong\u003e format makes it extremely practical to take with you everywhere.\u003c\/p\u003e\n\n\n\u003ch2\u003e How to use\u003c\/h2\u003e\n\n\u003ch3\u003e How to use Lady Presteril Cotton Power Day Sanitary Pads?\u003c\/h3\u003e\n\n\u003cp\u003e Remove the pad from the package, open it and place it on the underwear, making sure the wings adhere to ensure a better seal. Change the pad as needed to maintain a feeling of freshness and protection throughout the day.\u003c\/p\u003e\n\n\n\u003ch2\u003e Ingredients\u003c\/h2\u003e\n\n\u003ch3\u003e What ingredients does Lady Presteril Cotton Power Day Sanitary Pads contain?\u003c\/h3\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e \n\u003cstrong\u003e100% natural cotton\u003c\/strong\u003e : breathable and hypoallergenic, ideal for delicate skin.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eAbsorbent layer\u003c\/strong\u003e with high absorption capacity for long-lasting protection.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eSide barriers\u003c\/strong\u003e to prevent lateral leaks.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Warnings\u003c\/h2\u003e\n\n\u003ch3\u003e What are the warnings for Lady Presteril Cotton Power Day Sanitary Pads?\u003c\/h3\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e Single use product, do not reuse.\u003c\/li\u003e\n\n\u003cli\u003e Store in a cool, dry place, away from heat sources.\u003c\/li\u003e\n\n\u003cli\u003e If irritation or allergic reactions occur, discontinue use and consult a doctor.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Expiry and storage\u003c\/h2\u003e\n\n\u003ch3\u003e What are the expiration dates and storage of Lady Presteril Cotton Power Day Sanitary Pads?\u003c\/h3\u003e\n\n\u003cp\u003e Store the pads in a dry and cool place, away from sources of humidity and heat, to ensure their effectiveness. It does not have a specific expiration date.\u003c\/p\u003e\n\n\n\u003ch2\u003e Format\u003c\/h2\u003e\n\n         \u003cp\u003eLady Presteril Cotton Power Day Sanitary Pads are available in the \u003cstrong\u003epromotional format of 10 pieces\u003c\/strong\u003e , folded for maximum practicality.\u003c\/p\u003e\n\n","brand":"CORMAN SpA","offers":[{"title":"Default Title","offer_id":40207822618739,"sku":"983674437","price":3.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/corman-spa-lady-presteril-cotton-power-pocket-assorbenti-giorno-con-ali-ripiegati-promo-10-pezzi-farmacia-dottor-tili-1213792762.webp?v=1767125438"},{"product_id":"lady-presteril-cotton-power-assorbenti-notte-pocket-con-ali-ripiegati-promo-10-pezzi","title":"Lady Presteril Cotton Power Night Sanitary Pads Pocket With Folded Wings Promo 10 Pieces","description":"\u003cp\u003e\u003cstrong\u003eLady Presteril Cotton Power Night Pads\u003c\/strong\u003e have been specially designed to ensure maximum protection and comfort during the night. Thanks to the \u003cstrong\u003e100% natural cotton\u003c\/strong\u003e composition, these pads are particularly suitable for sensitive skin, offering extra protection against irritation. The long-absorbency technology and the anatomical shape with wings ensure an excellent seal, guaranteeing safety even during sleep. The folded \"Pocket\" format offers maximum discretion and practicality.\u003c\/p\u003e\n\n\n\u003ch2\u003e How to use\u003c\/h2\u003e\n\n\u003ch3\u003e How to use Lady Presteril Cotton Power Night Sanitary Pads?\u003c\/h3\u003e\n\n\u003cp\u003e Open the pad from the folded package, remove the adhesive and place it firmly on the underwear. The side wings fit perfectly to offer greater security and prevent shifting during the night. Change the pad as needed to maintain a feeling of freshness and hygiene.\u003c\/p\u003e\n\n\n\u003ch2\u003e Ingredients\u003c\/h2\u003e \n\u003ch3\u003eWhat ingredients does Lady Presteril Cotton Power Night Sanitary Pads contain?\u003c\/h3\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003e100% Natural Cotton\u003c\/strong\u003e : Offers softness and breathability, ideal for sensitive skin.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eCentral absorbent layer\u003c\/strong\u003e : with extra capacity for long-lasting protection.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eSide barriers\u003c\/strong\u003e : to avoid leaks and ensure maximum safety.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Warnings\u003c\/h2\u003e\n\n\u003ch3\u003e What are the warnings for Lady Presteril Cotton Power Night Sanitary Pads?\u003c\/h3\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e Disposable absorbent, do not reuse.\u003c\/li\u003e\n\n\u003cli\u003e Store in a cool, dry place, away from heat sources.\u003c\/li\u003e\n\n\u003cli\u003e If irritation or allergies occur, discontinue use and consult a doctor.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Expiry and storage\u003c\/h2\u003e\n\n\u003ch3\u003e What are the expiration dates and storage of Lady Presteril Cotton Power Night Sanitary Pads?\u003c\/h3\u003e\n\n         \u003cp\u003eLady Presteril Cotton Power Night Sanitary Pads do not have a specific expiry date, but it is advisable to store them in a cool, dry place, away from sources of heat and humidity to ensure their freshness.\u003c\/p\u003e\n\n\n\u003ch2\u003e Format\u003c\/h2\u003e\n\n\u003cp\u003e Lady Presteril Cotton Power Night Sanitary Pads are available in the \u003cstrong\u003epromo format of 10 pieces\u003c\/strong\u003e with folded wings, ideal for use during the night hours.\u003c\/p\u003e\n\n","brand":"CORMAN SpA","offers":[{"title":"Default Title","offer_id":40207822717043,"sku":"926427461","price":3.71,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/corman-spa-lady-presteril-cotton-power-assorbenti-notte-pocket-con-ali-ripiegati-promo-10-pezzi-farmacia-dottor-tili-1213792766.webp?v=1767125472"},{"product_id":"lady-presteril-cotton-power-proteggi-slip-pocket-anatomici-ripiegati-promo-24-pezzi","title":"Lady Presteril Cotton Power Pocket Anatomical Folded Slip Protectors Promo 24 Pieces","description":"\u003cp\u003e\u003cstrong\u003eLady Presteril Cotton Power Panty Liners\u003c\/strong\u003e are designed to offer protection and comfort throughout the day. Made with 100% \u003cstrong\u003enatural cotton\u003c\/strong\u003e , these panty liners are particularly suitable for sensitive skin, ensuring excellent breathability and a feeling of freshness. The \"Pocket Anatomical\" version offers an ergonomic shape that adapts perfectly to the body, while the folded format guarantees maximum practicality during travel.\u003c\/p\u003e\n\n\n\u003ch2\u003e How to use\u003c\/h2\u003e\n\n\u003ch3\u003e How to use Lady Presteril Cotton Power Panty Liner?\u003c\/h3\u003e\n\n\u003cp\u003e Remove the single panty liner from the package, open it and place it on the underwear, making sure the side wings adhere well. Thanks to its anatomical shape, it follows the curves of the body without moving, ensuring discreet protection throughout the day. Change the panty liner as needed to maintain freshness and hygiene.\u003c\/p\u003e\n\n\n\u003ch2\u003e Ingredients\u003c\/h2\u003e\n\n         \u003ch3\u003eWhat ingredients does Lady Presteril Cotton Power Panty Liner contain?\u003c\/h3\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003e100% natural cotton\u003c\/strong\u003e : guarantees softness and breathability.\u003c\/li\u003e\n\n\u003cli\u003e Internal absorbent layer with high absorption capacity.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eBreathable film\u003c\/strong\u003e on the bottom to avoid irritation.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Warnings\u003c\/h2\u003e\n\n\u003ch3\u003e What are the warnings of Lady Presteril Cotton Power Panty Liner?\u003c\/h3\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e Single use product, do not reuse.\u003c\/li\u003e\n\n\u003cli\u003e Store in a cool, dry place, away from heat sources.\u003c\/li\u003e\n\n\u003cli\u003e If irritation or allergies occur, discontinue use and consult a doctor.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Expiry and storage\u003c\/h2\u003e\n\n\u003ch3\u003e What are the expiration dates and storage of Lady Presteril Cotton Power Panty Liner?\u003c\/h3\u003e\n\n\u003cp\u003e Lady Presteril Cotton Power Panty Liners do not have a specific expiry date, but it is advisable to store them in a cool, dry place, away from sources of humidity and heat.\u003c\/p\u003e\n\n\n\u003ch2\u003e Format\u003c\/h2\u003e\n\n         \u003cp\u003eLady Presteril Cotton Power Panty Liner is available in the \u003cstrong\u003epromotional format of 24 pieces\u003c\/strong\u003e , ideal for prolonged daily use.\u003c\/p\u003e\n\n","brand":"CORMAN SpA","offers":[{"title":"Default Title","offer_id":40207822749811,"sku":"926427497","price":3.71,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/corman-spa-lady-presteril-cotton-power-proteggi-slip-pocket-anatomici-ripiegati-promo-24-pezzi-farmacia-dottor-tili-1213792769.webp?v=1767125556"},{"product_id":"elmex-protezione-carie-dentifricio-fluoruro-amminico-2-x-75-ml","title":"Elmex Cavity Protection Amine Fluoride Toothpaste 2 x 75 ml","description":"\u003cp\u003e\u003cstrong\u003eElmex Cavity Protection\u003c\/strong\u003e is a toothpaste formulated with \u003cstrong\u003eamine fluoride\u003c\/strong\u003e , a highly effective active ingredient in protecting against cavities. Amine fluoride creates a long-lasting protective layer on the teeth, which strengthens the enamel and remineralises demineralised areas, making the teeth more resistant to acid attack. Thanks to its advanced formula, Elmex Cavity Protection is suitable for daily use and helps maintain a healthy and protected mouth over time.\u003c\/p\u003e\n\n\n\u003ch2\u003e How to use\u003c\/h2\u003e\n\n\u003ch3\u003e How to use Elmex Cavity Protection Toothpaste?\u003c\/h3\u003e\n\n\u003cp\u003e For best results, we recommend brushing your teeth with \u003cstrong\u003eElmex Cavity Protection\u003c\/strong\u003e at least twice a day or as directed by your dentist. Gently brush your teeth for at least 2 minutes, making sure to reach all tooth surfaces. Do not swallow. Rinse with water after use.\u003c\/p\u003e\n\n\n\u003ch2\u003e Ingredients\u003c\/h2\u003e\n\n\u003ch3\u003e What ingredients does Elmex Cavity Protection contain?\u003c\/h3\u003e\n\n         \u003cp\u003eElmex Cavity Protection contains:\n\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eAmine Fluoride\u003c\/strong\u003e : 1400 ppm, which helps prevent tooth decay and strengthen enamel.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eHydrated silica\u003c\/strong\u003e : for effective, yet gentle cleaning.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eWater\u003c\/strong\u003e , \u003cstrong\u003eGlycerin\u003c\/strong\u003e , \u003cstrong\u003eSorbitol\u003c\/strong\u003e , and other excipients.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Warnings\u003c\/h2\u003e\n\n\u003ch3\u003e What are the warnings for Elmex Cavity Protection Toothpaste?\u003c\/h3\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e Not suitable for children under 6 years of age unless otherwise directed by a dentist.\u003c\/li\u003e\n\n\u003cli\u003e If you take fluoride from other sources, consult your dentist or doctor.\u003c\/li\u003e\n\n\u003cli\u003e Avoid ingesting the product.\u003c\/li\u003e\n\n\u003cli\u003e Keep out of reach of children.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Expiry and storage\u003c\/h2\u003e\n\n\u003ch3\u003e What are the expiry dates and storage of Elmex Cavity Protection?\u003c\/h3\u003e\n\n         \u003cp\u003eStore \u003cstrong\u003eElmex Cavity Protection\u003c\/strong\u003e in a cool, dry place, at room temperature, away from heat sources. Check the expiry date on the package and do not use the product beyond that date.\u003c\/p\u003e\n\n\n\u003ch2\u003e Format\u003c\/h2\u003e\n\n\u003cp\u003e Elmex Cavity Protection is available in the format of \u003cstrong\u003e2 tubes of 75 ml\u003c\/strong\u003e each, ideal for prolonged and continuous use.\u003c\/p\u003e\n\n","brand":"COLGATE-PALMOLIVE COMMERC.Srl","offers":[{"title":"Default Title","offer_id":40207822848115,"sku":"973145889","price":7.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/colgate-palmolive-commerc-srl-elmex-protezione-carie-dentifricio-fluoruro-amminico-2-x-75-ml-farmacia-dottor-tili-1213792768.jpg?v=1767125542"},{"product_id":"dicloreum-antinfiammatorio-locale-10-cerotti-medicati-180-mg","title":"Dicloreum Local Anti-inflammatory 10 Medicated Patches 180 mg","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eDicloreum Local Anti-Inflammatory\u003c\/span\u003e \u003cspan\u003eis a medicated patch based on\u003c\/span\u003e \u003cspan\u003ediclofenac sodium\u003c\/span\u003e \u003cspan\u003e(180 mg per patch) indicated for the local treatment of pain and inflammation. It is particularly effective in the treatment of muscle and joint pain of traumatic or rheumatic origin, such as strains, bruises, sprains or tendonitis. The patches gradually release the active ingredient directly on the affected area, offering a prolonged anti-inflammatory and analgesic action.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Dicloreum Local Anti-Inflammatory 10 Medicated Patches 180mg - What is the active ingredient in Dicloreum Local Anti-Inflammatory 10 Medicated Patches 180mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eOne 180 mg medicated plaster contains: Diclofenac hydroxyethylpyrrolidine 180 mg (equivalent to 140 mg of Diclofenac sodium). Excipients with known effect: 14 mg of methyl parahydroxybenzoate (E218), 7 mg of propyl parahydroxybenzoate (E216), 420 mg of propylene glycol and 2.8 mg of perfume (containing amyl cinnamal, amyl cinnamyl alcohol, benzyl alcohol, benzyl benzoate, benzyl salicylate, cinnamal, cinnamyl alcohol, citronellol, d-Limonene, eugenol, farnesol, geraniol, hexyl cinnamic aldehyde, hydroxycitronellal, isoeugenol, linalool, methyl heptine carbonate). For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Dicloreum Local Anti-inflammatory 10 Medicated Patches 180 mg - What does Dicloreum Local Anti-inflammatory 10 Medicated Patches 180 mg contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eGelatin, povidone, D-Sorbitol 70% solution, kaolin, titanium dioxide, propylene glycol, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), disodium edetate, tartaric acid, dihydroxyaluminium aminoacetate, sodium carmel, sodium polyacrylate, 1,3-butylene glycol, polysorbate 80, perfume, purified water, synthetic felt, plastic film.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Dicloreum Local Anti-inflammatory 10 Medicated Patches 180mg - Why is Dicloreum Local Anti-inflammatory 10 Medicated Patches 180 mg used? What is it for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eLocal treatment of painful and inflammatory conditions of rheumatic or traumatic nature of joints, muscles, tendons and ligaments.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Dicloreum Local Anti-Inflammatory 10 Medicated Patches 180mg - When should Dicloreum Local Anti-Inflammatory 10 Medicated Patches 180mg not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eHypersensitivity to diclofenac, acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs (NSAIDs) or to any of the excipients of the finished product, as well as to isopropanol. Patients who have experienced asthmatic attacks, urticaria or acute rhinitis after taking acetylsalicylic acid or other nonsteroidal inflammatory drugs (NSAIDs). Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns or wounds. Third trimester of pregnancy and breastfeeding (see section 4.6). Patients with active peptic ulcer. Children and adolescents: use in children and adolescents under 16 years of age is contraindicated.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Dicloreum Local Anti-Inflammatory 10 Medicated Patches 180mg - How do you take Dicloreum Local Anti-Inflammatory 10 Medicated Patches 180mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eFor cutaneous use only. Dosage: The product should only be applied to intact, healthy skin and should not be applied while bathing or showering. Diclofenac medicated plaster should be used for the shortest possible time in relation to the indication for use. Adults: The usual dosage regimen is 1 or 2 patches (or any other frequency evaluated in clinical trials for a specific product) per day (one application every 12 or 24 hours) for up to 14 days (or any other number of days evaluated in clinical trials for a specific product). If no improvement is seen following the recommended treatment period, a doctor should be consulted. Children and adolescents under 16 years: The use of this medicated plaster is not recommended in children and adolescents under 16 years of age because there are insufficient data to evaluate the safety and efficacy of the medicinal product (see section 4.3). In adolescents aged 16 years and over, if the product is required for a treatment period longer than 7 days for pain relief or if symptoms worsen, the patient or the adolescent's relatives are advised to consult a doctor. Elderly: This medicinal product should be used with caution in elderly patients as they are more susceptible to side effects (see section 4.4). Patients with hepatic or renal insufficiency. For the use of diclofenac medicated plasters in patients with hepatic or renal insufficiency, see section 4.4. Method of administration: Cut the sachet containing the medicated plaster as indicated. Take out a medicated plaster, remove the plastic film used to protect the adhesive surface and apply the plaster to the joint on the painful area. If necessary, the plaster can be held in place with an elastic band. Carefully close the sachet by pressing the edge where the drawstring is located. The plaster must be used whole.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Dicloreum Local Anti-Inflammatory 10 Medicated Patches 180mg - How do you store Dicloreum Local Anti-Inflammatory 10 Medicated Patches 180mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eStore at a temperature not exceeding 30 degrees C.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Dicloreum Local Anti-inflammatory 10 Medicated Patches 180mg - About Dicloreum Local Anti-inflammatory 10 Medicated Patches 180mg it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIf diclofenac medicated plasters are used on large areas of skin and for a prolonged period of time, the possibility of systemic adverse events cannot be excluded (see the Summary of Product Characteristics of the systemic formulations of diclofenac). The medicated plaster should only be applied to intact, healthy skin and should not be applied to broken skin or open wounds. The plasters should not come into contact with the eyes or mucous membranes. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms. Do not use with an occlusive dressing that does not allow air to pass through. Treatment should be discontinued immediately if a skin rash develops after application of the medicated plaster. Do not administer another medicinal product containing diclofenac or other NSAIDs topically or systemically at the same time. Although systemic effects should be limited, the medicated plaster should be used with caution in patients with renal, cardiac or hepatic impairment, history of peptic ulcer or inflammatory bowel disease or haemorrhagic diathesis. Nonsteroidal anti-inflammatory drugs should be used with particular caution in elderly patients who are more predisposed to adverse effects. Patients should be advised not to expose themselves to direct sunlight or sun lamps for approximately one day after removal of the medicated plaster in order to reduce the risk of photosensitivity. Dicloreum local anti-inflammatory contains: methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed). 420 mg of propylene glycol per patch which may cause skin irritation; a perfume containing in turn allergens (amyl cinnamal, amyl cinnamyl alcohol, benzyl alcohol, benzyl benzoate, benzyl salicylate, cinnamal, cinnamyl alcohol, citronellol, d-Limonene, eugenol, farnesol, geraniol, hexyl cinnamic aldehyde, hydroxycitronellal, isoeugenol, linalool, methyl heptine carbonate) which can cause allergic reactions.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Dicloreum Local Anti-inflammatory 10 Medicated Patches 180mg - Which medicines or foods can modify the effect of Dicloreum Local Anti-inflammatory 10 Medicated Patches 180 mg?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eSince systemic absorption of diclofenac following the use of medicated plasters is very low, the risk of developing clinically significant interactions with other medicinal products is negligible.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Dicloreum Antinflammatory Locale 10 Medicated Patches 180 mg can cause side effects - What are the side effects of Dicloreum Antinflammatory Locale 10 Medicated Patches 180 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eAdverse reactions are listed by frequency, the most frequent first, using the following convention: common (\u0026gt;= 1\/100, \u0026lt; 1\/10); uncommon (\u0026gt;= 1\/1,000, \u0026lt; 1\/100); rare (\u0026gt;= 1\/10,000, \u0026lt; 1\/1,000); very rare (\u0026lt; 1\/10,000); Not known: cannot be estimated from the available data. Infections and infestations. Very rare: rash with pustules. Immune system disorders. Very rare: hypersensitivity (including urticaria), angioneurotic oedema, anaphylactoid reaction. Respiratory, thoracic and mediastinal disorders. Very rare: asthma. Skin and subcutaneous tissue disorders. Common: rash, eczema, erythema, dermatitis (including allergic dermatitis and contact dermatitis), pruritus; rare: bullous dermatitis (e.g. erythema bullosum), dry skin; very rare: photosensitivity reactions. General disorders and administration site conditions. Common: administration site reactions. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Dicloreum Local Anti-inflammatory 10 Medicated Patches 180 mg\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003ePregnancy: The systemic concentration of diclofenac, compared to oral formulations, is lower after topical administration. Based on the experience of treatment with systemically administered NSAIDs, the following is recommended: Inhibition of prostaglandin synthesis may adversely affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increases from less than 1%, up to approximately 1.5%. The risk was considered to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be given unless clearly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction, which may progress to renal failure with oligo-hydroamniosis; the mother and neonate, at the end of pregnancy, to: possible prolongation of bleeding time, and an anti-aggregating effect which may occur even at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. Breastfeeding: Like other NSAIDs, diclofenac passes into breast milk in small amounts. However, at therapeutic doses of diclofenac medicated plasters, no effects on the infant are anticipated. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, diclofenac medicated plasters should not be applied to the breasts of nursing mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4).\u003c\/span\u003e\u003c\/p\u003e","brand":"ALFASIGMA SpA","offers":[{"title":"Default Title","offer_id":40207822913651,"sku":"042685014","price":23.81,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/alfasigma-spa-dicloreum-antinfiammatorio-locale-10-cerotti-medicati-180-mg-farmacia-dottor-tili-1213792767.jpg?v=1767125528"},{"product_id":"benagol-miele-e-limone-36-pastiglie-mal-di-gola","title":"Benagol Honey and Lemon 36 Tablets Sore Throat","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBenagol Pastiglie is an oral antiseptic useful for\u003c\/span\u003e \u003cspan\u003esoothing throat inflammation\u003c\/span\u003e \u003cspan\u003eand in cases of\u003c\/span\u003e \u003cspan\u003ecold-related illnesses of the upper respiratory tract\u003c\/span\u003e \u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Benagol Honey and Lemon 36 Sore Throat Lozenges - What is the active ingredient in Benagol Honey and Lemon 36 Sore Throat Lozenges?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eBenagol Ginger and Spice flavoured lozenges. Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), spice flavouring and ginger flavouring (containing cinnamal, citral, citronellol, eugenol, farnesol, geraniol, isoeugenol and linalool). Benagol Honey and Lemon flavoured lozenges. Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid glucose (containing sulphites and wheat starch), liquid sucrose, mint essence and lemon essence (containing citral, d-limonene, geraniol and linalool), honey (invert sugar). Benagol Lemon Flavor Sugar Free Lozenges. Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid maltitol, isomalt, lemon flavoring (containing benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool). Benagol Strawberry Flavor Sugar Free Lozenges. Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid maltitol, isomalt, strawberry flavoring (containing propylene glycol and benzyl alcohol). Benagol Cold Mint Flavor Lozenges. Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), mint flavour and eucalyptus essence (containing propylene glycol, benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool). Benagol Pastilles Menthol-Eucalyptus flavour. Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg; menthol 8.0 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch) and eucalyptus essence (containing d-limonene). Benagol Pastilles with Vitamin C Orange flavour. Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg; sodium ascorbate 74.9 mg; ascorbic acid 33.5 mg. Excipients with known effect: liquid sucrose, liquid glucose (containing sulphites and wheat starch), orange flavour (containing citral, citronellol, d-limonene, geraniol, linalool), propylene glycol. For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Benagol Honey and Lemon 36 Sore Throat Lozenges - What does Benagol Honey and Lemon 36 Sore Throat Lozenges contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eBenagol Ginger and Spice Flavor Lozenges. One lozenge contains: liquid sucrose, liquid glucose (containing sulphites and wheat starch), tartaric acid, enocyanin (E163) (containing sodium), plum flavor, cream flavor, spice flavor and ginger flavor (containing cinnamal, citral, citronellol, eugenol, farnesol, geraniol, isoeugenol and linalool), medium chain saturated triglycerides. Benagol Honey and Lemon Flavor Lozenges. One lozenge contains: mint essence and lemon essence (containing citral, d-limonene, geraniol and linalool), tartaric acid, honey (invert sugar), liquid glucose (containing sulphites and wheat starch), liquid sucrose. Benagol Menthol-Eucalyptol Flavor Lozenges. One tablet contains: indigo carmine (E 132) (containing sodium), eucalyptus essence (containing d-limonene), tartaric acid, liquid sucrose, liquid glucose (containing sulphites and wheat starch). Benagol Orange flavoured lozenges with Vitamin C. One tablet contains: liquid sucrose, liquid glucose (containing sulphites and wheat starch), tartaric acid, orange flavouring (containing citral, citronellol, d-limonene, geraniol and linalool), levomenthol, propylene glycol. Benagol Lemon flavoured lozenges without sugar. One tablet contains: lemon flavouring (containing benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool), sodium saccharin, tartaric acid, liquid maltitol, isomalt. Benagol Strawberry flavoured lozenges without sugar. One lozenge contains: strawberry flavour (containing propylene glycol and benzyl alcohol), anthocyanins (E163) (containing sodium), sodium saccharin, tartaric acid, liquid maltitol, isomalt. Benagol Cold Mint flavour lozenges. One lozenge contains: xylitol, levomenthol, mint flavour and eucalyptus essence (containing propylene glycol, benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool), liquid sucrose, liquid glucose (containing sulphites and wheat starch).\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Benagol Honey and Lemon 36 Sore Throat Pastilles - Why is Benagol Honey and Lemon 36 Sore Throat Pastilles used? What is it for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eOral antiseptic.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Benagol Honey and Lemon 36 Sore Throat Lozenges - When should Benagol Honey and Lemon 36 Sore Throat Lozenges not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Do not administer to children under 6 years of age. Benagol Menthol-Eucalyptus flavour is contraindicated in children with a history of epilepsy or febrile convulsions. Do not administer Benagol Cold Mint flavour and Benagol Ginger and Spice flavour to children under 12 years of age.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eQuantity and method of taking Benagol Honey and Lemon 36 Sore Throat Lozenges - How to take Benagol Honey and Lemon 36 Sore Throat Lozenges?\u003c\/span\u003e\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eDosage: the lowest effective dose should be used for the shortest duration necessary to relieve symptoms. Adults and children over 6 years of age: one lozenge every 2 or 3 hours. In children over 6 years of age, consult your doctor for an appropriate dosage. Do not exceed the recommended doses and in particular, for Benagol with Vitamin C Orange flavour and Benagol Cold Mint flavour, do not exceed the maximum daily dose of 8 lozenges. For all other Benagol flavours, do not exceed the maximum daily dose of 12 lozenges. Administer Benagol Cold Mint flavour and Benagol Ginger and Spice flavour to adults and children over 12 years of age. The duration of treatment with Benagol Menthol-Eucalyptus flavour should not exceed 3 days. Benagol Lemon flavour Sugar Free and Benagol Strawberry flavour Sugar Free are suitable for those patients who need to control their sugar and calorie intake. Elderly population: no data are available. Method of administration: oromucosal administration. The tablet should be dissolved slowly in the mouth.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Benagol Honey and Lemon 36 Sore Throat Lozenges - How do you store Benagol Honey and Lemon 36 Sore Throat Lozenges?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eDo not store above 25 degrees C.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Benagol Honey and Lemon 36 Sore Throat Lozenges - About Benagol Honey and Lemon 36 Sore Throat Lozenges it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eBe careful with preschool children as if the tablets are swallowed whole they may cause choking. If sensitization or irritation occurs, administration should be stopped and appropriate treatment should be instituted. Benagol Menthol-Eucalyptus flavour contains terpene derivatives which, in excessive doses, may cause neurological disorders such as convulsions in infants and children. Treatment with Benagol Menthol-Eucalyptus flavour should not be prolonged for more than 3 days due to the risks associated with the accumulation of terpene derivatives, such as camphor, cineole, niaouli, wild thyme, terpineol, terpin, citral, menthol and essential oils of pine needles, eucalyptus and turpentine (due to their lipophilic properties the speed of metabolism and disposal is unknown) in the tissues and brain, in particular neuropsychological disorders. A higher dose than recommended should not be used to avoid a higher risk of adverse reactions to the medicinal product and disorders associated with overdose (see section 4.9). Benagol Menthol-Eucalyptus flavour is flammable, it should not be brought close to flames. Important information about some of the excipients. Benagol Ginger and Spice flavour Lozenges, Benagol Honey and Lemon flavour Lozenges, Benagol Menthol-Eucalyptus flavour Lozenges, Benagol Orange flavour Lozenges with Vitamin C, Benagol Cold Mint flavour Lozenges contain liquid Glucose: patients with rare hereditary problems of glucose-galactose malabsorption should not take this medicine. To be taken into consideration in people with diabetes mellitus: Benagol Ginger and Spice flavour Lozenges contain 1.10 g of glucose per lozenge; Benagol Honey and Lemon flavour Lozenges contain 0.98 g of glucose per lozenge; Benagol Pastilles Menthol-Eucalyptus flavour contains 1.01 g of glucose per lozenge; Benagol Pastilles with Vitamin C Orange flavour contains 0.97 g of glucose per lozenge; Benagol Pastilles Cold Mint flavour contains 1.10 g of glucose per lozenge; the liquid glucose contains sulphites. These medicines can rarely cause serious hypersensitivity reactions and bronchospasm; the liquid glucose contains wheat starch. These medicines contain only a very small amount of gluten (from wheat starch). These medicines are considered \"gluten-free\" and are very unlikely to cause problems if the patient is coeliac. One lozenge of Benagol Pastilles Ginger and Spice flavour contains no more than 22.04 micrograms of gluten. One lozenge of Benagol Pastilles Honey and Lemon flavour contains no more than 19.52 micrograms of gluten. One Benagol Menthol-Eucalyptus flavour lozenge contains no more than 20.26 micrograms of gluten. One Benagol Pastiglie with Vitamin C Orange flavour lozenge contains no more than 19.38 micrograms of gluten. One Benagol Pastiglie Cold Mint flavour lozenge contains no more than 22.04 micrograms of gluten. If the patient is allergic to wheat (other than coeliac disease) he\/she should not take these medicines. Liquid sucrose: patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should not take this medicine. To be taken into consideration in people with diabetes mellitus: Benagol Pastiglie Ginger and Spice flavour contains 1.38 g of sucrose per lozenge; Benagol Pastiglie Honey and Lemon flavour contains 1.44 g of sucrose per lozenge; Benagol Menthol-Eucalyptus flavour lozenges contain 1.50 g of sucrose per lozenge; Benagol Orange flavour lozenges with Vitamin C contain 1.44 g of sucrose per lozenge; Benagol Cold Mint flavour lozenges contain 1.38 g of sucrose per lozenge. Benagol Ginger and Spice flavour lozenges, Benagol Menthol-Eucalyptus flavour lozenges, Benagol Orange flavour lozenges with Vitamin C, Benagol Lemon flavour lozenges Sugar Free, Benagol Strawberry flavour lozenges Sugar Free: these medicines contain less than 1 mmol sodium (23 mg) per dose, that is to say essentially \"sodium-free\". Benagol Lemon flavour lozenges Sugar Free and Benagol Strawberry flavour lozenges Sugar Free: these medicines contain liquid maltitol and isomalt. Patients with rare hereditary problems of fructose intolerance should not take this medicine. They may have a mild laxative effect. The caloric value of maltitol and isomalt is 2.3 kcal\/g. Benagol Pastilles Ginger and Spice flavour: this medicine contains a flavouring containing cinnamal, citral, citronellol, eugenol, farnesol, geraniol, isoeugenol and linalool. Cinnamal, citral, citronellol, eugenol, farnesol, geraniol, isoeugenol and linalool may cause allergic reactions. This medicine contains excipients that can induce a sensation of heat in the mouth and throat when sucking the lozenge. Benagol Pastilles Honey and Lemon flavour: this medicine contains a flavouring containing citral, d-limonene, geraniol and linalool. Citral, d-limonene, geraniol and linalool may cause allergic reactions. This medicinal product contains honey (invert sugar). Patients with rare hereditary problems of fructose intolerance or glucose-galactose malabsorption should not take this medicine. Benagol Pastilles Menthol-Eucalyptol flavour: this medicinal product contains a flavouring containing d-limonene. D-limonene may cause allergic reactions. Benagol Pastilles with Vitamin C Orange flavour: this medicinal product contains a flavouring containing citral, citronellol, d-limonene, geraniol and linalool. Citral, citronellol, d-limonene, geraniol and linalool may cause allergic reactions. This medicinal product contains 3 mg of propylene glycol per lozenge. Benagol Lemon Flavor Sugar Free Lozenges: This medicine contains a flavoring containing benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool. Benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool may cause allergic reactions. Benagol Strawberry Flavor Sugar Free Lozenges: This medicine contains a flavoring containing benzyl alcohol. Benzyl alcohol may cause allergic reactions. This medicine contains 7.30 mg of propylene glycol in each lozenge. Benagol Cold Mint Flavor Lozenges: This medicine contains a flavoring containing benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool. Benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool may cause allergic reactions. This medicine contains 1.89 mg propylene glycol in each lozenge.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Benagol Honey and Lemon 36 Sore Throat Pastilles - Which medicines or foods can modify the effect of Benagol Honey and Lemon 36 Sore Throat Pastilles?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eNo interactions with other drugs are known. Benagol Menthol-Eucalyptus flavour should not be used in conjunction with other products (medicines or cosmetics) containing terpene derivatives, regardless of the route of administration (oral, rectal, cutaneous, nasal or inhalation).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Benagol Honey and Lemon 36 Pastiglie Mal di Gola can cause side effects - What are the side effects of Benagol Honey and Lemon 36 Pastiglie Mal di Gola?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eBenagol flavour Menthol. Eucalyptol: due to the presence of menthol and in case of non-compliance with the recommended doses, a risk of convulsions may occur in children and infants. Adverse reactions associated with the use of 2,4 dichlorobenzyl alcohol, amylmetacresol, levomenthol and ascorbic acid are listed below, divided by frequency and organ class. The frequencies are defined as: very common (\u0026gt;=1\/10); common (\u0026gt;=1\/100 and \u0026lt;1\/10); uncommon (\u0026gt;=1\/1000 and \u0026lt;1\/100); rare (\u0026gt;=1\/10000 and \u0026lt;1\/1000); very rare (\u0026lt;1\/10000); not known (frequency cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in decreasing order of seriousness. Immune system disorders. Rare: hypersensitivity. Gastrointestinal disorders. Rare: glossitis; not known: abdominal pain, nausea, gastrointestinal discomfort. Skin and subcutaneous tissue disorders. Not known: rash.Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Benagol Honey and Lemon 36 Tablets Sore Throat\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIn pregnant women and during breastfeeding, the product should be administered only in case of real need. Pregnancy: there are no, or limited, data on the use of the active ingredients of Benagol in pregnant women. Benagol Menthol-Eucalyptus flavour is not recommended during pregnancy and in women of childbearing age who do not use contraceptive measures. Breastfeeding: it is not known whether the active ingredients or their metabolites are excreted in breast milk. A risk for newborns and infants cannot be excluded. Ascorbic acid or its metabolites are excreted in breast milk. Fertility: no data on fertility are available. Benagol Menthol-Eucalyptus flavour is not recommended in women of childbearing age who do not use contraceptive measures.\u003c\/span\u003e\u003c\/p\u003e","brand":"RECKITT BENCKISER H.(IT.) SpA","offers":[{"title":"Default Title","offer_id":40207822946419,"sku":"016242149","price":15.72,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/reckitt-benckiser-h-it-spa-benagol-miele-e-limone-36-pastiglie-mal-di-gola-farmacia-dottor-tili-1213792763.webp?v=1767125572"},{"product_id":"moment-200mg-analgesico-36-compresse-rivestite","title":"Moment 200mg Analgesic 36 Coated Tablets","description":"\u003cp\u003eMoment 200 mg 36 Coated Tablets is an over-the-counter drug without a prescription based on ibuprofen, \u003cstrong\u003ean analgesic, anti-inflammatory and antipyretic molecule\u003c\/strong\u003e . Moment 36 Tablets is indicated for the treatment of \u003cstrong\u003epain of various origins and natures\u003c\/strong\u003e such as: \u003cstrong\u003eheadache, toothache\u003c\/strong\u003e , \u003cstrong\u003eneuralgia\u003c\/strong\u003e , \u003cstrong\u003eosteoarticular and muscular pain, menstrual pain\u003c\/strong\u003e .\u003c\/p\u003e\n\n\u003cp\u003e The \u003cstrong\u003eantipyretic action\u003c\/strong\u003e of ibuprofen in Moment 36 Tablets \u003cstrong\u003elowers temperature\u003c\/strong\u003e and contributes to the symptomatic treatment of feverish and flu-like conditions.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Moment 200mg Analgesic 36 Coated Tablets - What is the active ingredient in Moment 200mg Analgesic 36 Coated Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eEach coated tablet contains active substance: ibuprofen 200 mg. Excipients with known effect: sucrose, sodium. For a full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n \u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Moment 200mg Analgesic 36 Coated Tablets - What does Moment 200mg Analgesic 36 Coated Tablets contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eEach tablet contains: maize starch, sodium starch glycolate, povidone, colloidal anhydrous silica, talc, hydroxypropylcellulose, gum arabic, sucrose, macrogol 6000, light magnesium carbonate, titanium dioxide.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Moment 200 Mg Ibuprofen 12 Coated Tablets - Why is Moment 200mg Analgesic 36 Coated Tablets used? What is it used for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003ePain of various origins and natures (headache, toothache, neuralgia, osteo-articular and muscular pain, menstrual pain). Adjuvant in the symptomatic treatment of feverish and flu states.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eContraindications Moment 200mg Analgesic 36 Coated Tablets - When should Moment 200mg Analgesic 36 Coated Tablets not be used?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eHypersensitivity to the active substance, to other antirheumatics (acetylsalicylic acid, etc.) or to any of the excipients listed in section 6.1; children under 12 years of age; third trimester of pregnancy and breastfeeding (see section 4.6); active or severe gastroduodenal ulcer or other gastropathies; history of gastrointestinal bleeding or perforation related to previous active treatments or history of recurrent peptic ulcer\/haemorrhage (two or more distinct episodes of proven ulceration or bleeding); severe hepatic or renal insufficiency; severe cardiac insufficiency (NYHA class IV); severe dehydration (caused by vomiting, diarrhoea or insufficient fluid intake).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eQuantity and method of taking Moment 200mg Analgesic 36 Coated Tablets - How to take Moment 200 Mg Ibuprofen 12 Coated Tablets?\u003c\/span\u003e\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eDosage, adults and adolescents over 12 years: 1-2 tablets, 2-3 times a day. Do not exceed the dose of 1200 mg (6 tablets) per day. If the use of the medicinal product is necessary for more than 3 days in adolescents aged 12 years and over, or in case of worsening of symptoms, a doctor should be consulted. Do not exceed the recommended doses. Elderly patients should adhere to the minimum dosages indicated above (see section 4.4). Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). Renal impairment: in patients with mild or moderate reduction of renal function, the dosage should be kept as low as possible for the shortest duration necessary to control symptoms and renal function should be monitored. Hepatic impairment: In patients with mild or moderate reduction of liver function, the dosage should be kept as low as possible for the shortest duration necessary to control symptoms and liver function should be monitored. Moment is contraindicated in patients with severe hepatic impairment (see section 4.3). Paediatric population: Moment is contraindicated in children under 12 years of age (see section 4.3). Method of administration: Moment can be taken on an empty stomach. In subjects with gastric tolerability problems, it is preferable to take the medicine on a full stomach.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Moment 200mg Analgesic 36 Coated Tablets - How to store Moment 200mg Analgesic 36 Coated Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThis medicine does not require any special storage temperatures.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Moment 200mg Analgesic 36 Coated Tablets - About Moment 200mg Analgesic 36 Coated Tablets it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIn asthmatic patients the product should be used with caution, following medical evaluation. The use of Moment, as with any drug inhibiting the synthesis of prostaglandins and cyclooxygenase is not recommended in women who intend to become pregnant. The administration of Moment should be suspended in women who have fertility problems or who are undergoing investigation of fertility. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see paragraphs below on gastrointestinal and cardiovascular risks). Elderly: elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal (see section 4.2). Cardiovascular and cerebrovascular effects Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day), may be associated with a modest increased risk of arterial thrombotic events (e.g. myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low doses of ibuprofen (e.g. \u0026lt;= 1200 mg\/day) are associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III), established ischaemic heart disease, peripheral arterial disease, and\/or cerebrovascular disease should only be treated with ibuprofen after careful consideration and high doses (2400 mg\/day) should be avoided. Careful consideration should also be exercised before initiating long-term treatment of patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking), particularly if high doses (2400 mg\/day) of ibuprofen are required. Caution is advised before initiating treatment in patients with a history of hypertension and\/or heart failure since fluid retention, hypertension and oedema have been reported in association with NSAID therapy. NSAIDs may reduce the effect of diuretics, unlike other antihypertensive agents (see section 4.5). Gastrointestinal bleeding, ulceration and perforation: the use of Moment should be avoided in combination with NSAIDs, including selective cyclooxygenase-2 (COX-2) inhibitors due to an increased risk of ulceration and bleeding (see section 4.5). Gastrointestinal bleeding, ulceration and perforation, which may be fatal, have been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious GI events. The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in the elderly and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3). These patients should start treatment on the lowest dose available. Concomitant use of protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients taking low dose aspirin or other drugs likely to increase GI risk (see below and section 4.5). Patients with a history of GI toxicity, particularly when elderly, should report any unusual GI symptoms (especially GI bleeding) particularly in the initial stages of treatment. Carefully monitor patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or anti-platelet agents such as aspirin (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients receiving Moment, the treatment should be withdrawn. NSAIDs should be given with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Renal effects: Caution should be exercised in patients with considerable dehydration when initiating treatment with ibuprofen. Ibuprofen may cause water, sodium and potassium retention in patients with no history of renal disease due to its effects on renal perfusion. This may lead to oedema or cardiac failure or hypertension in predisposed patients. Long-term use of ibuprofen, as with other NSAIDs, has led to renal papillary necrosis and other pathological renal changes. In general, the habitual use of analgesics, especially combinations of several analgesic active ingredients, can lead to permanent renal damage, with risk of onset of renal failure (analgesic nephropathy). Renal toxicity has been observed in patients in whom renal prostaglandins have a compensatory role in maintaining renal perfusion. The administration of NSAIDs in these patients may lead to a dose-dependent reduction in prostaglandin formation and, as a secondary effect, renal blood flow which can quickly lead to renal failure. Patients most at risk of these reactions are those with reduced renal function, heart failure, liver dysfunction, the elderly and all those patients taking diuretics and ACE inhibitors. Discontinuation of NSAID therapy is usually followed by recovery to the pre-treatment state. There is a risk of impaired renal function in dehydrated adolescents. In case of prolonged use, renal function should be monitored, particularly in cases of diffuse lupus erythematosus. Severe skin reactions: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at highest risk early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first month of treatment. Acute generalized exanthematous pustulosis (AGEP) has been reported in relation to medicinal products containing ibuprofen.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Moment 200mg Analgesic 36 Coated Tablets - Which medicines or foods can modify the effect of Moment 200mg Analgesic 36 Coated Tablets?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIbuprofen (like other NSAIDs) should be used with caution in combination with the substances listed below. Corticosteroids: increased risk of gastrointestinal ulceration or bleeding (see section 4.4). Anticoagulants: NSAIDs may increase the effects of anticoagulants, such as warfarin or heparin (see section 4.4). In case of concomitant treatment, monitoring of the coagulation status is recommended. Acetylsalicylic acid: concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased adverse effects. Experimental data suggest that ibuprofen may competitively inhibit platelet aggregation with low dose acetylsalicylic acid when the two drugs are administered concomitantly. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No clinically relevant effect is considered likely following occasional use of ibuprofen (see section 5.1). Cyclooxygenase-2 (COX-2) inhibitors and other NSAIDs: These substances may increase the risk of adverse reactions affecting the gastrointestinal tract (see section 4.4). However, it is advisable not to combine ibuprofen with acetylsalicylic acid or other NSAIDs, including selective COX-2 inhibitors, due to the potential additive effect (see section 4.4). Anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs): Increased risk of gastrointestinal bleeding (see section 4.4). Diuretics, ACE inhibitors (such as captopril), beta blockers and angiotensin II antagonists: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. Diuretics may also increase the risk of nephrotoxicity associated with NSAIDs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit cyclooxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking Moment concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and thereafter. Phenytoin and lithium: Concomitant administration of ibuprofen and phenytoin or lithium preparations may result in reduced elimination of these drugs with consequent increase in their plasma levels with the possibility of reaching the toxic threshold. If this combination is deemed necessary, monitoring of plasma levels of phenytoin and lithium is recommended in order to adapt the dosage during concomitant treatment with ibuprofen. Methotrexate: NSAIDs may inhibit the tubular secretion of methotrexate and some metabolic interactions may occur resulting in reduced methotrexate clearance and increased risk of toxicity. Moclobemide: increases ibuprofen. Aminoglycosides: NSAIDs may decrease the excretion of aminoglycosides increasing toxicity. Cardiac glycosides: NSAIDs may exacerbate cardiac failure, reduce the glomerular filtration rate and increase plasma levels of cardiac glycosides. Monitoring of serum glycoside levels is recommended. Cholestyramine: Concomitant administration of ibuprofen and cholestyramine may reduce the absorption of ibuprofen from the gastrointestinal tract. However, the clinical relevance of this interaction is unknown. Ciclosporin: Concomitant administration of ciclosporin and some NSAIDs causes an increased risk of renal damage. This effect cannot be excluded for the combination of ciclosporin and ibuprofen. Plant extracts: Ginkgo Biloba may increase the risk of bleeding in association with NSAIDs. Mifepristone: Due to the anti-prostaglandin properties of NSAIDs, their use after mifepristone administration may result in a reduction of mifepristone. Limited evidence suggests that co-administration of NSAIDs and prostaglandins on the same day does not adversely affect the effects of mifepristone or the prostaglandin on cervical ripening or uterine contractility and does not reduce the clinical efficacy of the medicinal product on pregnancy termination. Quinolone antibiotics: Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions. Sulfonylureas: NSAIDs may increase the hypoglycaemic effect of sulfonylureas. Monitoring of blood glucose levels is recommended in the case of simultaneous treatment. Tacrolimus: Co-administration of NSAIDs and tacrolimus may increase the risk of nephrotoxicity. Zidovudine: There is evidence of an increased risk of haemarthrosis and haematoma in HIV-positive haemophiliac patients receiving concomitant treatment with zidovudine and other NSAIDs. A blood test is recommended 1-2 weeks after starting treatment. Ritonavir: may cause an increase in plasma concentrations of NSAIDs. Probenecid: slows the excretion of ibuprofen, with possible increase in its plasma concentrations. CYP2C9 inhibitors: Concomitant administration of ibuprofen with CYP2C9 inhibitors may slow the elimination of ibuprofen (CYP2C9 substrate) resulting in increased exposure to ibuprofen. In a study with voriconazole and fluconazole (CYP2C9 inhibitors), an increased exposure to S(+)-ibuprofen of approximately 80% to 100% was observed. Consideration should be given to reducing the dose of ibuprofen when co-administered with strong CYP2C9 inhibitors, particularly when high doses of ibuprofen are administered with voriconazole or fluconazole. Alcohol, bisphosphonates and oxpentifylline (pentoxifylline): may enhance gastrointestinal side effects and the risk of bleeding and ulceration. Baclofen: high toxicity of baclofen.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Moment 200mg Analgesic 36 Coated Tablets can cause side effects - What are the side effects of Moment 200mg Analgesic 36 Coated Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe undesirable effects observed with ibuprofen are generally common to other analgesics, antipyretics, non-steroidal anti-inflammatory drugs and are reported below using the following convention: very common (\u0026gt;=1\/10); common (\u0026gt;=1\/100, \u0026lt; 1\/10); uncommon (\u0026gt;= 1\/ 1,000, \u0026lt; 1\/100); rare (\u0026gt;=1\/10,000, \u0026lt; 1\/1,000); very rare (\u0026lt;1\/10,000); not known (frequency cannot be estimated from the available data). The most commonly observed adverse events are gastrointestinal in nature. Gastrointestinal disorders: peptic ulcers, perforation or gastrointestinal bleeding, sometimes fatal, particularly in the elderly, may occur (see section 4.4). Gastrointestinal perforation with the use of ibuprofen has been observed rarely. After administration of Moment the following have been reported: feeling of heaviness in the stomach, nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, epigastric pain, heartburn, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4). Uncommon: gastritis; very rare: pancreatitis. Immune system disorders: following treatment with NSAIDs the following undesirable effects have been reported: non-specific allergic reaction and anaphylaxis; uncommon: hypersensitivity reactions such as various types of skin rash, urticaria, pruritus, purpura, angioedema, exanthema, respiratory tract reactions including bronchospasm, dyspnoea, asthmatic attack (sometimes with hypotension); rare: lupus erythematosus syndrome; very rare: severe hypersensitivity reactions. Symptoms may include: severe asthma, facial oedema, tongue oedema, laryngeal oedema, airway oedema with bronchospasm, dyspnoea, tachycardia, anaphylaxis, exfoliative and bullous dermatitis. Cardiac and vascular disorders: Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day), may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). Very rare: palpitations, heart failure, myocardial infarction, acute pulmonary oedema, hypertension. Other adverse events for which causality has not necessarily been established include: Blood and lymphatic system disorders: Rare: leucopenia, thrombocytopenia, neutropenia, agranulocytosis, aplastic anaemia and haemolytic anaemia, inhibition of platelet aggregation. Psychiatric disorders. Uncommon: insomnia, anxiety; rare: depression, confusional state, hallucinations. Nervous system disorders. Common: dizziness; uncommon: paraesthesia, somnolence, rare: optic neuritis. Infections and infestations. Uncommon: rhinitis; rare: aseptic meningitis. Rhinitis and aseptic meningitis have been observed especially in patients with pre-existing autoimmune disorders (such as systemic lupus erythematosus and mixed connective tissue disease) with symptoms of stiff neck, headache, nausea, vomiting, fever or disorientation (see section 4.4). Exacerbation of infection-related inflammation (e.g. development of necrotising fasciitis) has been described. Respiratory, thoracic and mediastinal disorders. Uncommon: bronchospasm, dyspnoea, apnoea. Eye disorders. Uncommon: visual disturbances; rare: ocular impairment resulting in visual disturbances, toxic optic neuropathy. Ear and labyrinth disorders. Uncommon: impaired hearing, tinnitus, vertigo. Hepatobiliary disorders. Uncommon: abnormal liver function, hepatitis and jaundice; very rare: liver failure. Skin and subcutaneous tissue disorders. Allergic skin rashes (erythema, pruritus, urticaria) may occasionally occur. Uncommon: photosensitivity reactions; very rare: bullous dermatitis including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme. In exceptional cases, serious skin infections and soft tissue disorders may occur during chickenpox infection (see \"Infections and infestations\"). Not known: drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), acute generalized exanthematous pustulosis (AGEP). Renal and urinary disorders. Uncommon: impaired renal function and toxic nephropathy in various forms, including interstitial nephritis, nephrotic syndrome and renal failure; rare: azotaemia. General disorders and administration site conditions. Common: malaise, fatigue; rare: oedema. Diagnostic tests. Rare: increased transaminases, increased alkaline phosphatase, decreased haemoglobin, decreased haematocrit, prolonged bleeding time, decreased blood calcium, increased blood uric acid. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Moment 200mg Analgesic 36 Coated Tablets.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003ePregnancy: Inhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or embryo\/fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased from less than 1%, up to approximately 1.5%. The risk was believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo-fetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals administered prostaglandin synthesis inhibitors during the organogenetic period. From the twentieth week of pregnancy onwards, the use of Moment may cause oligohydramnios resulting from fetal renal dysfunction. This may occur soon after initiation of treatment and is usually reversible upon discontinuation. In addition, cases of constriction of the ductus arteriosus have been reported after treatment in the second trimester, most of which resolved upon discontinuation of treatment. Therefore, during the first and second trimester of pregnancy, Moment should not be given unless clearly necessary. If Moment is used by a woman attempting to conceive or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible. Following exposure to Moment for several days from gestational week 20 onwards, antenatal monitoring for oligohydramnios and constriction of the ductus arteriosus should be considered. Moment should be discontinued if oligohydramnios or constriction of the ductus arteriosus is observed. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: cardiopulmonary toxicity (premature constriction\/closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction (see above); the mother and the neonate, at the end of pregnancy, to: possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, Moment is contraindicated during the third trimester of pregnancy (see and sections 4.3 and 5.3). Breast-feeding: Ibuprofen is excreted in breast milk, but at therapeutic doses during short-term treatment, the risk of influence on the neonate seems unlikely. If, however, treatment is longer term, early weaning should be considered. NSAIDs should be avoided during breast-feeding. Fertility: The use of Ibuprofen may impair female fertility and is not recommended in women attempting to conceive. This effect is reversible upon discontinuation of treatment. In women who have difficulties conceiving or who are undergoing investigation of infertility, discontinuation of ibuprofen should be considered.\u003c\/span\u003e\u003c\/p\u003e","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":40207823011955,"sku":"025669185","price":14.42,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-moment-200mg-analgesico-36-compresse-rivestite-farmacia-dottor-tili-1213792749.jpg?v=1767125589"},{"product_id":"lactoflorene-plus-fermenti-lattici-vivi-18-flaconcini-180-ml","title":"Lactoflorene Plus Live Lactic Ferments 18 vials 180 ml.","description":"\u003cp\u003eLactoflorene Plus is a food supplement based on \u003cstrong\u003elive lactic ferments with probiotic action\u003c\/strong\u003e enriched with \u003cstrong\u003eZinc and B vitamins\u003c\/strong\u003e . The Florene Blend (containing live and active lactic ferments) promotes the balance of intestinal bacterial flora. Taking Lactoflorene Plus Live Lactic Ferments is important when the \u003cstrong\u003ebacterial flora is deficient or altered\u003c\/strong\u003e , following the intake of \u003cstrong\u003eantibiotics or eating disorders\u003c\/strong\u003e that weaken it. \u003cstrong\u003eZinc contributes to the proper functioning of the immune system\u003c\/strong\u003e and to the protection of cells from oxidative stress. It also contains B vitamins.\u003c\/p\u003e\n\n\u003cp\u003eLactoflorene Plus Vivi Lactic Ferments is \u003cstrong\u003egluten-free and lactose-free.\u003c\/strong\u003e \u003cbr data-mce-fragment=\"1\"\u003e\u003cbr data-mce-fragment=\"1\"\u003e\u003cbr data-mce-fragment=\"1\"\u003e\u003c\/p\u003e\n\n\u003ch3 align=\"justify\"\u003eIngredients and nutritional characteristics Lactoflorene Plus Live Lactic Ferments 18 vials 180 ml.\u003c\/h3\u003e\n\n \u003cp\u003eIn the separator cap: hydrolyzed corn dextrin, maltodextrin, anti-caking agents: talc and silicon dioxide (nano); Florene Blend; (LA-5; (Lactobacillus acidophilus DSM13241), BB-12; (Bifidobacterium animalis subsp. lactis DSM15954) and L. CASEI 431; (Lactobacillus paracasei ATCC55544) with maltodextrin); brewer's yeast lysate (glucans), hydroxypropyl methylcellulose, sodium phosphate, Bacillus coagulans BC513 LMG S-24828 (maltodextrin). In the vial: purified water, fructose, honey, short-chain fructo-oligosaccharides, flavourings, zinc bisglycinate (maltodextrin from corn, cellulose, sodium carbonate), preservatives: potassium sorbate and sodium benzoate; acidifier: citric acid; Nicotinamide (Niacin), colour: caramel; Calcium D-pantothenate (Vitamin B5), Pyridoxine hydrochloride (Vitamin B6), Riboflavin (Vitamin B2), Thiamine hydrochloride (Vitamin B1), Cyanocobalamin (Vitamin B12, citric acid, corn maltodextrin, trisodium citrate).\u003cbr data-mce-fragment=\"1\"\u003e\u003cbr data-mce-fragment=\"1\"\u003e\u003c\/p\u003e\n\n \u003ch3\u003e\u003cb\u003eHow to use Lactoflorene Plus Live Lactic Ferments 18 vials 180 ml.\u003c\/b\u003e\u003c\/h3\u003e\n\n\u003ch4\u003eHow to take Lactoflorene Plus Live Lactic Ferments 18 vials 180 ml.?\u003c\/h4\u003e\n\n\u003cp\u003eTake 1-2 vials of Lactoflorene Plus a day, preferably away from meals.\u003cbr\u003e \u003cstrong\u003eIn case of simultaneous administration of antibiotic therapies\u003c\/strong\u003e it is recommended to take Lactoflorene Plus a few hours after the drug.\u003c\/p\u003e\n\n\u003cp\u003e\u003cbr data-mce-fragment=\"1\"\u003eHow to take Lactoflorene Plus from the vial:\u003cbr data-mce-fragment=\"1\"\u003e\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli\u003eFirmly press the stopper with both thumbs so that its contents fall into the solution; this may require 2 shots.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp\u003eor\u003c\/p\u003e\n\n\u003cul\u003e\n\n \u003cli\u003ePlace the vial on a flat surface and push the stopper firmly all the way in with the palm of your hand.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eShake well before drinking the contents\u003c\/strong\u003e . During the opening of the vial it is possible to observe a slight leakage of the powders.\u003cbr data-mce-fragment=\"1\"\u003e\u003cbr data-mce-fragment=\"1\"\u003e\u003c\/p\u003e\n\n\u003ch3\u003e\u003cb\u003eWarnings Lactoflorene Plus Live Lactic Ferments 18 vials 180 ml.\u003c\/b\u003e\u003c\/h3\u003e\n\n\u003cp\u003eSupplements are not intended as substitutes for a varied, balanced diet and a healthy lifestyle.\u003cbr data-mce-fragment=\"1\"\u003e Keep out of the reach of children under 3 years of age.\u003cbr data-mce-fragment=\"1\"\u003e Do not exceed the recommended daily dose.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch3\u003e\u003cb\u003eConservation Lactoflorene Plus Live Lactic Ferments 18 vials 180 ml.\u003c\/b\u003e\u003c\/h3\u003e\n\n \u003cp\u003eStore away from light in a cool, dry place. Validity with unopened package: 24 months. \u003cspan style=\"text-align: justify;\" data-mce-style=\"text-align: justify;\"\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"MONTEFARMACO OTC SpA","offers":[{"title":"Default Title","offer_id":40207823044723,"sku":"939143703","price":20.83,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/montefarmaco-otc-spa-lactoflorene-plus-fermenti-lattici-vivi-18-flaconcini-180-ml-farmacia-dottor-tili-1213792757.jpg?v=1767125690"},{"product_id":"magnesio-supremo-300-gr","title":"Supreme Magnesium 300 gr.","description":"\u003cp\u003e\u003cspan style=\"text-align: justify;\"\u003eMagnesium Supreme is a dietary supplement of magnesium, a mineral useful for combating \u003cstrong\u003etiredness and fatigue\u003c\/strong\u003e especially in periods of greater psycho-physical stress. Magnesium also \u003cstrong\u003esupports the physiological functioning of the muscles and nervous system\u003c\/strong\u003e .\u003c\/span\u003e Suitable for Vegans.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 12pt;\"\u003e \u003cstrong\u003eDOSAGE SCHEMES\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 12pt;\"\u003e The Cistite.info association in collaboration with numerous professionals in the sector has developed schemes that help to use this product in the correct ways and timing. Download them now from the links below!\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 12pt;\"\u003e \u003cstrong\u003eSchemes that include the product:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp style=\"margin-bottom: 12pt;\"\u003e\u003cspan style=\"color: #2b00ff;\"\u003e\u003c\/span\u003e\u003cspan style=\"color: #2b00ff;\"\u003e\u003c\/span\u003e \u003cspan style=\"color: #2b00ff;\"\u003e- \u003ca style=\"color: #2b00ff;\" title=\"Treat Prevent Chronic Cystitis\" href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Schema-Cura-Cistite-Cronica.pdf?v=1666792371\" data-mce-fragment=\"1\" target=\"_blank\"\u003eDownload the Chronic Cystitis diagram\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 12pt;\"\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 12pt;\"\u003e \u003cstrong\u003eDiagrams that do not include the product:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 12pt;\"\u003e \u003cspan style=\"color: #2b00ff;\"\u003e- \u003ca style=\"color: #2b00ff;\" title=\"How to take D-mannose\" href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Assunzione-Mannosio-Schema.pdf?v=1666792371\" target=\"_blank\"\u003eDownload the generic D-mannose intake chart\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 12pt;\"\u003e \u003cspan style=\"color: #2b00ff;\"\u003e- \u003ca style=\"color: #2b00ff;\" title=\"Treating acute bacterial cystitis\" href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Schema-Cura-Cistite-Acuta.pdf?v=1666792371\" target=\"_blank\"\u003eDownload the Acute Cystitis diagram\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 12pt;\"\u003e \u003cspan style=\"color: #2b00ff;\"\u003e- \u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Schema-Cura-Cistite-Postcoitale.pdf?v=1666792371\" title=\"Cure Prevent Honeymoon Post Coital Cystitis\" style=\"color: #2b00ff;\" target=\"_blank\"\u003eDownload the Post-coital Cystitis diagram\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 12pt;\"\u003e\u003cspan style=\"color: #2b00ff;\"\u003e\u003c\/span\u003e \u003cspan style=\"color: #2b00ff;\"\u003e- \u003ca style=\"color: #2b00ff;\" title=\"Treat and prevent cystitis during pregnancy and breastfeeding\" href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Schema_gravidanza_allattamento.pdf?v=1666792371\" target=\"_blank\"\u003eDownload the Cystitis in Pregnancy and Breastfeeding chart\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 12pt;\"\u003e \u003cspan style=\"color: #2b00ff;\"\u003e- \u003ca style=\"color: #2b00ff;\" href=\"https:\/\/www.dottortili.it\/img\/cms\/Schema_Protocollo_Dada.pdf\"\u003eDownload\u003c\/a\u003e \u003ca style=\"color: #2b00ff;\" title=\"Treat Prevent Cystitis in Menopause\" href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Schema_Protocollo_Dada.pdf?v=1666792371\" target=\"_blank\"\u003ethe Dada Cystitis in Menopause diagram\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 12pt;\"\u003e\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 12pt;\"\u003e \u003cb\u003eIngredients\u003c\/b\u003e\u003cbr\u003e Acidifier: citric acid, magnesium carbonate. Gluten free \u003cb\u003e.\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003cdiv align=\"justify\"\u003e \u003cb\u003eNutritional characteristics\u003c\/b\u003e \u003c\/div\u003e\n\u003cdiv align=\"justify\"\u003e\n\n\u003ctable border=\"1\" cellpadding=\"1\" cellspacing=\"0\" width=\"400\"\u003e\n\n\u003ctbody\u003e\n\n\u003ctr align=\"center\"\u003e\n\n\u003ctd\u003e Medium Contents\u003c\/td\u003e\n\n\u003ctd\u003e for 2 teaspoons\u003c\/td\u003e\n\n\u003ctd\u003e %NRV*\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Magnesium\u003c\/td\u003e\n\n\u003ctd align=\"center\"\u003e 430 mg\u003c\/td\u003e\n\n\u003ctd align=\"center\"\u003e 114.6\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\n\u003c\/tbody\u003e\n\n\n\u003c\/table\u003e\n\n\u003cbr\u003e *Nutritional Reference Values according to EU Reg. 1169\/2011\u003c\/div\u003e\n\u003cdiv align=\"justify\"\u003e\n\n\u003cbr\u003e\u003cbr\u003e \u003cb\u003eHow to use\u003c\/b\u003e\u003cbr\u003e Dissolve one teaspoon of Supreme Magnesium (about 2.4 g) in hot water, once or twice a day. Wait until the powder has dissolved before drinking. Supreme Magnesium, once dissolved in water, transforms into magnesium citrate.\u003c\/div\u003e\n\u003cdiv align=\"justify\"\u003e\n\n\u003cbr\u003e\u003cbr\u003e \u003cb\u003eWarnings\u003c\/b\u003e\u003cbr\u003e Keep the package out of reach of children under three years. Do not exceed the recommended dose. Supplements are not intended as a substitute for a varied and balanced diet and a healthy lifestyle. \u003c\/div\u003e\n\u003cdiv align=\"justify\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv align=\"justify\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv align=\"justify\"\u003e\n\n\u003cbr\u003e \u003cb\u003eConservation\u003c\/b\u003e\u003cbr\u003e Keep away from heat sources. Slight variations in taste and smell, from one batch to another, do not affect the quality and goodness of the product. \u003c\/div\u003e\n\u003cdiv align=\"justify\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv align=\"justify\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv align=\"justify\"\u003e\n\n\u003cbr\u003e \u003cb\u003eFormat\u003c\/b\u003e\u003cbr\u003e Net weight: 300 g.\u003c\/div\u003e","brand":"NATURAL POINT Srl","offers":[{"title":"Default Title","offer_id":40207823077491,"sku":"905972081","price":27.34,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/natural-point-srl-magnesio-supremo-300-gr-farmacia-dottor-tili-1213792759.jpg?v=1767125672"},{"product_id":"thermacare-menstrual-3-pezzi","title":"Thermacare Menstrual 3 Pieces","description":"\u003cp\u003e \u003cstrong\u003eThermacare Menstrual\u003c\/strong\u003e is a medical device designed to relieve menstrual pain through therapeutic heat. These patches are designed to provide up to 8 hours of constant heat, aimed at relieving menstrual cramps and relaxing abdominal muscles. Thermacare Menstrual is a non-pharmacological solution to reduce menstrual pain and improve well-being during the cycle. The patches are discreet, comfortable to wear under clothing and allow you to carry out normal daily activities without discomfort.\u003c\/p\u003e\n\n\n\u003ch2\u003e How to use\u003c\/h2\u003e\n\n\u003ch3\u003e How to use Thermacare Menstrual?\u003c\/h3\u003e\n\n         \u003cp\u003e1. \u003cstrong\u003eApplication\u003c\/strong\u003e : Remove the patch from the packaging and place it directly on the skin of the abdominal area or lower back. The patch begins to warm up within a few minutes.\u003c\/p\u003e\n\n\u003cp\u003e 2. \u003cstrong\u003eDuration\u003c\/strong\u003e : Use the patch for up to 8 consecutive hours. If necessary, it can also be used more than once a day, but always with at least 24 hours of pause between one application and another.\u003c\/p\u003e\n\n\u003cp\u003e 3. \u003cstrong\u003eRemoval\u003c\/strong\u003e : After use, remove the patch and dispose of it safely.\u003c\/p\u003e\n\n\n\u003ch2\u003e Package Contents\u003c\/h2\u003e\n\n\u003ch3\u003e What's in the Thermacare Menstrual package?\u003c\/h3\u003e\n\n\u003cp\u003e The package contains \u003cstrong\u003e3 disposable heating patches\u003c\/strong\u003e for the treatment of menstrual pain. Each patch is individually packaged to ensure freshness and safety of use.\u003c\/p\u003e\n\n\n\u003ch2\u003e Warnings\u003c\/h2\u003e\n\n\u003ch3\u003e What are the warnings for Thermacare Menstrual?\u003c\/h3\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e Do not use on damaged or irritated skin.\u003c\/li\u003e\n\n         \u003cli\u003eDiscontinue use if irritation or burning occurs.\u003c\/li\u003e\n\n\u003cli\u003e Do not use while sleeping.\u003c\/li\u003e\n\n\u003cli\u003e Avoid applying excessive pressure to the patch during use.\u003c\/li\u003e\n\n\u003cli\u003e Keep out of reach of children.\u003c\/li\u003e\n\n\u003cli\u003e Consult your doctor before use if you are pregnant or have diabetes, circulation problems or skin conditions.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Expiry and storage\u003c\/h2\u003e\n\n\u003ch3\u003e What are the expiration dates and storage of Thermacare Menstrual?\u003c\/h3\u003e\n\n\u003cp\u003e Store \u003cstrong\u003eThermacare Menstrual\u003c\/strong\u003e in a cool, dry place. Do not use after the expiry date printed on the package.\u003c\/p\u003e\n\n\n\u003ch2\u003e Format\u003c\/h2\u003e\n\n\u003cp\u003e Thermacare Menstrual is available in a pack of \u003cstrong\u003e3 disposable, ready-to-use heating patches\u003c\/strong\u003e .\u003c\/p\u003e\n\n","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":40207823110259,"sku":"981076134","price":11.31,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-thermacare-menstrual-3-pezzi-farmacia-dottor-tili-1213792761.jpg?v=1767125652"},{"product_id":"mag-2-orosolubile-20-bustine-2-25-g","title":"Mag 2 Orosolubile 20 Sachets 2.25 g","description":"\u003cp\u003e\u003cstrong\u003eMag 2 Orosolubile\u003c\/strong\u003e is a \u003cstrong\u003emagnesium\u003c\/strong\u003e -based food supplement formulated to combat magnesium deficiency states that can manifest themselves with tiredness, fatigue, muscle cramps or irritability. Magnesium is an essential mineral for the correct functioning of muscles, the nervous system and to reduce the feeling of tiredness and fatigue. The orosoluble sachets of Mag 2 offer a practical and fast method of intake, without the need for water.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Mag 2 Orosolubile 20 Sachets 2.25 g - What is the active ingredient in Mag 2 Orosolubile 20 Sachets 2.25 g?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eOne vial of oral solution contains, active ingredient: 1,500 g of magnesium pidolate (corresponding to 122 mg of Mg^++ ion). Excipients with known effects: sucrose, sodium methyl parahydroxybenzoate E219, sodium propyl parahydroxybenzoate E217, ethanol (contained in the orange flavour excipient). One single-dose sachet of oral solution contains, active ingredient: 1,500 g of magnesium pidolate (corresponding to 122 mg of Mg^++ ion). Excipients with known effects: sucrose, sodium methyl parahydroxybenzoate E219, sodium propyl parahydroxybenzoate E217, ethanol (contained in the orange flavour excipient). One sachet of powder for oral solution contains, active ingredient: 2,250 g of magnesium pidolate (corresponding to 184 mg of Mg^++ ion). Excipients with known effect: sucrose. For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Mag 2 Orosolubile 20 Sachets 2.25 g - What does Mag 2 Orosolubile 20 Sachets 2.25 g contain?\u003c\/span\u003e\n\u003c\/h2\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eMag2 1.5 g\/10 ml oral solution: sucrose, orange flavouring (containing ethanol), sodium methyl parahydroxybenzoate E 219, sodium propyl parahydroxybenzoate E217, purified water. Mag2 2.25 g powder for oral solution: sodium saccharin, citric acid monohydrate, sucrose, lemon flavouring.\u003c\/span\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eDIRECTIONS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Mag 2 Orosolubile 20 Sachets 2.25 g - Why is Mag 2 Orosolubile 20 Sachets 2.25 g used? What is it for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eMagnesium deficiency states.\u003c\/span\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eCONTRAINDICATIONS - SIDE EFFECTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Mag 2 Orosolubile 20 Sachets 2.25 g - When should Mag 2 Orosolubile 20 Sachets 2.25 g not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1; severe renal insufficiency (creatinine clearance less than 30 mL\/min); not to be administered to subjects undergoing digitalis therapy.\u003c\/span\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eDOSAGE\u003c\/span\u003e\n\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eQuantity and method of taking Mag 2 Orosolubile 20 Sachets 2.25 g - How do you take Mag 2 Orosolubile 20 Sachets 2.25 g?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eDosage, for adults only: 3 vials or 3 single-dose sachets of solution or 2 sachets of powder per day. Paediatric population: in children, the dosage may be established by a previously consulted doctor. Caution: use only for short periods of treatment. Instructions for use, Mag2 1.5 g\/10 ml oral solution: it is advisable to shake before use. To open the vial, twist the top and detach it. Take the contents of the vial as is or dilute it in water. Mag2 2.25 g powder for oral solution: dissolve the contents of one sachet in water.\u003c\/span\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eCONSERVATION\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Mag 2 Orosolubile 20 Sachets 2.25 g - How do you store Mag 2 Orosolubile 20 Sachets 2.25 g?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eOral solution: Store below 25 degrees C. Powder for oral solution: This medicine does not require any special storage conditions.\u003c\/span\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eWARNINGS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Mag 2 Orosolubile 20 Sachets 2.25 g - About Mag 2 Orosolubile 20 Sachets 2.25 g it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIn case of concomitant calcium deficiency, magnesium deficiency should be corrected before administering supplemental calcium. In patients with moderate renal insufficiency, it is necessary to reduce the dosage and monitor renal function and magnesium levels, due to the risk associated with hypermagnesemia. It is advisable to consider the possibility that cardiovascular depression may occur during treatment. MAG2 oral solution contains sucrose: patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. Parahydroxybenzoates (sodium methyl parahydroxybenzoate E219 and sodium propyl parahydroxybenzoate E217): may cause allergic reactions (possibly delayed); sodium: this medicine contains less than 1 mmol sodium (23 mg) per vial or sachet, i.e. essentially \"sodium-free\"; ethanol: This medicine contains 18 mg of alcohol (ethanol) in each vial or sachet, which is equivalent to 1.8 mg\/ml. The amount in each dose of this medicine is equivalent to less than 0.2 ml of wine or 0.5 ml of beer. The small amount of alcohol in this medicine will not produce any relevant effects. MAG2 powder for oral solution contains sucrose: Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. Sodium: This medicine contains less than 1 mmol (23 mg) per dose, that is to say essentially 'sodium-free'.\u003c\/span\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Mag 2 Orosolubile 20 Sachets 2.25 g - Which medicines or foods can modify the effect of Mag 2 Orosolubile 20 Sachets 2.25 g?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eIn case of concomitant treatment with oral tetracyclines, the administration of MAG2 should be delayed by at least 3 hours. Quinolones should be administered at least 2 hours before or 6 hours after the administration of magnesium-containing products to avoid interference with their absorption. The concomitant administration of magnesium-containing products and cholecalciferol (vitamin D3) may lead to the onset of hypercalcemia. The concomitant use of preparations containing calcium or phosphate salts is not recommended because these products prevent intestinal absorption of magnesium. The simultaneous intake of magnesium-containing products with drugs that depress the Central Nervous System may potentiate the effects of magnesium on the CNS and should be carefully evaluated.\u003c\/span\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003c\/p\u003e\n\n \u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Mag 2 Orosolubile 20 Sachets 2.25 g can cause side effects - What are the side effects of Mag 2 Orosolubile 20 Sachets 2.25 g?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe following convention has been used for the classification of undesirable effects: very common \u0026gt;= 1\/10; common \u0026gt;= 1\/100 and \u0026lt; 1\/10; uncommon \u0026gt;= 1\/1,000 and \u0026lt; 1\/100; rare \u0026gt;= 1\/10,000 and \u0026lt; 1\/1,000); very rare \u0026lt; 1\/10,000 and not known (frequency cannot be estimated from the available data). Gastrointestinal disorders. Frequency Not known: gastrointestinal disorders, diarrhoea, abdominal pain. Skin and subcutaneous tissue disorders. Frequency not known: skin reactions. Immune system disorders. Frequency not known: hypersensitivity. Exceptional cases of individual intolerance to magnesium have been reported, which can be treated with oral or parenteral antihistamines. Reporting of suspected adverse reactions. Reporting of suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003cb\u003e \u003cbr\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Mag 2 Orosolubile 20 Sachets 2.25 g\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThere are limited data on the use of MAG2 in pregnant women. However, no conclusions can be drawn as to whether the use of MAG2 is safe during pregnancy. MAG2 can be used during pregnancy only if the potential benefits to the mother outweigh the potential risks, including those to the fetus. Magnesium is considered compatible with breastfeeding.\u003c\/span\u003e\u003c\/p\u003e","brand":"SANOFI SpA","offers":[{"title":"Default Title","offer_id":40207823143027,"sku":"025519048","price":16.65,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/sanofi-spa-mag-2-orosolubile-20-bustine-2-25-g-farmacia-dottor-tili-1213792760.jpg?v=1767125746"},{"product_id":"aspirina-dolore-infiammazione-20-compresse-500-mg","title":"Aspirin Pain Inflammation 20 Tablets 500mg","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAspirin Pain and Inflammation\u003c\/span\u003e \u003cspan\u003eis a drug based on\u003c\/span\u003e \u003cspan\u003eacetylsalicylic acid\u003c\/span\u003e \u003cspan\u003e(500 mg per tablet) indicated for the symptomatic treatment of mild and moderate pain, as well as to reduce inflammatory conditions. Thanks to its analgesic, anti-inflammatory and antipyretic properties, Aspirin is effective in reducing muscle pain, headache, toothache and in controlling fever.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Aspirin Pain Inflammation 20 Tablets 500 mg - What is the active ingredient of Aspirin Pain Inflammation 20 Tablets 500 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eEach tablet contains 500 mg of acetylsalicylic acid. Excipients with known effect: One coated tablet contains 3.12 mmol (or 71.7 mg) of sodium. For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eComposition of Aspirin Pain Inflammation 20 Tablets 500 mg - What does Aspirin Pain Inflammation 20 Tablets 500 mg contain?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eTablet core: colloidal silicon dioxide, sodium carbonate. Coating: carnauba wax, hypromellose, zinc stearate.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Aspirin Pain Inflammation 20 Tablets 500 mg - Why is Aspirin Pain Inflammation 20 Tablets 500 mg used? What is it used for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eSymptomatic treatment of fever and\/or mild to moderate pain, such as headache, flu-like syndrome, toothache, muscle aches.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Aspirin Pain Inflammation 20 Tablets 500 mg - When should Aspirin Pain Inflammation 20 Tablets 500 mg not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e\/SECONDARY EFFECTS Hypersensitivity to acetylsalicylic acid or other salicylates, or to any of the excipients listed in section 6.1; history of asthma or hypersensitivity reactions (e.g. urticaria, angioedema, severe rhinitis, shock) induced by the administration of salicylates or substances with a similar action, in particular non-steroidal anti-inflammatory drugs (NSAIDs); active peptic ulcer; haemorrhagic diathesis; severe renal insufficiency (GFR \u0026lt; 30 ml\/min\/ 1.73 m^2); severe hepatic insufficiency; severe uncontrolled cardiac insufficiency; concomitant administration of methotrexate in doses greater than 15 mg per week, for anti-inflammatory doses of acetylsalicylic acid, or for analgesic or antipyretic doses (see section 4.5); concomitant administration of oral anticoagulants for anti-inflammatory doses of acetylsalicylic acid, or for analgesic or antipyretic doses and in patients with a history of gastroduodenal ulcers (see section 4.5); from the beginning of the sixth month of pregnancy (beyond the twenty-fourth week of amenorrhea) (see section 4.6); children and adolescents under 16 years of age.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Aspirin Pain Inflammation 20 Tablets 500 mg - How to take Aspirin Pain Inflammation 20 Tablets 500 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eDosage. Adults and children (16 years and older): 1 to 2 tablets for each dose to be repeated as needed after a minimum period of 4 hours. The maximum daily dose must not exceed 6 tablets. Elderly (65 years and older): 1 tablet for each dose to be repeated as needed after a minimum period of 4 hours. The maximum daily dose must not exceed 4 tablets. Acetylsalicylic acid should not be taken for more than 3 days (in case of fever) or 3 - 4 days (in case of pain) unless otherwise indicated by the doctor. Paediatric population: Acetylsalicylic acid should not be used in children and children under 16 years without a medical prescription. Acetylsalicylic acid should be used with caution in patients with abnormal liver or kidney function or with circulatory problems. Method of administration: for oral use. The tablets should be taken with an adequate amount of water. To open the strip, tear from the edge in any position.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Aspirin Pain Inflammation 20 Tablets 500 mg - How do you store Aspirin Pain Inflammation 20 Tablets 500 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eDo not store above 30 degrees C. Store in the original package to protect from light and moisture.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Aspirin Pain Inflammation 20 Tablets 500 mg - About Aspirin Pain Inflammation 20 Tablets 500 mg it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIn case of combination with other medicinal products, to avoid any risk of overdose, check that acetylsalicylic acid is not in the composition of these other medicinal products. Reye's syndrome, a very rare and potentially fatal disease, has been described in children with symptoms of viral infections (especially chickenpox and flu-like episodes) with or without taking acetylsalicylic acid. Consequently, acetylsalicylic acid should be administered to children in these conditions only after medical advice and when other measures have proven ineffective. In case of persistent vomiting, altered state of consciousness or abnormal behaviour, treatment with acetylsalicylic acid should be stopped. In case of prolonged administration of high dose analgesics, the headache attack should not be treated with higher doses. Regular use of analgesics, especially a combination of analgesics, may lead to permanent kidney damage, with risk of kidney failure. The medicinal product should be used with particular caution in the following cases: patients with mild to moderate renal impairment (GFR \u0026gt;= 30 to \u0026lt; 90 ml\/min\/ 1.73 m^2) or patients with impaired cardiovascular circulation (e.g. renal vascular disease, congestive heart failure, volume depletion, major surgery, sepsis or major haemorrhagic events) since acetylsalicylic acid may further increase the risk of renal impairment and acute renal failure. In some severe forms of G6PD deficiency, high doses of acetylsalicylic acid may cause haemolysis. In case of G6PD deficiency, acetylsalicylic acid should be administered under medical supervision. Treatment monitoring should be intensified in the following cases: in patients with a history of gastric or duodenal ulcer, gastrointestinal bleeding, or gastritis; in patients with renal insufficiency; in patients with hepatic insufficiency; in patients with asthma: the occurrence of an asthma attack, in some patients, may be linked to an allergy to nonsteroidal anti-inflammatory drugs or to acetylsalicylic acid; in this case, this medicinal product is contraindicated (see section 4.3); in patients with metrorrhagia or menorrhagia (risk of an increase in the volume and duration of the cycle). Gastrointestinal bleeding or ulcers\/perforations may occur at any time during treatment, without necessarily having any warning signs or medical history in the patient. The relative risk increases in elderly subjects, in subjects with low body weight, and in patients receiving anticoagulants or platelet aggregation inhibitors (see section 4.5). In case of gastrointestinal bleeding, treatment must be stopped immediately. Given the inhibitory effect of acetylsalicylic acid on platelet aggregation, which occurs even at very low doses and persists for several days, the patient should be aware of the risk of haemorrhage in case of surgical interventions, even minor ones (e.g. tooth extraction). In analgesic or antipyretic doses, acetylsalicylic acid inhibits the excretion of uric acid; in doses used in rheumatology (anti-inflammatory doses), acetylsalicylic acid has a uricosuric effect. The use of this medicinal product is not recommended during breastfeeding (see section 4.6). The administration of acetylsalicylic acid is not recommended with: oral anticoagulants with analgesic or antipyretic doses of acetylsalicylic acid (\u0026gt;=500 mg per administration and\/or \u0026lt; 3 g per day) and in patients without a history of gastro-duodenal ulcers (see section 4.5); other nonsteroidal anti-inflammatory drugs (NSAIDs) with anti-inflammatory doses of acetylsalicylic acid (\u0026gt;= 1 g per administration and\/or \u0026gt;=3 g per day) or with analgesic or antipyretic doses of acetylsalicylic acid (\u0026gt;=500 mg per administration and\/or \u0026lt; 3 g per day) (see section 4.5). Low molecular weight heparins (and related molecules) and unfractionated heparins with therapeutic doses or in elderly patients (\u0026gt;65 years) regardless of the heparin dose, and for anti-inflammatory doses of acetylsalicylic acid (\u0026gt;= 1 g per administration and\/or \u0026gt;= 3 g per day) or with analgesic or antipyretic doses of acetylsalicylic acid (\u0026gt;=500 mg per administration and\/or \u0026lt; 3 g per day) (see section 4.5). Clopidogrel (beyond the approved indications for this combination in patients with acute coronary disease) (see section 4.5). Ticlopidine (see section 4.5); uricosurics (see section 4.5); glucocorticoids (except hydrocortisone replacement therapy) for anti-inflammatory doses of acetylsalicylic acid (\u0026gt;= 1g per administration and\/or \u0026gt;= 3g per day) (see section 4.5); pemetrexed in patients with mild to moderately reduced renal function (creatinine clearance between 45 ml\/min and 80 ml\/min) (see section 4.5); anagrelide: increased risk of haemorrhage and decreased antithrombotic effect (see section 4.5). Important information about some of the excipients This medicinal product contains 71.7 mg sodium per dose equivalent to 3.6% of the WHO recommended maximum daily intake of 2 g sodium for an adult.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Aspirin Pain Inflammation 20 Tablets 500 mg - Which medicines or foods can modify the effect of Aspirin Pain Inflammation 20 Tablets 500 mg?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIn the following text, the following definitions apply: Anti-inflammatory doses of acetylsalicylic acid are defined as \"\"\u0026gt;= 1g per administration and\/or \u0026gt;= 3g per day\"\". Analgesic or antipyretic doses of acetylsalicylic acid are defined as \"\"\u0026gt;=500 mg per administration and\/or \u0026lt; 3 g per day\"\" Several substances give rise to interactions, due to their properties of platelet aggregation inhibitors: abciximab, acetylsalicylic acid, cilostazol, clopidogrel, epoprostenol, eptifibatide, iloprost, iloprost trometamol, prasugrel, ticlopidine, tirofiban, ticagrelor. The risk of bleeding increases with the use of multiple platelet aggregation inhibitors as well as with their use in combination with heparin or related molecules, oral anticoagulants or other thrombolytics, and must be assessed through constant clinical monitoring. Contraindicated combinations (see section 4.3): Methotrexate in doses greater than 15 mg per week, with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: increased toxicity of methotrexate, in particular haematological toxicity (due to reduced renal elimination of methotrexate caused by acetylsalicylic acid). Oral anticoagulants with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid and in patients with a history of gastroduodenal ulcers: increased risk of haemorrhage. Combinations not recommended: Oral anticoagulants with analgesic or antipyretic doses of acetylsalicylic acid and in patients without a history of gastroduodenal ulcers: increased risk of haemorrhage. Other nonsteroidal anti-inflammatory drugs (NSAIDs) with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: increased risk of gastrointestinal ulcers and haemorrhage. Low molecular weight heparins (and related molecules) and unfractionated heparins at curative doses, or in elderly patients (\u0026gt;=65 years) regardless of the heparin dose, and for anti-inflammatory doses of acetylsalicylic acid or analgesic or antipyretic doses of acetylsalicylic acid: increased risk of haemorrhage (inhibition of platelet aggregation and aggression of the gastroduodenal mucosa by acetylsalicylic acid). Another anti-inflammatory drug, or another analgesic or antipyretic should be used. Clopidogrel (outside the approved indication for this combination in patients with acute coronary syndrome): increased risk of haemorrhage. If concomitant administration cannot be avoided, clinical monitoring is recommended. Ticlopidine: increased risk of haemorrhage. If concomitant administration cannot be avoided, clinical monitoring is recommended. Uricosurics (benzbromarone, probenecid): decreased uricosuric effect due to competition for uric acid elimination in the renal tubules. Glucocorticoids (excluding hydrocortisone replacement therapy) for anti-inflammatory doses of acetylsalicylic acid: increased risk of haemorrhage. Pemetrexed in patients with mild to moderate renal impairment (creatinine clearance between 45 ml\/min and 80 ml\/min); increased risk of pemetrexed toxicity (due to decreased renal elimination of pemetrexed caused by acetylsalicylic acid) anti-inflammatory doses of acetylsalicylic acid. Anagrelide: Increased risk of haemorrhage and decreased antithrombotic effect. If concomitant administration cannot be avoided, clinical monitoring is recommended. Combinations requiring precautions for use: diuretics, angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists, with anti-inflammatory doses of acetylsalicylic acid or with analgesic or antipyretic doses of acetylsalicylic acid: Acute renal failure may occur in dehydrated patients due to a reduction in glomerular filtration rate resulting from decreased synthesis of renal prostaglandins. In addition, there may be a reduction in the antihypertensive effect. Ensure that the patient is hydrated and that renal function is monitored at the start of treatment. Methotrexate in doses \u0026lt;= 15 mg per week, with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: Increased toxicity of methotrexate, particularly haematological toxicity (due to reduced renal elimination of methotrexate caused by acetylsalicylic acid). Blood counts should be monitored weekly during the first weeks of concomitant administration. Patients with reduced renal function (even mild) and elderly patients should be closely monitored. Clopidogrel (in the approved indication for this combination in patients with acute coronary syndrome): Increased risk of haemorrhage. Clinical monitoring is recommended. Gastrointestinal topical treatments, antacids and activated charcoal: Increased renal excretion of acetylsalicylic acid due to alkalinisation of urine. It is recommended that antacids and topical gastrointestinal treatments be administered at least two hours after acetylsalicylic acid. Pemetrexed in patients with normal renal function: increased risk of pemetrexed toxicity (due to decreased renal elimination of pemetrexed caused by acetylsalicylic acid) with anti-inflammatory doses of acetylsalicylic acid. Renal function should be monitored. Combinations that should be considered: glucocorticoids (excluding hydrocortisone replacement therapy) for analgesic and antipyretic doses of acetylsalicylic acid: increased risk of haemorrhage. Deferasirox: with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: increased risk of gastrointestinal ulcers and haemorrhage.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Aspirin Pain Inflammation 20 Tablets 500 mg can cause side effects - What are the side effects of Aspirin Pain Inflammation 20 Tablets 500 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eFrequencies: Not known (cannot be estimated from the available data). Blood and lymphatic system disorders: Bleeding and tendency to bleed (epistaxis, bleeding gums, purpura, etc.) with increased bleeding time. The risk of bleeding may persist for 4-8 days after stopping acetylsalicylic acid. May cause an increased risk of haemorrhage in case of surgery. Intracranial and gastrointestinal haemorrhages may also occur. Immune system disorders: Hypersensitivity reactions, anaphylactic reactions, asthma, angioedema. Nervous system disorders: Headache, dizziness, sensation of hearing loss, tinnitus, usually indicating an overdose. Intracranial haemorrhage. Gastrointestinal disorders: Abdominal pain. Occult or overt gastrointestinal haemorrhage (haematemesis, melaena, etc.) resulting in iron deficiency anaemia. The risk of bleeding is dose-related. Gastric ulcers and perforations. Intestinal diaphragm disease (especially in long-term treatment). Renal and urinary disorders: renal impairment and acute kidney injury have been reported. Hepatobiliary disorders: elevated liver enzymes usually reversible with discontinuation of treatment, liver damage, mainly hepatocellular in nature. Skin and subcutaneous tissue disorders: urticaria, rash. General disorders: Reye's syndrome (see section 4.4). Reporting of adverse reactions It is important to report adverse reactions after authorisation of the medicinal product. This allows continued monitoring of the risk-benefit ratio of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the website: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Aspirin Pain Inflammation 20 Tablets 500 mg\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eInflammation 20 Tablets 500 mg Pregnancy: Inhibition of prostaglandin synthesis may adversely affect the course of pregnancy and\/or embryo-foetal development. Data from epidemiological studies suggest an increased risk of miscarriage, cardiac malformations and gastroschisis following the use of prostaglandin synthesis inhibitors in early pregnancy. The absolute risk of cardiovascular malformations is increased from not less than 1% to approximately 1.5%. The risk appears to increase with dose and duration of treatment. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-foetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period of gestation. From the twentieth week of pregnancy onwards, the use of acetylsalicylic acid may cause oligohydramnios resulting from fetal renal dysfunction. This condition may be encountered soon after the start of treatment and is usually reversible upon discontinuation of treatment. In addition, cases of constriction of the ductus arteriosus have been reported following treatment in the second trimester, most of which resolved after discontinuation of treatment. Therefore, during the first 24 weeks of amenorrhea, acetylsalicylic acid should not be administered unless clearly necessary. If acetylsalicylic acid is used by a woman planning a pregnancy, or during the first 24 weeks of amenorrhea, the lowest possible dose should be used for the shortest possible duration. Following exposure to acetylsalicylic acid for several days from the 20th week of gestation onwards, antenatal monitoring for oligohydramnios and constriction of the ductus arteriosus should be considered. If oligohydramnios or constriction of the ductus arteriosus occurs, treatment with acetylsalicylic acid should be discontinued. Beyond the 24th week of amenorrhea, all prostaglandin synthesis inhibitors may expose the fetus to: cardiopulmonary toxicity (premature constriction\/closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction (see above); in the final phase of pregnancy, the mother and the neonate may experience: prolongation of bleeding time, due to inhibition of platelet aggregation which may occur even at very low doses of acetylsalicylic acid; inhibition of uterine contractions resulting in delay or prolongation of labor. Consequently, acetylsalicylic acid is contraindicated after the 5th month of pregnancy (over 24 weeks of amenorrhea) (see section 4.3). Breastfeeding. Acetylsalicylic acid passes into breast milk: therefore the use of acetylsalicylic acid is not recommended during breastfeeding (see section 4.4). Fertility: There is some evidence that drugs that inhibit cyclooxygenase\/prostaglandin synthesis may cause impairment of female fertility due to an effect on ovulation. This effect is reversible upon discontinuation of treatment.\u003c\/span\u003e\u003c\/p\u003e","brand":"BAYER SpA","offers":[{"title":"Default Title","offer_id":40207823208563,"sku":"041962034","price":9.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/bayer-spa-aspirina-dolore-infiammazione-20-compresse-500-mg-farmacia-dottor-tili-1213792747.jpg?v=1767125728"},{"product_id":"tachipirina-sciroppo-bambini-paracetamolo-120-mg-5-ml","title":"Tachipirina Syrup Children Paracetamol 120 mg\/5 ml","description":"\u003cp\u003eTachipirina Sciroppo 120 mg\/5 ml is an over-the-counter medicine based \u003cstrong\u003eon low-dose Paracetamol\u003c\/strong\u003e for children (from 7.2 kg and up). \u003cstrong\u003eParacetamol is preferable in children\u003c\/strong\u003e as an antipyretic to lower temperature and in the symptomatic treatment of febrile conditions such as \u003cstrong\u003einfluenza, exanthematous diseases, acute respiratory tract conditions\u003c\/strong\u003e , etc.\u003c\/p\u003e\n\n\u003cp\u003e Tachipirina Syrup 120 mg\/5 also has \u003cstrong\u003ean analgesic action\u003c\/strong\u003e in cases of \u003cstrong\u003eheadache\u003c\/strong\u003e , \u003cstrong\u003eneuralgia\u003c\/strong\u003e , \u003cstrong\u003emyalgia\u003c\/strong\u003e and other painful manifestations of medium severity and of various origins.\u003cbr\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml - What is the active ingredient of Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eTACHIPIRINA 120 mg\/5 ml syrup, 5 ml of syrup contain; active ingredient: paracetamol 120 mg. Excipients with known effects: sucrose, methyl parahydroxybenzoate, sodium. TACHIPIRINA 100 mg\/ml oral drops solution, 1 ml of solution contains; active ingredient: paracetamol 100 mg. Excipients with known effects: sorbitol, propylene glycol.For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml - What does Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eSyrup: sucrose, sodium citrate, sodium saccharin, methyl parahydroxybenzoate, potassium sorbate, macrogol 6000, citric acid monohydrate, strawberry flavouring, mandarin flavouring, purified water. Oral drops: propylene glycol, macrogol 6000, sorbitol, sodium saccharin, citrus-vanilla flavouring, propyl gallate, caramel (E150a), sodium edetate, purified water.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eTherapeutic indications Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml - Why is Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml used? What is it used for?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eAs an antipyretic: symptomatic treatment of febrile conditions such as influenza, exanthematous diseases, acute respiratory tract conditions, etc. As an analgesic: headaches, neuralgia, myalgia and other moderately severe painful conditions of various origins.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml - When should Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eHypersensitivity to the active substance or to any of the excipients listed in section 6.1. Patients with severe haemolytic anaemia (this contraindication does not apply to the 500 mg oral formulations). Severe hepatocellular insufficiency (this contraindication does not apply to the 500 mg oral formulations).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml - How do you take Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIn children up to 10 years of age, it is essential to respect the dosage defined based on body weight and not on age, which is approximate and indicated for information purposes only. If the age of the child does not correspond to the weight shown in the table, always refer to body weight when choosing the dosage. In children weighing up to 7.2 kg, it is recommended to use the formulation in drops, between 7.2 and 11 kg it is possible to use drops or syrup as the dosage for each weight group is identical, between 12 and 32 kg it is recommended to use syrup. In the case of jaundice in children under three months, it is advisable to reduce the single dose. In children over 10 years of age, the relationship between weight and age becomes no longer homogeneous due to pubertal development which, at the same age, has a different impact on body weight depending on the sex and individual characteristics of the child. Therefore, above 10 years of age, the dosage of the syrup is indicated in terms of weight and age ranges, as follows. Children weighing between 33 and 40 kg (over 10 years and under 12 years of age): 20 ml of syrup at a time (corresponding to 480 mg), to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Adolescents weighing more than 40 kg (aged 12 years or over) and adults: 20 ml of syrup at a time (corresponding to 480 mg), to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. The doctor must evaluate the need for treatments for more than 3 consecutive days. Method of administration The package contains a dosing syringe with level marks corresponding to 1 ml, 2 ml, 3 ml, 4 ml, 4.5 ml and 5 ml and a dosing cup with level marks corresponding to 5.5 ml, 6 ml, 6.5 ml, 7.5 ml, 8.5 ml, 10 ml, 11 ml, 12.5 ml, 13.5 ml, 15.5 ml, 17.5 ml, 19 ml Syrup The syrup contains 24 mg of paracetamol per ml of product. To open the bottle, push the cap downwards and at the same time turn to the left. To use the syringe, insert the tip of the syringe fully into the hole in the undercap, turn the bottle upside down, holding the syringe firmly, gently pull the plunger downwards filling the syringe up to the mark corresponding to the desired dose; Return the bottle to an upright position, remove the syringe by gently rotating it, insert the tip of the syringe into the child's mouth and apply gentle pressure to the plunger to release the solution. The product must be used immediately after taking it from the bottle. Any residual product in the syringe must be discarded. For doses greater than 5 ml, take the required amount with the syringe and pour the contents into the cup. Repeat the procedure until the mark corresponding to the indicated dosage is reached, and administer to the child, inviting him to drink. For doses in children over 10 years of age and in adults, equal to 20 ml, use the cup, filling it twice up to the 10 ml mark. The product must be used immediately after taking it from the bottle. Any residual product in the syringe or cup must be discarded. After use, close the bottle by screwing the cap tightly and wash the syringe and cup with hot water. Leave them to dry, keeping them out of the reach and sight of children. Drops Each drop contains 4 mg of paracetamol. Turn the bottle upside down and pour the number of drops corresponding to the dosage to be used in 25-50 ml of water, and give the child to drink. Renal insufficiency In case of severe renal insufficiency (creatinine clearance less than 10 ml\/min), the interval between administrations must be at least 8 hours.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml - How is Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml stored?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThis medicinal product does not require any special storage conditions.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml - About Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIn rare cases of allergic reactions, administration should be suspended and appropriate treatment should be instituted. Use with caution in cases of chronic alcoholism, excessive alcohol intake (3 or more alcoholic drinks per day), anorexia, bulimia or cachexia, chronic malnutrition (low reserves of hepatic glutathione), dehydration, hypovolemia. Paracetamol should be administered with caution to patients with mild to moderate hepatocellular insufficiency (including Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh\u0026gt;9), acute hepatitis, in concomitant treatment with drugs that alter liver function, glucose-6-phosphate dehydrogenase deficiency, hemolytic anemia. High or prolonged doses of the product can cause alterations to the kidney and blood, even serious, therefore administration to subjects with renal insufficiency should be carried out only if really necessary and under direct medical supervision. In case of prolonged use it is advisable to monitor liver and renal function and blood count. During treatment with paracetamol, before taking any other medicine, check that it does not contain the same active ingredient, since if paracetamol is taken in high doses, serious adverse reactions may occur. Invite the patient to contact the doctor before combining any other medicine (see section 4.5). Important information about some of the excipients. Tachipirina drops, solution contains, sorbitol: patients with rare hereditary problems of fructose intolerance, should not take this medicine; propylene glycol: may cause symptoms similar to those caused by alcohol. The container of Tachipirina drops, solution is made of latex rubber. May cause serious allergic reactions. Tachipirina syrup contains, sucrose: patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency, should not take this medicine. For the 15 ml dose this medicinal product contains 5.25 g sucrose, for the 16.5 ml dose it contains 5.78 g sucrose, for the 18.5 ml dose it contains 6.48 g sucrose and for the 20 ml dose it contains 7 g sucrose. To be taken into consideration by people with diabetes mellitus. Methyl parahydroxybenzoate: may cause allergic reactions (possibly delayed). Sodium: this medicinal product contains 1.2 mmol (or 27.6 mg) sodium per 20 ml equivalent to 1.38% of the WHO recommended maximum daily intake of 2 g sodium for an adult. To be taken into consideration by people on a controlled sodium diet.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml - Which medicines or foods can modify the effect of Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe oral absorption of paracetamol depends on the rate of gastric emptying. Therefore, the concomitant administration of drugs that slow (e.g. anticholinergics, opioids) or increase (e.g. prokinetics) the rate of gastric emptying may determine a decrease or increase respectively in the bioavailability of the product. The concomitant administration of cholestyramine reduces the absorption of paracetamol. The simultaneous intake of paracetamol and chloramphenicol may induce an increase in the half-life of chloramphenicol, with the risk of increasing toxicity. Concomitant use of paracetamol (4 g daily for at least 4 days) with oral anticoagulants may cause slight variations in INR values. In these cases, more frequent monitoring of INR values ​​should be performed during concomitant use and after its interruption. Use with extreme caution and under close supervision during chronic treatment with drugs that can determine the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutethimide, phenobarbital, carbamazepine). The same applies in cases of alcoholism and in patients treated with zidovudine. The administration of paracetamol may interfere with the determination of uricemia (by the phosphotungstic acid method) and with that of glycemia (by the glucose-oxidase-peroxidase method).\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml can cause side effects - What are the side effects of Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe following are the adverse reactions of paracetamol organised according to the MedDRA system organ classification. There are insufficient data to establish the frequency of the individual effects listed. Blood and lymphatic system disorders: thrombocytopenia, leukopenia, anaemia, agranulocytosis. Immune system disorders: hypersensitivity reactions (urticaria, laryngeal edema, angioedema, anaphylactic shock). Nervous system disorders: dizziness. Gastrointestinal disorders: gastrointestinal reaction. Hepatobiliary disorders: abnormal liver function, hepatitis. Skin and subcutaneous tissue disorders: erythema multiforme, Stevens Johnson syndrome, epidermal necrolysis, rash. Renal and urinary disorders: acute renal failure, interstitial nephritis, haematuria, anuria. Very rare cases of serious skin reactions have been reported. Reporting of suspected adverse reactions. Reporting of suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003ePregnancy: A large amount of data on pregnant women indicate neither malformative nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. Breastfeeding: It is recommended to take\/administer this medicine only in cases of real need and under direct medical supervision.\u003c\/span\u003e\u003c\/p\u003e","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":40207823241331,"sku":"012745016","price":7.25,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-tachipirina-sciroppo-bambini-paracetamolo-120-mg-5-ml-farmacia-dottor-tili-1213792758.png?v=1767125710"},{"product_id":"spray-nasale-physiomer-ipertonico-confezione-135-ml","title":"Physiomer Hypertonic Nasal Spray 135 ml","description":"\u003cp\u003e\u003cstrong\u003ePhysiomer Hypertonic\u003c\/strong\u003e is a nasal spray indicated for decongestion of the nasal passages. Formulated with a hypertonic solution of sea water, Physiomer offers a natural and gentle action, helping to reduce swelling of the nasal mucosa and improving breathing. Thanks to its composition free of chemical additives, Physiomer is suitable for daily use and can also be used by people with sensitivity to traditional decongestant drugs.\u003c\/p\u003e\n\n\n\u003ch2\u003e How to use\u003c\/h2\u003e\n\n\u003ch3\u003e How to use Physiomer Hypertonic?\u003c\/h3\u003e\n\n\u003cp\u003e 1. \u003cstrong\u003eNose cleaning\u003c\/strong\u003e : Gently blow your nose before use.\u003c\/p\u003e\n\n\u003cp\u003e 2. \u003cstrong\u003eApplication\u003c\/strong\u003e : Hold the bottle upright and tilt your head slightly. Insert the spray nozzle into one nostril and gently press to spray the solution. Repeat the process in the other nostril.\u003c\/p\u003e\n\n         \u003cp\u003e3. \u003cstrong\u003eFrequency of use\u003c\/strong\u003e : It is recommended to use Physiomer Hypertonic 1 to 3 times a day, or as needed. After use, wash and dry the nozzle.\u003c\/p\u003e\n\n\n\u003ch2\u003e Package Contents\u003c\/h2\u003e\n\n\u003ch3\u003e What does the Physiomer Hypertonic package contain?\u003c\/h3\u003e\n\n\u003cp\u003e The \u003cstrong\u003ePhysiomer Hypertonic\u003c\/strong\u003e package contains a \u003cstrong\u003e135 ml\u003c\/strong\u003e bottle of hypertonic sea water solution, rich in minerals and natural trace elements. The spray is equipped with an ergonomic nozzle for easy and comfortable application.\u003c\/p\u003e\n\n\n\u003ch2\u003e Warnings\u003c\/h2\u003e\n\n\u003ch3\u003e What are the warnings of Physiomer Hypertonic?\u003c\/h3\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e Avoid use in case of hypersensitivity to any of the ingredients.\u003c\/li\u003e\n\n\u003cli\u003e Do not use the product if the bottle or nozzle is damaged.\u003c\/li\u003e\n\n\u003cli\u003e Do not use if you have any lesions or acute nasal infections without consulting your doctor.\u003c\/li\u003e\n\n\u003cli\u003e Keep out of reach of children.\u003c\/li\u003e\n\n\u003cli\u003e If symptoms persist, consult a doctor.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n         \u003ch2\u003eExpiry and storage\u003c\/h2\u003e\n\n\u003ch3\u003e What are the expiration and storage conditions of Physiomer Hypertonic?\u003c\/h3\u003e\n\n\u003cp\u003e Store \u003cstrong\u003ePhysiomer Hypertonic\u003c\/strong\u003e at room temperature, away from heat and direct light. Avoid contact with contaminated surfaces to keep the product hygienic. Do not use after the expiry date shown on the package.\u003c\/p\u003e\n\n\n\u003ch2\u003e Format\u003c\/h2\u003e\n\n\u003cp\u003e Physiomer Hypertonic is available in a \u003cstrong\u003e135 ml\u003c\/strong\u003e spray bottle, easy to use and ideal for precise and hygienic application.\u003c\/p\u003e\n\n","brand":"PERRIGO ITALIA Srl","offers":[{"title":"Default Title","offer_id":40207823339635,"sku":"931340804","price":14.79,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/perrigo-italia-srl-spray-nasale-physiomer-ipertonico-confezione-135-ml-farmacia-dottor-tili-1213792754.jpg?v=1767125808"},{"product_id":"mag-notte-24-bustine-orosolubili","title":"Mag Notte 24 Orosoluble Sachets","description":"\u003cp\u003e\u003cstrong\u003eMag Notte\u003c\/strong\u003e is a food supplement based on \u003cstrong\u003emagnesium\u003c\/strong\u003e , \u003cstrong\u003emelatonin\u003c\/strong\u003e and natural extracts such as \u003cstrong\u003ehawthorn\u003c\/strong\u003e and \u003cstrong\u003epassionflower\u003c\/strong\u003e , specially formulated to promote relaxation and improve the quality of sleep. This supplement helps reduce the time it takes to fall asleep and contributes to a deeper and more restful sleep. The orosoluble sachets are convenient to use and offer rapid intake, without the need for water.\u003c\/p\u003e\n\n\n\u003ch2\u003e Dosage and method of use\u003c\/h2\u003e\n\n\u003ch3\u003e How to take Mag Notte?\u003c\/h3\u003e\n\n\u003cp\u003e It is recommended to take \u003cstrong\u003e1 sachet\u003c\/strong\u003e per day, preferably in the evening, just before bedtime. The orosoluble sachets can be taken directly without water, making the intake practical and fast. It is recommended to follow a treatment cycle for at least 15-30 days to obtain the best results.\u003c\/p\u003e\n\n\n\u003ch2\u003e Ingredients\u003c\/h2\u003e\n\n\u003ch3\u003e What ingredients does Mag Notte contain?\u003c\/h3\u003e\n\n         \u003cp\u003eMag Notte contains a combination of natural and nutritional ingredients designed to promote relaxation and sleep:\n\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eMagnesium\u003c\/strong\u003e : essential for the normal functioning of the nervous system and to reduce tiredness.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eMelatonin\u003c\/strong\u003e : helps reduce the time it takes to fall asleep.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003ePassionflower\u003c\/strong\u003e : a natural extract with relaxing and anxiolytic properties.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eHawthorn\u003c\/strong\u003e : promotes relaxation and mental well-being, supporting sleep.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eVitamin B6\u003c\/strong\u003e : supports normal psychological function and contributes to the reduction of tiredness and fatigue.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Average analysis\u003c\/h2\u003e\n\n\u003cp\u003e Each sachet of Mag Notte contains:\n\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eMagnesium\u003c\/strong\u003e : 150 mg (40% NRV*)\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eMelatonin\u003c\/strong\u003e : 1 mg\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003ePassionflower dry extract\u003c\/strong\u003e : 100 mg\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eHawthorn dry extract\u003c\/strong\u003e : 100 mg\u003c\/li\u003e\n\n\u003cli\u003e \n\u003cstrong\u003eVitamin B6\u003c\/strong\u003e : 1.4 mg (100% VNR*)\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp\u003e *Nutritional Reference Values ​​(NRV)\u003c\/p\u003e\n\n\n\u003ch2\u003e Warnings\u003c\/h2\u003e\n\n\u003ch3\u003e What are the warnings of Mag Notte?\u003c\/h3\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e Do not exceed the recommended daily dose.\u003c\/li\u003e\n\n\u003cli\u003e Food supplements are not a substitute for a varied and balanced diet.\u003c\/li\u003e\n\n\u003cli\u003e Consult your doctor before use if you are pregnant, breastfeeding or have any medical conditions.\u003c\/li\u003e\n\n\u003cli\u003e Store in a cool, dry place, away from heat sources and direct light.\u003c\/li\u003e\n\n\u003cli\u003e Keep out of reach of children.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Format\u003c\/h2\u003e\n\n\u003cp\u003e Mag Notte is available in a pack of \u003cstrong\u003e24 orosoluble sachets\u003c\/strong\u003e . The sachets are practical to carry with you and allow for rapid intake without the need for water.\u003c\/p\u003e\n\n","brand":"SANOFI SpA","offers":[{"title":"Default Title","offer_id":40207823372403,"sku":"933194728","price":13.86,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/sanofi-spa-mag-notte-24-bustine-orosolubili-farmacia-dottor-tili-1213792756.jpg?v=1767125790"},{"product_id":"durex-natural-gel-100-ml","title":"Durex Natural Gel 100ml","description":"\u003cp\u003e\u003cstrong\u003eDurex Natural Gel\u003c\/strong\u003e is a water-based intimate lubricant designed to improve comfort during sexual intercourse. This gel is formulated to reduce friction and relieve vaginal dryness, providing a smoother and more pleasurable experience. Durex Natural Gel is condom compatible and can be used with both latex and polyurethane, providing protection and safety without compromising the effectiveness of the condom.\u003c\/p\u003e\n\n\n\u003ch2\u003e Directions\u003c\/h2\u003e\n\n\u003ch3\u003e When is Durex Natural Gel indicated?\u003c\/h3\u003e\n\n\u003cp\u003e Durex Natural Gel is indicated for:\n\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eRelieve vaginal dryness\u003c\/strong\u003e and discomfort associated with sexual intercourse.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eImprove comfort\u003c\/strong\u003e during intercourse by reducing friction.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eCompatibility with condoms\u003c\/strong\u003e , ideal for combined use during intercourse.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e How to use\u003c\/h2\u003e\n\n\u003ch3\u003e How to use Durex Natural Gel?\u003c\/h3\u003e\n\n         \u003cp\u003eApply a small amount of gel directly to intimate areas or the outside of the condom. Add more gel during intercourse if necessary. Durex Natural Gel can be used with any type of Durex condom or without a condom. It is easy to rinse and leaves no sticky residue. It is recommended to reapply the gel if the feeling of dryness persists.\u003c\/p\u003e\n\n\n\u003ch2\u003e Ingredients\u003c\/h2\u003e\n\n\u003ch3\u003e What ingredients does Durex Natural Gel contain?\u003c\/h3\u003e\n\n\u003cp\u003e Durex Natural Gel is formulated with water-based ingredients that are gentle and safe for everyday use. Ingredients include:\n\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e \u003cstrong\u003eWaterfall\u003c\/strong\u003e\n\u003c\/li\u003e\n\n\u003cli\u003e \u003cstrong\u003eGlycerine\u003c\/strong\u003e\n\u003c\/li\u003e\n\n\u003cli\u003e \u003cstrong\u003eCarbomer\u003c\/strong\u003e\n\u003c\/li\u003e\n\n\u003cli\u003e \u003cstrong\u003eSodium hydroxide\u003c\/strong\u003e\n\u003c\/li\u003e\n\n\u003cli\u003e \u003cstrong\u003eSodium benzoate\u003c\/strong\u003e\n\u003c\/li\u003e\n\n\u003cli\u003e \u003cstrong\u003ePotassium sorbate\u003c\/strong\u003e\n\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Warnings\u003c\/h2\u003e\n\n\u003ch3\u003e What are the warnings for Durex Natural Gel?\u003c\/h3\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\u003cul\u003e\n\n         \u003cli\u003eAvoid contact with eyes. If irritation occurs, discontinue use and consult a physician.\u003c\/li\u003e\n\n\u003cli\u003e Do not use if you are allergic to any of the listed ingredients.\u003c\/li\u003e\n\n\u003cli\u003e It is not a contraceptive and does not contain spermicide.\u003c\/li\u003e\n\n\u003cli\u003e Store in a cool, dry place, away from heat sources and direct sunlight.\u003c\/li\u003e\n\n\u003cli\u003e Use within three months of opening the bottle.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Expiry and storage\u003c\/h2\u003e\n\n\u003ch3\u003e What are the expiration dates and storage of Durex Natural Gel?\u003c\/h3\u003e\n\n\u003cp\u003e Store Durex Natural Gel below 25°C. Once opened, use within three months. Do not use after the expiry date shown on the package. Keep out of reach of children.\u003c\/p\u003e\n\n\n\u003ch2\u003e Format\u003c\/h2\u003e\n\n\u003cp\u003e Durex Natural Gel is available in a \u003cstrong\u003e100 ml\u003c\/strong\u003e bottle, equipped with a practical dispenser that allows for easy and precise application.\u003c\/p\u003e\n\n","brand":"RECKITT BENCKISER H.(IT.) SpA","offers":[{"title":"Default Title","offer_id":40207823405171,"sku":"971377561","price":13.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/reckitt-benckiser-h-it-spa-durex-natural-gel-100-ml-farmacia-dottor-tili-1213792755.jpg?v=1767125771"},{"product_id":"profilattico-ansell-akuel-skin-elite-6-pezzi","title":"Ansell Akuel Skin Elite Condom 6 Pieces","description":"\u003cp\u003e \u003cstrong\u003eAkuel Skin Elite\u003c\/strong\u003e is an ultra-thin condom, designed to offer a natural sensory experience and a high level of protection. Made of \u003cstrong\u003enatural rubber latex\u003c\/strong\u003e , these condoms are transparent and lubricated, ensuring safety and comfort during sexual intercourse. Thanks to their thinness, Akuel Skin Elite allows for greater sensitivity, without compromising protection against unwanted pregnancies and sexually transmitted diseases (STDs).\u003c\/p\u003e\n\n\n\u003ch2\u003e Directions\u003c\/h2\u003e\n\n\u003ch3\u003e When is the Akuel Skin Elite Condom indicated?\u003c\/h3\u003e\n\n\u003cp\u003e Akuel Skin Elite condoms are indicated for:\n\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003ePrevention of unwanted pregnancies\u003c\/strong\u003e .\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eProtection against sexually transmitted diseases (STDs)\u003c\/strong\u003e .\u003c\/li\u003e\n\n         \u003cli\u003eEnsure a natural sensory experience thanks to their ultra-thin formulation.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e How to use\u003c\/h2\u003e\n\n\u003ch3\u003e How to use the Akuel Skin Elite Condom?\u003c\/h3\u003e\n\n\u003cp\u003e 1. \u003cstrong\u003eOpening\u003c\/strong\u003e : Open the package carefully to avoid damaging the condom. Do not use scissors or sharp objects.\u003c\/p\u003e\n\n\u003cp\u003e 2. \u003cstrong\u003eApplication\u003c\/strong\u003e : Place the condom on the erect penis and gently unroll to the base. Make sure there are no air bubbles inside the condom.\u003c\/p\u003e\n\n\u003cp\u003e 3. \u003cstrong\u003eRemoval\u003c\/strong\u003e : After intercourse, remove the condom before the penis loses its erection, taking care not to spill any fluids. Dispose of the condom safely, avoiding flushing it down the toilet.\u003c\/p\u003e\n\n\n\u003ch2\u003e Package Contents\u003c\/h2\u003e\n\n\u003ch3\u003e What does the Akuel Skin Elite package contain?\u003c\/h3\u003e\n\n\u003cp\u003e The package contains \u003cstrong\u003e6 Akuel Skin Elite condoms\u003c\/strong\u003e :\n\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e Made of \u003cstrong\u003enatural rubber latex\u003c\/strong\u003e , transparent and lubricated.\u003c\/li\u003e \n\u003cli\u003eUltra-thin design for greater sensitivity and naturalness during intercourse.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Warnings\u003c\/h2\u003e\n\n\u003ch3\u003e What are the warnings of Akuel Skin Elite?\u003c\/h3\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e Akuel condoms are \u003cstrong\u003edisposable\u003c\/strong\u003e : use a new condom for each sexual intercourse.\u003c\/li\u003e\n\n\u003cli\u003e Store in a cool, dry place, away from heat sources and direct light.\u003c\/li\u003e\n\n\u003cli\u003e Do not use oil or grease based lubricants, as they may damage the latex.\u003c\/li\u003e\n\n\u003cli\u003e Do not use the condom if the packaging is damaged or expired.\u003c\/li\u003e\n\n\u003cli\u003e If you have any allergies to latex, discontinue use and consult a doctor.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Expiry and storage\u003c\/h2\u003e\n\n\u003ch3\u003e What are the expiration dates and storage of Akuel Skin Elite?\u003c\/h3\u003e\n\n\u003cp\u003e Store Akuel Skin Elite condoms at a temperature below 30°C, away from heat sources and direct light. Check the expiry date on the package before use and do not use them beyond the date indicated.\u003c\/p\u003e\n\n\n\u003ch2\u003e Format\u003c\/h2\u003e\n\n         \u003cp\u003eAkuel Skin Elite is available in packs of \u003cstrong\u003e6 condoms\u003c\/strong\u003e , each individually packaged to ensure maximum hygiene and safety.\u003c\/p\u003e\n\n","brand":"NOVA ARGENTIA SpA","offers":[{"title":"Default Title","offer_id":40207823470707,"sku":"934880877","price":12.08,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/nova-argentia-spa-profilattico-ansell-akuel-skin-elite-6-pezzi-farmacia-dottor-tili-1213792751.jpg?v=1767125858"},{"product_id":"pursennid-30-compresse-lassative-12-mg","title":"Pursennid 30 Laxative Tablets 12 mg","description":"\u003cp\u003ePursennid Laxative Tablets is a preparation based on \u003cstrong\u003eactive ingredients extracted from the senna plant\u003c\/strong\u003e with a \u003cstrong\u003elaxative action\u003c\/strong\u003e . Pursennid Laxative Tablets is indicated in cases of \u003cstrong\u003eoccasional constipation, difficulty evacuating and hard stools.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e Pursennid Laxative Tablets works within 6-12 hours, by stimulating the large intestine, activating the evacuation of feces \u003cstrong\u003eapproximately 8 hours after taking it\u003c\/strong\u003e .\u003cbr\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Pursennid 30 Laxative Tablets 12 mg - What is the active ingredient in Pursennid 30 Laxative Tablets 12 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eOne coated tablet contains the active substance: sennosides A + B (as calcium salts) 12 mg. Excipients with known effect: lactose monohydrate; glucose anhydrous; sucrose. For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eComposition of Pursennid 30 Laxative Tablets 12 mg - What does Pursennid 30 Laxative Tablets 12 mg contain?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eLactose monohydrate; stearic acid; talc; corn starch; anhydrous glucose; sucrose; gum arabic; colloidal anhydrous silica; titanium dioxide; cetyl palmitate.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Pursennid 30 Laxative Tablets 12 mg - Why is Pursennid 30 Laxative Tablets 12 mg used? What is it used for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eShort-term treatment of occasional constipation.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Pursennid 30 Laxative Tablets 12 mg - When should Pursennid 30 Laxative Tablets 12 mg not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eHypersensitivity to the active substance or to any of the excipients listed in section 6.1. Contraindicated in the following medical conditions: inflammatory diseases of the digestive system (i.e. Crohn's disease, ulcerative colitis, liver disease, peritonitis and inflammatory bowel disease); irritation or obstruction of the gastrointestinal tract (i.e. spastic constipation, obstruction of the ileum\/pre-ileum, cramps and pain, nausea, vomiting and colic); abdominal symptoms which may be due to an undiagnosed underlying condition, such as acute intestinal conditions which may require surgery (i.e. acute diverticulitis, appendicitis and massive diarrhoea); states of severe dehydration, with loss of water and electrolytes, especially hypokalaemia. Contraindicated in children under 10 years of age.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eQuantity and method of taking Pursennid 30 Laxative Tablets 12 mg - How to take Pursennid 30 Laxative Tablets 12 mg?\u003c\/span\u003e\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eDosage. Adults and children over 12 years of age: 2-4 coated tablets per day. Children between 10 and 12 years: 1-2 coated tablets per day. After a short period of treatment without appreciable results, consult your doctor. The correct dose is the minimum sufficient to produce easy evacuation of soft stools. It is advisable to initially use the minimum doses indicated. When necessary, the dose can then be increased, but without ever exceeding the maximum indicated. Paediatric population: contraindicated in children under 10 years of age. Method of administration: preferably take in the evening. Pursennid's action occurs after 6-12 hours. Administered in the evening, Pursennid appears the following morning. Laxatives should be used as infrequently as possible and for no more than seven days. Use for longer periods of time requires a doctor's prescription after adequate evaluation of the individual case. Swallow together with an adequate quantity of water (a large glass). A diet rich in liquids favors the use of the medicine.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Pursennid 30 Laxative Tablets 12 mg - How to store Pursennid 30 Laxative Tablets 12 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThis medicinal product does not require any special storage conditions.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Pursennid 30 Laxative Tablets 12 mg - About Pursennid 30 Laxative Tablets 12 mg it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe established dose should not be exceeded. Prolonged indiscriminate use of laxatives may lead to habituation and deterioration of intestinal function. The lowest effective dosage for the restoration of normal intestinal function should be used. If no intestinal improvement has been achieved, the dosage may be increased under medical supervision. Products containing senna and sennosides should only be used if a therapeutic effect cannot be achieved by changing the diet or administering bulking agents. The use of these drugs requires medical supervision: if no positive effects are achieved following treatment; if use is prolonged beyond one week of treatment; if symptoms persist or worsen; after laparotomy or abdominal surgery; if a skin rash is present, as this may be a sign of hypersensitivity; if nausea and vomiting are present, as these symptoms may be signs of a potential or existing intestinal blockage (ileus); in children between 10 and 12 years. Information on excipients. Lactose: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Glucose: Patients with rare hereditary problems of glucose-galactose malabsorption should not take this medicine. Sucrose: Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Pursennid 30 Laxative Tablets 12 mg - Which medicines or foods can modify the effect of Pursennid 30 Laxative Tablets 12 mg?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eConcomitant use of other drugs that induce hypokalemia (hydiuretics, adrenocorticosteroids and liquorice) may increase electrolyte imbalance. Hypokalemia (resulting from abuse of laxatives taken for a long time) potentiates the action of cardiac glycosides and interferes with antiarrhythmic drugs, with other drugs that induce a return to sinus rhythm (quinidine) and with drugs that induce QT interval prolongation.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Pursennid 30 Laxative Tablets 12 mg can cause side effects - What are the side effects of Pursennid 30 Laxative Tablets 12 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThis medicine may cause mild abdominal discomfort such as abdominal pain, cramps, irritation of the colonic and gastric mucosa. Other effects such as dehydration, hypotension, fatigue, myopathies, stomach pain, hyponatremia, renal disorders, secondary hyperaldosteronism, hypocalcemia and hypomagnesemia have also been reported. These adverse reactions are usually reversible once the laxative is stopped. Prolonged use or overdose of this medicine may cause nausea, diarrhea with excessive loss of electrolytes, especially potassium (hypokalaemia). There is also the possibility of developing megacolon. During treatment, a yellow-brownish (pH-dependent) coloration of the urine due to metabolites may occur, which has no clinical significance. Habituation has been reported after prolonged treatment. The adverse reactions are listed below by system organ class and frequency. The frequencies are defined as: very common (\u0026gt;= 1\/10); common (\u0026gt;= 1\/100, \u0026lt; 1\/10); uncommon (\u0026gt;= 1\/1,000, \u0026lt; 1\/100); rare (\u0026gt;= 1\/10,000; \u0026lt; 1\/1,000); very rare (\u0026lt; 1\/10,000); or not known (frequency cannot be estimated from the available data). Undesirable effects in post-marketing experience. Immune system disorders. Not known: hypersensitivity reactions (pruritus, urticaria, local or generalized rash). Gastrointestinal disorders. Not known: megacolon, abdominal pain, diarrhoea, nausea, abdominal discomfort. General disorders and administration site conditions. Not known: fatigue, drug tolerance. Musculoskeletal and connective tissue disorders. Not known: myopathy. Renal and urinary disorders. Not known: kidney problems, chromaturia. Metabolism and nutrition disorders. Not known: hyperaldosteronism, hypocalcemia, hypomagnesemia, dehydration, hypokalaemia, hyponatremia, decreased blood electrolytes. Vascular disorders. Not known: hypotension. The adverse events listed above are based on spontaneous post-marketing reports and are a less precise estimate of the incidence that would be obtained in clinical trials. Paediatric population: the same frequency, type and severity of adverse events are expected in children and adults. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Pursennid 30 Laxative Tablets 12 mg.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003ePregnancy: There are no adequate data on the use of sennosides in pregnant women. Studies in animals have not shown reproductive toxicity. The potential risk for humans is unknown. Pregnant women should consult their doctor before taking this medicine. Breastfeeding: Use during breastfeeding is not recommended as there are insufficient data on the excretion of metabolites in breast milk. Small amounts of metabolites (rhein) are excreted in breast milk. No laxative effect on breast-fed infants has been reported. Fertility: Preclinical studies with sennosides do not indicate any particular risk for fertility at therapeutically relevant doses.\u003c\/span\u003e\u003c\/p\u003e","brand":"GLAXOSMITHKLINE C.HEALTH.SpA","offers":[{"title":"Default Title","offer_id":40207823732851,"sku":"004758025","price":12.28,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/glaxosmithkline-c-health-spa-pursennid-30-compresse-lassative-12-mg-farmacia-dottor-tili-1213792748.jpg?v=1767125872"},{"product_id":"enterogermina-4-miliardi-5-ml-20-flaconcini","title":"Enterogermina 4 Billion\/5 Ml 20 Vials","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eEnterogermina 4 Billion\/5 Ml 20 Vials\u003c\/span\u003e \u003cspan\u003elactic ferments with probiotic action\u003c\/span\u003e \u003cspan\u003efor the\u003c\/span\u003e \u003cspan\u003etreatment and prophylaxis of intestinal dysbiosis.\u003c\/span\u003e \u003cspan\u003eHelps\u003c\/span\u003e \u003cspan\u003erestore intestinal balance\u003c\/span\u003e \u003cspan\u003ethanks to the spores of Bacillus clausii polyantibiotic resistant.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eEnterogermina 4 Billion\/5 Ml 20 Vials is indicated for:\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e \u003cspan\u003ePrevention\u003c\/span\u003e \u003cspan\u003eand treatment of alterations in the normal balance of intestinal bacterial flora\u003c\/span\u003e \u003cspan\u003e(intestinal dysbiosis) and vitamin deficiencies in the body resulting from an imbalance in intestinal bacterial flora (endogenous dysvitaminosis).\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e \u003cspan\u003eAdjuvant therapy for the\u003c\/span\u003e \u003cspan\u003erestoration of the intestinal microbial flora\u003c\/span\u003e \u003cspan\u003e, altered during antibiotic or chemotherapy treatments.\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n \u003cp role=\"presentation\" dir=\"ltr\"\u003e\u003cspan\u003eTreatment\u003c\/span\u003e \u003cspan\u003eof acute and chronic gastrointestinal diseases\u003c\/span\u003e \u003cspan\u003eof infants caused by intoxication or alterations in the normal balance of intestinal bacterial flora (intestinal dysmicrobism) or vitamin deficiencies in the body (dysvitaminosis).\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Enterogermina 4 Billion\/5 Ml 20 Vials - What is the active ingredient in Enterogermina 4 Billion\/5 Ml 20 Vials?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eOne vial contains, active substance: spores of polyantibiotic-resistant Bacillus clausii (strains SIN, O\/C, T, N\/R) 4 billion. For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Enterogermina 4 Billion\/5 Ml 20 Vials - What does Enterogermina 4 Billion\/5 Ml 20 Vials contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eVials: purified water.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eTherapeutic indications Enterogermina 4 Billion\/5 Ml 20 Vials - Why is Enterogermina 4 Billion\/5 Ml 20 Vials used? What is it used for?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eTreatment and prophylaxis of intestinal dysmicrobism and consequent endogenous dysvitaminosis. Adjuvant therapy for the restoration of intestinal microbial flora, altered during antibiotic or chemotherapy treatments. Acute and chronic gastro-intestinal disorders in infants, attributable to intoxications or intestinal dysmicrobism and dysvitaminosis.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Enterogermina 4 Billion\/5 Ml 20 Vials - When should Enterogermina 4 Billion\/5 Ml 20 Vials not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eQuantity and method of taking Enterogermina 4 Billion\/5 Ml 20 Vials - How is Enterogermina 4 Billion\/5 Ml 20 Vials taken?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eDosage. Adults: 1 vial per day. Infants and children: 1 vial per day. Method of administration: take the contents of the vial as is or diluted in water or other drinks (e.g. milk, tea, orange juice). This medicine is for oral use only. Do not inject or administer in any other way (see section 4.4).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Enterogermina 4 Billion\/5 Ml 20 Vials - How is Enterogermina 4 Billion\/5 Ml 20 Vials stored?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eStore below 30 degrees C.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Enterogermina 4 Billion\/5 Ml 20 Vials - It is important to know that about Enterogermina 4 Billion\/5 Ml 20 Vials:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eSpecial warnings. Bacteremia\/sepsis: Cases of bacteremia, septicaemia and sepsis have been reported in immunocompromised or critically ill patients and in preterm infants since the introduction into the market. In some critically ill patients, the outcome was fatal. Enterogermina should be avoided in these groups of patients (see section 4.8). This medicinal product is for oral use only. Do not inject or administer by other routes. Incorrect use of the medicinal product has caused serious anaphylactic reactions such as anaphylactic shock. Precautions for use: during antibiotic therapy, it is advisable to administer the preparation in the interval between one and the other antibiotic administration. Any visible corpuscles in the vials of Enterogermina are due to aggregates of Bacillus clausii spores; therefore, they do not indicate an altered product. Shake the vial before use.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eInteractions Enterogermina 4 Billion\/5 Ml 20 Vials - Which medicines or foods can modify the effect of Enterogermina 4 Billion\/5 Ml 20 Vials?'\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eNo interaction studies have been performed.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Enterogermina 4 Billion\/5 Ml 20 Vials can cause side effects - What are the side effects of Enterogermina 4 Billion\/5 Ml 20 Vials?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe following undesirable effects have been observed during treatment with this medicinal product, classified according to the MedDRA organ class and frequency categories: very common (\u0026gt;=1\/10); common (\u0026gt;=1\/100, \u0026lt;1\/10); uncommon (\u0026gt;=1\/1,000, \u0026lt;1\/100); rare (\u0026gt;=1\/10,000, \u0026lt;1\/1,000); very rare \u0026lt;1\/10,000); not known (frequency cannot be estimated from the available data). Infections and infestations. Not known: bacteraemia, septicaemia and sepsis (in immunocompromised or severely ill patients) (see section 4.4). Skin and subcutaneous tissue disorders. Not known: hypersensitivity reactions, including rash, urticaria and angioedema. Reporting of suspected adverse reactions. Reporting of suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Enterogermina 4 Billion\/5 Ml 20 Vials.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003ePregnancy: There are no data available on the use of Enterogermina in pregnant women; therefore, it is not possible to draw conclusions on the safety of using Enterogermina during pregnancy. Enterogermina should be used during pregnancy only if the potential benefits for the mother outweigh the potential risks, including those for the fetus. Breastfeeding: There are no data available on the use of Enterogermina during breastfeeding regarding the composition of breast milk and the effects on the child. It is not possible to draw conclusions on the safety of using Enterogermina during breastfeeding. Enterogermina should be used during breastfeeding only if the potential benefits for the mother outweigh the potential risks, including those for the breastfed child. Fertility: There are no data available on the effect of Enterogermina on human fertility.\u003c\/span\u003e\u003c\/p\u003e","brand":"SANOFI SpA","offers":[{"title":"Default Title","offer_id":40207823798387,"sku":"013046089","price":25.02,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sanofi-spa-enterogermina-4-miliardi-5-ml-20-flaconcini-farmacia-dottor-tili-1213792750.webp?v=1767125928"},{"product_id":"voltaren-emulgel-gel-60-gr-2","title":"Voltaren Emulgel Gel 60 Gr 2%","description":"\u003cp\u003eVoltaren Emulgel Gel\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003epain reliever and anti-inflammatory\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eFor\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003emuscle and joint pain\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003ebased on Diclofenac (2%). Voltaren Emulgel is a local treatment of\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003epainful and inflammatory conditions\u003c\/strong\u003e : of a rheumatic or traumatic nature of the joints, such as \u003cstrong\u003eosteoarthritis and arthritis\u003c\/strong\u003e ; of the muscles, in case of\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003econtractures or injuries\u003c\/strong\u003e ; of tendons and ligaments, in the presence of\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003etendonitis\u003c\/strong\u003e .\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Voltaren Emulgel Gel 60 Gr 2% - What is the active ingredient in Voltaren Emulgel Gel 60 Gr 2%?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e100 g of Voltaren Emulgel contain 2.32 g of diclofenac diethylammonium, equivalent to 2 g of diclofenac sodium. Excipients with known effect: propylene glycol (50 mg\/g of gel), butylhydroxytoluene (0.2 mg\/g of gel), pungent eucalyptus perfume. For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Voltaren Emulgel Gel 60 Gr 2% - What does Voltaren Emulgel Gel 60 Gr 2% contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eButylated hydroxytoluene, carbomers, cocoyl caprylocaprate, diethylamine, isopropyl alcohol, liquid paraffin, macrogol cetostearyl ether, oleic alcohol, propylene glycol, pungent eucalyptus perfume, purified water.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Voltaren Emulgel Gel 60 Gr 2% - Why is Voltaren Emulgel Gel 60 Gr 2% used? What is it used for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eLocal treatment of painful and inflammatory conditions of rheumatic or traumatic nature of the joints (such as osteoarthritis and arthritis), muscles (such as contractures or injuries), tendons and ligaments (such as tendinitis).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Voltaren Emulgel Gel 60 Gr 2% - When should Voltaren Emulgel Gel 60 Gr 2% not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eHypersensitivity to the active substance or to any of the excipients listed in section 6.1; history of asthma, angioedema, urticaria or acute rhinitis following the intake of acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs (NSAIDs); during the third trimester of pregnancy; use in children and adolescents under 14 years of age is contraindicated.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Voltaren Emulgel Gel 60 Gr 2% - How is Voltaren Emulgel Gel 60 Gr 2% taken?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eFor cutaneous use. Adults over 18 years, Voltaren Emulgel 2% gel provides pain relief for up to 12 hours: apply Voltaren Emulgel 2% gel 2 times a day to the area to be treated (preferably in the morning and evening), rubbing in lightly. The amount to be applied depends on the size of the affected area. For example, 2-4 g of Voltaren Emulgel 2% gel (an amount between the size of a cherry and a walnut) is sufficient to treat an area of ​​400-800 cm^2. After application, clean your hands with absorbent paper and then wash them, unless they are the site to be treated. Absorbent paper should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 2% to dry before showering or bathing. Caution: Use only for short periods of treatment. The duration of treatment depends on the indication for use and the clinical response. The gel should not be used for more than 14 days without medical advice. Consult your doctor if symptoms persist or worsen after 7 days of treatment. Adolescents aged 14 to 18 years: apply Voltaren Emulgel 2% gel 2 times a day to the area to be treated (preferably in the morning and evening), rubbing in lightly. The amount to be applied depends on the size of the affected area. For example, 2-4 g of Voltaren Emulgel 2% gel (an amount between the size of a cherry and a walnut) is sufficient to treat an area of ​​400-800 cm^2. After application, clean your hands with absorbent paper and then wash them, unless they are the site to be treated. Absorbent paper should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 2% to dry before showering or bathing. If this product is needed for more than 7 days to relieve pain or if symptoms worsen, consult a doctor. Children under 14 years: insufficient data are available on the efficacy and safety in children and adolescents under 14 years of age (see section 4.3 Contraindications). Therefore, the use of Voltaren Emulgel 2% gel is contraindicated in children under 14 years of age. Elderly (over 65 years): the usual adult dosage may be used.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Voltaren Emulgel Gel 60 Gr 2% - How is Voltaren Emulgel Gel 60 Gr 2% stored?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThis medicinal product does not require any special storage conditions.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Voltaren Emulgel Gel 60 Gr 2% - On Voltaren Emulgel Gel 60 Gr 2% it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe possibility of systemic adverse events with the application of Voltaren Emulgel 2% cannot be excluded if the preparation is used on large areas of skin and for a prolonged period. Voltaren Emulgel 2% must be applied only to intact, non-diseased skin and not to skin wounds or open lesions. It must not be allowed to come into contact with the eyes or mucous membranes and must not be ingested. Discontinue treatment if a skin rash develops after application of the product. Voltaren Emulgel 2% can be used with non-occlusive dressings, but must not be used with an occlusive dressing that does not allow air to pass through. Important information about some of the excipients: Voltaren Emulgel 2% gel contains 200 mg of propylene glycol per dose (4 g) equivalent to 50 mg\/g which may cause skin irritation. Voltaren Emulgel 2% gel contains butylhydroxytoluene which may cause localised skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes. Voltaren Emulgel 2% gel contains pungent eucalyptus perfume, a flavouring containing benzyl alcohol, citronellol, coumarin, d-limonene, eugenol, geraniol, linalool which may cause allergic reactions.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Voltaren Emulgel Gel 60 Gr 2% - Which medicines or foods can modify the effect of Voltaren Emulgel Gel 60 Gr 2%?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eSince systemic absorption of diclofenac following topical application is very low, interactions are very unlikely.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Voltaren Emulgel Gel 60 Gr 2% can cause side effects - What are the side effects of Voltaren Emulgel Gel 60 Gr 2%?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eUndesirable effects include mild and transient skin reactions at the application site. In very rare cases, allergic reactions may occur. Undesirable effects are listed below by system organ class and MedDRA frequency. Frequencies are defined as: very common (\u0026gt;= 1\/10); common (\u0026gt;= 1\/100 to \u0026lt;1\/10); uncommon (\u0026gt;= 1\/1,000 to \u0026lt; 1\/100); rare (\u0026gt;= 1\/10,000 to \u0026lt; 1\/1,000); very rare (\u0026lt; 1\/10,000) not known (frequency cannot be estimated from the available data). Infections and infestations. Very rare: rash with pustules. Immune system disorders. Very rare: hypersensitivity (including urticaria), angioedema. Respiratory, thoracic and mediastinal disorders. Very rare: asthma. Skin and subcutaneous tissue disorders. Common: dermatitis (including contact dermatitis), rash, erythema, eczema, pruritus; rare: bullous dermatitis; very rare: photosensitivity reaction, allergic reactions; not known: burning sensation at the application site, dry skin. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Voltaren Emulgel Gel 60 Gr 2%\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003ePregnancy: The systemic concentration of diclofenac compared to oral formulations is lower after topical administration. Based on experience with treatment with systemic NSAIDs, the following is recommended: Inhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or embryo\/fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increases from less than 1%, up to approximately 1.5%. The risk is believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to cause increased pre- and post-implantation loss and embryo\/fetal mortality; In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be given unless clearly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction, which may progress to renal failure with oligo-hydroamniosis; the mother and neonate, at the end of pregnancy, to: possible prolongation of bleeding time, and an anti-aggregating effect which may occur even at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labor. Diclofenac is contraindicated during the third trimester of pregnancy. Breastfeeding: Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of Voltaren Emulgel 2% no effects on the infant are anticipated. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, Voltaren Emulgel 2% should not be applied to the breasts of nursing mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4 Special warnings and precautions for use).\u003c\/span\u003e\u003c\/p\u003e","brand":"NOVARTIS FARMA SpA","offers":[{"title":"Default Title","offer_id":40207823929459,"sku":"034548065","price":13.67,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/novartis-farma-spa-voltaren-emulgel-gel-60-gr-2-farmacia-dottor-tili-1213792743.webp?v=1767125980"},{"product_id":"aspirina-c-20-compresse-effervescenti-400-240-mg","title":"Aspirin C 20 Effervescent Tablets 400+240 mg ","description":"\u003cdiv style=\"text-align: left;\"\u003eAspirin C Effervescent tablets with vitamin C is a treatment for the \u003cstrong\u003esymptoms of fever\u003c\/strong\u003e , flu and \u003cstrong\u003ecold\u003c\/strong\u003e \u003cstrong\u003esyndromes\u003c\/strong\u003e based on \u003cstrong\u003eAcetylsalicylic acid\u003c\/strong\u003e . Aspirin C Tablets has an \u003cstrong\u003eeffective\u003c\/strong\u003e antipyretic and \u003cstrong\u003eanalgesic\u003c\/strong\u003e \u003cstrong\u003eaction\u003c\/strong\u003e . Indicated for the symptomatic treatment of headache, toothache, neuralgia, menstrual pain, rheumatic and muscular pain.\u003cbr\u003e\n\n\u003c\/div\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\n\u003ch3\u003e Active ingredients contained in Aspirin C 20 Effervescent Tablets 400+240 mg - What is the active ingredient in Aspirin C 20 Effervescent Tablets 400+240 mg?\u003c\/h3\u003e\n\n\u003cp\u003e Aspirin 400 mg effervescent tablets with vitamin C, one tablet contains active ingredients: acetylsalicylic acid 400 mg; ascorbic acid (Vitamin C) 240 mg. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\n \u003ch3\u003eComposition of Aspirin C 20 Effervescent Tablets 400+240 mg - What does Aspirin C 20 Effervescent Tablets 400+240 mg contain?\u003c\/h3\u003e\n\n\u003cp\u003e Excipients: monosodium citrate, sodium bicarbonate, sodium carbonate, citric acid.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Therapeutic indications Aspirin C 20 Effervescent Tablets 400+240 mg - Why is Aspirin C 20 Effervescent Tablets 400+240 mg used? What is it used for?\u003c\/h3\u003e\n\n\u003cp\u003e Symptomatic treatment of feverish states and flu and cold syndromes. Symptomatic treatment of headache and toothache, neuralgia, menstrual pain, rheumatic and muscular pain.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2\u003e CONTRAINDICATIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Contraindications Aspirin C 20 Effervescent Tablets 400+240 mg - When should Aspirin C 20 Effervescent Tablets 400+240 mg not be used?\u003c\/h3\u003e\n\n \u003cp\u003e\/SECONDARY EFFECTS Aspirin effervescent tablets with vitamin C is contraindicated in case of: hypersensitivity to the active substances (acetylsalicylic acid and ascorbic acid), to other analgesics (painkillers)\/antipyretics (feverkillers)\/nonsteroidal anti-inflammatory drugs (NSAIDs) or to any of the excipients; gastroduodenal ulcer; haemorrhagic diathesis; severe renal, cardiac or hepatic insufficiency; glucose-6-phosphate dehydrogenase (G6PD\/favism) deficiency; concomitant treatment with methotrexate (at doses of 15 mg\/week or more) or with warfarin (see section 4.5); history of asthma induced by the administration of salicylates or substances with similar activity, in particular nonsteroidal anti-inflammatory drugs; last trimester of pregnancy and breastfeeding (see section 4.6); children and adolescents under 16 years of age. Nephrolithiasis or previous history of nephrolithiasis; hyperoxaluria; hemochromatosis\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\n \u003ch3\u003eQuantity and method of taking Aspirin C 20 Effervescent Tablets 400+240 mg - How to take Aspirin C 20 Effervescent Tablets 400+240 mg?\u003c\/h3\u003e\n\n \u003cp\u003eAdults: 1-2 tablets as a single dose, repeating, if necessary, the dose at intervals of 4-8 hours up to 3-4 times a day. Aspirin C must always be dissolved before use (1 tablet in half a glass of water). The product is reserved for adult patients only. Always use the lowest effective dosage and increase it only if it is not sufficient to relieve the symptoms (pain and fever). Those most at risk of serious side effects, who can use the medicine only if prescribed by a doctor, must carefully follow the instructions (see section 4.4). Use the medicine for the shortest possible period. Do not take the product for more than 3 - 5 days without consulting a doctor. Consult your doctor if symptoms persist. Take the medicine preferably after main meals or, in any case, on a full stomach. Special populations. Paediatric population: Aspirin effervescent tablets with vitamin C are not indicated for use in the paediatric population (see section 4.4). Elderly: In elderly patients, use the lowest effective dosage. Patients with impaired hepatic function: Acetylsalicylic acid should be used with caution in patients with impaired hepatic function (see section 4.4). Patients with impaired renal function: Acetylsalicylic acid should be used with caution in patients with impaired renal function (see section 4.4).\u003c\/p\u003e\n\n \u003cp\u003e\u003c\/p\u003e\n\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\n\u003ch3\u003e Storage Aspirin C 20 Effervescent Tablets 400+240 mg - How to store Aspirin C 20 Effervescent Tablets 400+240 mg?\u003c\/h3\u003e\n\n\u003cp\u003e Store below 25 degrees C.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\n\u003ch3\u003e Warnings Aspirin C 20 Effervescent Tablets 400+240 mg - About Aspirin C 20 Effervescent Tablets 400+240 mg it is important to know that:\u003c\/h3\u003e\n\n \u003cp\u003eHypersensitivity reactions: acetylsalicylic acid and other NSAIDs may cause hypersensitivity reactions (including asthma attacks, rhinitis, angioedema or urticaria). The risk is higher in subjects who have already shown a hypersensitivity reaction after using this type of drug in the past (see section 4.3) and in subjects who have allergic reactions to other substances (e.g. skin reactions, itching, urticaria). In subjects with asthma and\/or rhinitis (with or without nasal polyposis) and\/or urticaria, reactions may be more frequent and severe. In rare cases, reactions may be very serious and potentially fatal. In the following cases, administration of the drug requires a doctor's prescription after careful evaluation of the risk\/benefit ratio. Subjects at increased risk of hypersensitivity reactions (see above). Subjects at increased risk of gastrointestinal lesions: acetylsalicylic acid and other NSAIDs may cause serious gastrointestinal side effects (bleeding, ulcer, perforation). For this reason, these drugs should not be used by subjects suffering from gastrointestinal ulcers or gastrointestinal bleeding. It is also prudent that those who have suffered from gastrointestinal ulcers or gastrointestinal bleeding in the past should avoid their use. The risk of gastrointestinal lesions is a dose-related effect, as gastrolesivity is greater in subjects who use higher doses of acetylsalicylic acid. Subjects who are used to drinking large quantities of alcohol are also more exposed to the risk of gastrointestinal lesions (bleeding in particular) (see section 4.5). Subjects with coagulation defects or undergoing treatment with anticoagulants: in subjects suffering from coagulation defects or undergoing treatment with anticoagulants, acetylsalicylic acid and other NSAIDs can cause a serious reduction in haemostatic capacity, exposing them to the risk of haemorrhage. Subjects with impaired renal or cardiac or hepatic function: acetylsalicylic acid and other NSAIDs may cause a critical reduction in renal function and fluid retention; the risk is greater in subjects treated with diuretics. This can be particularly dangerous for the elderly and for subjects with impaired renal or cardiac or hepatic function. Subjects suffering from asthma: acetylsalicylic acid and other NSAIDs may cause an aggravation of asthma. Geriatric age (especially over 75 years): the risk of serious adverse effects is greater in geriatric subjects. Subjects over 70 years of age, especially in the presence of concomitant therapies, should use Aspirin only after consulting a doctor. Aspirin should not be used in the paediatric population (see section 4.3). Products containing acetylsalicylic acid should not be used in children and adolescents under 16 years of age with viral infections, regardless of whether or not fever is present. In certain viral infections, especially influenza A, influenza B and chickenpox, there is a risk of Reye's Syndrome, a very rare but life-threatening disease that requires immediate medical attention. The risk may be increased by concomitant intake of acetylsalicylic acid, although a causal relationship has not been demonstrated. Persistent vomiting in patients with these diseases may be a sign of Reye's Syndrome. Subjects with hyperuricaemia\/gout: acetylsalicylic acid may interfere with the elimination of uric acid: high doses have a uricosuric effect while (very) low doses may reduce its excretion. It should also be considered that acetylsalicylic acid and other NSAIDs may mask the symptoms of gout, delaying its diagnosis. An antagonistic effect with uricosuric drugs is also possible (see section 4.5). Subjects with a predisposition to calcium-oxalate nephrolithiasis (kidney stones) or with recurrent nephrolithiasis. Aspirin effervescent tablets with vitamin C: Vitamin C (ascorbic acid) should be used with caution by subjects with a predisposition to calcium-oxalate nephrolithiasis (kidney stones) or with recurrent nephrolithiasis. Combinations of drugs not recommended or requiring special precautions or dosage adjustment: the use of acetylsalicylic acid in combination with certain drugs may increase the risk of serious side effects (see section 4.5). Do not use acetylsalicylic acid together with another NSAID or, in any case, do not use more than one NSAID at a time. If you are undergoing surgery (even a minor one, for example tooth extraction) and have used acetylsalicylic acid or another NSAID in the previous few days, you must inform the surgeon due to the possible effects on coagulation. Since acetylsalicylic acid can cause gastrointestinal bleeding, this must be taken into account if a search for occult blood is necessary. Before administering any medicine, all useful precautions must be taken to prevent unwanted reactions; particularly important is the exclusion of previous hypersensitivity reactions to this or other medicines and the exclusion of other contraindications or conditions that may expose you to the risk of potentially serious unwanted effects listed above. If in doubt, consult your doctor or pharmacist. Imperfect and prolonged storage of Aspirin C may cause variations in the colour of the tablet which in themselves do not affect either the activity or the tolerability of the active ingredient. In this case, it is advisable to ask the pharmacy to replace the package. The product must be taken on a full stomach. Information on excipients: this medicine contains 467 mg of sodium per effervescent tablet equivalent to 23% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult.\u003c\/p\u003e\n\n \u003cp\u003e\u003c\/p\u003e\n\n\u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Interactions Aspirin C 20 Effervescent Tablets 400+240 mg - Which medicines or foods can modify the effect of Aspirin C 20 Effervescent Tablets 400+240 mg?'\u003c\/h3\u003e\n\n \u003cp\u003eContraindicated combinations (avoid concomitant use - see section 4.3). Methotrexate (doses greater than or equal to 15 mg\/week): increased plasma levels and toxicity of methotrexate; the risk of toxic effects is greater if renal function is impaired. Warfarin: severely increased risk of haemorrhage due to increased anticoagulant effect. Combinations not recommended (the concomitant use of the two drugs requires a doctor's prescription after careful evaluation of the risk\/benefit ratio - see section 4.4): Antiplatelet agents: increased risk of haemorrhage due to the addition of the antiaggregant effect. Thrombolytics or oral or parenteral anticoagulants: increased risk of haemorrhage due to increased pharmacological effect. NSAIDs (excluding topical use): increased risk of serious adverse effects. Methotrexate (doses less than 15 mg\/week): the increased risk of toxic effects (see above) must also be considered for treatment with low-dose methotrexate. Selective serotonin reuptake inhibitors (SSRIs): increased risk of upper gastrointestinal bleeding due to a possible synergistic effect. Combinations requiring special precautions or dosage adjustment (the concomitant use of the two drugs requires a doctor's prescription after careful evaluation of the risk\/benefit ratio - see paragraph 4.4). ACE inhibitors: reduction of the hypotensive effect; increased risk of renal impairment. Valproic acid: increased effect of valproic acid (risk of toxicity). Antacids: antacids taken simultaneously with other drugs may reduce their absorption; the excretion of acetylsalicylic acid increases in alkaline urine. Antidiabetics (e.g. insulin and oral hypoglycaemics): increased hypoglycaemic effect; the use of acetylsalicylic acid in subjects treated with antidiabetics must take into account the risk of inducing hypoglycaemia. Digoxin: increased plasma concentration of digoxin due to decreased renal elimination. Diuretics: increased risk of nephrotoxicity of acetylsalicylic acid and other NSAIDs; reduced effect of diuretics. Acetazolamide: reduced elimination of acetazolamide (risk of toxicity). Phenytoin: increased effect of phenytoin. Corticosteroids (excluding those for topical use and those used for the treatment of adrenal insufficiency): a) increased risk of gastrointestinal lesions; b) due to the increased elimination of salicylates induced by corticosteroids, plasma salicylate levels are reduced. Conversely, after stopping corticosteroid treatment, salicylate overdose may occur. Metoclopramide: increased effect of acetylsalicylic acid by increasing the rate of absorption. Uricosurics (e.g. probenecid, benzbromarone): decreased uricosuric effect. Zafirlukast: increased plasma concentration of zafirlukast. Deferoxamine. Aspirin effervescent tablets with vitamin C: concomitant use of ascorbic acid may cause increased tissue toxicity of iron, especially at cardiac level, and cause cardiac failure. Aspirin effervescent tablets with Vitamin C contain buffer systems that may reduce the effects of the thyroid hormone Levothyroxine. Alcohol (see section 4.4): the sum of the effects of alcohol and acetylsalicylic acid causes increased damage to the gastrointestinal mucosa and prolongation of bleeding time. However, it is advisable not to administer other oral medications within 1 or 2 hours of using the product. Interference with clinical laboratory tests. Vitamin C: since vitamin C is a reducing agent (i.e. an electron donor), it can cause chemical interference in laboratory tests that involve oxidation-reduction reactions, such as glucose, creatinine, carbamazepine, uric acid in urine, serum and occult blood in stool. Vitamin C can interfere with tests that measure urine and blood glucose leading to a false reading of the results even if it has no effect on blood glucose levels.\u003c\/p\u003e\n\n \u003cp\u003e\u003c\/p\u003e\n\n\u003ch2\u003eSIDE EFFECTS\u003c\/h2\u003e\n\n\u003ch3\u003e Like all medicines, Aspirin C 20 Effervescent Tablets 400+240 mg can cause side effects - What are the side effects of Aspirin C 20 Effervescent Tablets 400+240 mg?\u003c\/h3\u003e\n\n \u003cp\u003eThe most frequently observed side effects are those affecting the gastrointestinal system and may occur in approximately 4% of subjects taking acetylsalicylic acid as an analgesic-antipyretic. This percentage increases significantly in subjects at risk of gastrointestinal disorders. These disorders can be partially alleviated by taking the medicine on a full stomach. Most of the side effects are dependent on both the dose and the duration of treatment. The side effects observed with acetylsalicylic acid are generally common to other NSAIDs. Blood and lymphatic system disorders: prolonged bleeding time, anaemia due to gastrointestinal haemorrhage, reduction in platelets (thrombocytopenia) in extremely rare cases. Haemorrhagic\/iron deficiency anaemia (due, for example, to occult microhaemorrhages) may occur following haemorrhage, with related alterations in laboratory parameters and related clinical signs and symptoms such as asthenia, pallor and hypoperfusion. Nervous system disorders: headache, dizziness. Rarely: Reye's syndrome (*). Rarely to very rarely: cerebral haemorrhage, especially in patients with uncontrolled hypertension and\/or on anticoagulant therapy, which, in isolated cases, may be life-threatening. Ear and labyrinth disorders: tinnitus (buzzing\/rustling\/ringing\/whistling in the ears). Respiratory, thoracic and mediastinal disorders: respiratory disease exacerbated by acetylsalicylic acid, asthma syndrome, rhinitis (profuse rhinorrhoea), nasal congestion (associated with hypersensitivity reactions). Epistaxis. Cardiac disorders: cardiorespiratory distress (associated with hypersensitivity reactions). Eye disorders: conjunctivitis (associated with hypersensitivity reactions). Gastrointestinal disorders: (occult) gastrointestinal bleeding, gastric disturbances, heartburn, gastrointestinal pain, gingival bleeding. Vomiting, diarrhoea, nausea, crampy abdominal pain (associated with hypersensitivity reactions). Rarely: gastrointestinal inflammation, gastrointestinal erosion, gastrointestinal ulceration, haematemesis (vomiting blood or material), melaena (passage of black, tarry stools), oesophagitis. Very rarely: haemorrhagic gastrointestinal ulcer and\/or gastrointestinal perforation with associated clinical signs and symptoms and alterations in laboratory parameters. Frequency not known (especially in long-term treatment): intestinal diaphragm disease. Hepatobiliary disorders. Rarely: hepatotoxicity (usually mild and asymptomatic hepatocellular injury) manifested by increased transaminases. Skin and subcutaneous tissue disorders: rash, oedema, urticaria, pruritus, erythema, angioedema (associated with hypersensitivity reactions). Renal and urinary disorders: alteration of renal function (in the presence of conditions of altered renal haemodynamics) and acute renal injury, urogenital haemorrhages. Systemic disorders and conditions related to the site of administration: procedural haemorrhages, haematomas. Immune system disorders. Rarely: anaphylactic shock with related alterations of laboratory parameters and clinical manifestations. (*) Reye's syndrome (RS). RS initially manifests itself with vomiting (persistent or recurrent) and with other signs of encephalic suffering of varying degrees: from listlessness, drowsiness or personality changes (irritability or aggressiveness) to disorientation, confusion or delirium up to convulsions or loss of consciousness. The variability of the clinical picture must be taken into account: vomiting may also be absent or replaced by diarrhoea. If these symptoms occur in the days immediately following an episode of influenza (or flu-like or chickenpox or another viral infection) during which acetylsalicylic acid or other medicinal products containing salicylates were administered, the doctor's attention must immediately be drawn to the possibility of an RS. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system of the Italian Medicines Agency at: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\n \u003cp\u003e\u003c\/p\u003e\n\n\u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Aspirin C 20 Effervescent Tablets 400+240 mg.\u003c\/h3\u003e\n\n \u003cp\u003eFertility: The use of acetylsalicylic acid, as with any drug inhibiting the synthesis of prostaglandins and cyclooxygenase, may interfere with fertility; female subjects, particularly women who have fertility problems or who are undergoing investigations of fertility, must be informed of this. Pregnancy: Inhibition of prostaglandin synthesis may adversely affect pregnancy and\/or embryo\/fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations was increased from less than 1%, up to approximately 1.5%. It has been estimated that the risk increases with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-fetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. From the twentieth week of pregnancy onwards, the use of acetylsalicylic acid may cause oligohydramnios resulting from fetal renal dysfunction. This condition may be encountered soon after initiation of treatment and is usually reversible upon discontinuation of treatment. In addition, cases of constriction of the ductus arteriosus have been reported following treatment in the second trimester, most of which resolved after discontinuation of treatment. Therefore, during the first and second trimester of pregnancy, acetylsalicylic acid should not be administered unless clearly necessary. If acetylsalicylic acid is used by a woman planning to become pregnant, or during the first and second trimester of pregnancy, the lowest possible dose should be used for the shortest possible duration. Following exposure to acetylsalicylic acid for several days from the twentieth week of gestation onwards, antenatal monitoring for oligohydramnios and constriction of the ductus arteriosus should be considered. If oligohydramnios or constriction of the ductus arteriosus occurs, treatment with Aspirin with vitamin C should be discontinued. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: cardiopulmonary toxicity (premature constriction\/closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction (see above); the mother and the unborn child, at the end of pregnancy, to: possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses; inhibition of uterine contractions resulting in delay or prolongation of labor. Consequently, Aspirin with Vitamin C is contraindicated during the third trimester of pregnancy. Breastfeeding: Aspirin with Vitamin C is contraindicated during breastfeeding (see section 4.3).\"\u003c\/p\u003e","brand":"BAYER SpA","offers":[{"title":"Default Title","offer_id":40207823962227,"sku":"004763330","price":10.59,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/bayer-spa-aspirina-c-20-compresse-effervescenti-400-240-mg-farmacia-dottor-tili-1213792741.png?v=1767126011"},{"product_id":"tachipirina-bambini-10-supposte-250-mg","title":"Tachipirina Children 10 Suppositories 250 mg","description":"\u003cp\u003e\u003cstrong\u003eTachipirina Bambini Suppositories\u003c\/strong\u003e 250 mg is an analgesic and antipyretic drug indicated for the treatment of fever and mild to moderate pain in children. The active ingredient, \u003cstrong\u003eparacetamol\u003c\/strong\u003e , is widely used for its effect in reducing fever and relieving pain associated with flu-like conditions, sore throat, toothache or muscle pain. Thanks to the suppository formulation, Tachipirina offers a convenient administration method for children, particularly useful in cases where oral administration is difficult.\u003c\/p\u003e\n\n\u003cp\u003e Tachipirina Bambini is indicated for:\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eTreatment of fever\u003c\/strong\u003e caused by infections or vaccinations.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eRelieve mild to moderate pain\u003c\/strong\u003e associated with toothache, headache, sore throat, muscle and joint pain.\u003c\/li\u003e\n\n\u003cli\u003e Also used for the management of post-vaccination fever.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eActive ingredients contained in Tachipirina Bambini 10 Suppositories 250 mg - What is the active ingredient of Tachipirina Bambini 10 Suppositories 250 mg?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThis medicine 500 mg tablets. Each tablet contains: paracetamol 500 mg. This medicine 500 mg effervescent granules. Each sachet contains: paracetamol 500 mg. This medicine 125 mg effervescent granules. Each sachet contains: paracetamol 125 mg. This medicine - newborns 62.5 mg suppositories. Each suppository contains: paracetamol 62.5 mg. This medicine - early childhood 125 mg suppositories. Each suppository contains: paracetamol 125 mg. This medicine - children 250 mg suppositories. Each suppository contains: paracetamol 250 mg. This medicine - children 500 mg suppositories. Each suppository contains: paracetamol 500 mg. This medicine - adults 1000 mg suppositories. Each suppository contains: paracetamol 1000 mg.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eComposition of Tachipirina Bambini 10 Suppositories 250 mg - What does Tachipirina Bambini 10 Suppositories 250 mg contain?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eTablets: microcrystalline cellulose, povidone, pregelatinized starch, stearic acid, croscarmellose sodium. Effervescent granules: maltitol, mannitol, sodium bicarbonate, anhydrous citric acid, citrus flavouring, aspartame, sodium docusate. Suppositories: solid semi-synthetic glycerides.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Tachipirina Children 10 Suppositories 250 mg - Why is Tachipirina Painkiller 500mg 20 Tablets used? What is it for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eAs an antipyretic: symptomatic treatment of febrile conditions such as influenza, exanthematous diseases, acute respiratory tract conditions, etc. As an analgesic: headaches, neuralgia, myalgia and other moderately severe painful conditions of various origins.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eContraindications Tachipirina Bambini 10 Suppositories 250 mg - When should Tachipirina Bambini 10 Suppositories 250 mg not be used?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eHypersensitivity to paracetamol or to any of the excipients. Patients with severe haemolytic anaemia (this contraindication does not apply to the 500 mg oral formulations). Severe hepatocellular insufficiency (this contraindication does not apply to the 500 mg oral formulations).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Tachipirina Bambini 10 Suppositories 250 mg - How to take Tachipirina Bambini 10 Suppositories 250 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eFor children, it is essential to respect the dosage defined according to their body weight, and therefore choose the appropriate formulation. The approximate ages according to body weight are given for information purposes only. In adults, the maximum oral dosage is 3000 mg and rectal dosage is 4000 mg of paracetamol per day. The doctor must evaluate the need for treatments for more than 3 consecutive days. The dosage schedule of this medicine in relation to body weight and administration route is as follows. 500 mg tablets. Children weighing between 21 and 25 kg (approximately between 6.5 and less than 8 years): 1\/2 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day (3 tablets). Children weighing between 26 and 40 kg (approximately 8 to 11 years): 1 tablet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 41 and 50 kg (approximately 12 to 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Children weighing more than 50 kg (approximately over 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Adults: 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. In the case of severe pain or high fever, 2 tablets of 500 mg to be repeated if necessary after not less than 4 hours. Effervescent granules of 500 mg in sachets. Dissolve the effervescent granules in a glass of water. Children weighing between 26 and 40 kg (approximately 8 to 11 years): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 41 and 50 kg (approximately 12 to 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Children weighing more than 50 kg (approximately over 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Adults: 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. In the case of severe pain or high fever, 2 sachets of 500 mg to be repeated if necessary after not less than 4 hours. Effervescent granules of 125 mg in sachets. Dissolve the effervescent granules in a glass of water. Children weighing between 7 and 10 kg (approximately between 6 and 19 months): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 11 and 12 kg (approximately between 20 and 29 months): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Children weighing between 13 and 20 kg (approximately between 30 months and less than 6.5 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 21 and 25 kg (approximately between 6.5 and less than 8 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Suppositories Neonates 62.5 mg. Children weighing between 3.2 and 5 kg (approximately between birth and 2 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Suppositories Early Childhood 125 mg. Children weighing between 6 and 7 kg (approximately between 3 and 5 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 7 and 10 kg (approximately between 6 and 19 months): 1 suppository at a time, to be repeated if necessary after 4 - 6 hours, without exceeding 5 administrations per day. Children weighing between 11 and 12 kg (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Suppositories Children 250 mg. Children weighing between 11 and 12 kg (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. Children weighing between 13 and 20 kg (approximately between 30 months and less than 6.5 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Suppositories Children 500 mg. Children weighing between 21 and 25 kg (approximately between 6.5 and less than 8 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. Children weighing between 26 and 40 kg (approximately between 8 and 11 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Suppositories Adults 1000 mg. Children weighing between 41 and 50 kg (approximately between 12 and 15 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. Children weighing more than 50 kg (approximately over 15 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Adults: 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Renal insufficiency. In case of severe renal insufficiency (creatinine clearance less than 10 ml\/min), the interval between administrations must be at least 8 hours.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Tachipirina Bambini 10 Suppositories 250 mg - How is Tachipirina Bambini 10 Suppositories 250 mg stored?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eTablets and effervescent granules: no special precautions for storage. Suppositories: store at a temperature not exceeding 25 degrees C.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Tachipirina Bambini 10 Suppositories 250 mg - About Tachipirina Bambini 10 Suppositories 250 mg it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIn rare cases of allergic reactions, administration should be suspended and appropriate treatment should be instituted. Use with caution in cases of chronic alcoholism, excessive alcohol intake (3 or more alcoholic drinks per day), anorexia, bulimia or cachexia, chronic malnutrition (low reserves of hepatic glutathione), dehydration, hypovolemia. Paracetamol should be administered with caution to patients with mild to moderate hepatocellular insufficiency (including Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh\u0026gt;9), acute hepatitis, in concomitant treatment with drugs that alter liver function, glucose-6-phosphate dehydrogenase deficiency, hemolytic anemia. High or prolonged doses of the product can cause alterations to the kidney and blood, even serious, therefore administration to subjects with renal insufficiency should be carried out only if really necessary and under direct medical supervision. In case of prolonged use it is advisable to monitor liver and renal function and blood count. During treatment with paracetamol, before taking any other medicine, check that it does not contain the same active ingredient, since if paracetamol is taken in high doses, serious adverse reactions may occur. Invite the patient to contact the doctor before combining any other medicine. Important information about some of the excipients. This 125 mg effervescent granules medicine contains: aspartame, which is a source of phenylalanine. It may be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk associated with the accumulation of the amino acid phenylalanine. Maltitol: use with caution in patients with rare hereditary problems of fructose intolerance. 70.6 mg of sodium per sachet equivalent to 3.53% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult: to be taken into consideration by people with reduced kidney function or who follow a low-sodium diet. This 500 mg effervescent granules medicinal product contains: aspartame, a source of phenylalanine. It may be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk associated with the accumulation of the amino acid phenylalanine. Maltitol: use with caution in patients with rare hereditary problems of fructose intolerance. 283 mg of sodium per sachet is equivalent to 14.1% of the WHO recommended maximum daily intake of 2 g of sodium for an adult. The maximum dose for this product is equivalent to 84.6% of the WHO recommended maximum daily intake of sodium: to be taken into consideration by patients with reduced kidney function or who follow a low-sodium diet.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Tachipirina Bambini 10 Suppositories 250 mg - Which medicines or foods can modify the effect of Tachipirina Bambini 10 Suppositories 250 mg?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eOral absorption of paracetamol depends on the rate of gastric emptying. Therefore, concomitant administration of drugs that slow (e.g. anticholinergics, opioids) or increase (e.g. prokinetics) the rate of gastric emptying may lead to a decrease or increase in the bioavailability of the product, respectively. Concomitant administration of cholestyramine reduces the absorption of paracetamol. Concomitant intake of paracetamol and chloramphenicol may lead to an increase in the half-life of chloramphenicol, with the risk of increasing toxicity. Concomitant use of paracetamol (4 g daily for at least 4 days) with oral anticoagulants may induce slight variations in INR values. In these cases, more frequent monitoring of INR values ​​should be performed during concomitant use and after its interruption. Use with extreme caution and under close supervision during chronic treatment with drugs that can determine the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutethimide, phenobarbital, carbamazepine). The same applies in cases of alcoholism and in patients treated with zidovudine. The administration of paracetamol may interfere with the determination of uricemia (by the phosphotungstic acid method) and with that of glycemia (by the glucose-oxidase-peroxidase method).\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Tachipirina Bambini 10 Suppositories 250 mg can cause side effects - What are the side effects of Tachipirina Bambini 10 Suppositories 250 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe following are the adverse reactions of paracetamol organised according to the MedDRA system organ classification. There are insufficient data to establish the frequency of the individual effects listed. Blood and lymphatic system disorders: thrombocytopenia, leukopenia, anaemia, agranulocytosis. Immune system disorders: hypersensitivity reactions (urticaria, laryngeal edema, angioedema, anaphylactic shock). Nervous system disorders: dizziness. Gastrointestinal disorders: gastrointestinal reaction. Hepatobiliary disorders: abnormal liver function, hepatitis. Skin and subcutaneous tissue disorders: erythema multiforme, Stevens Johnson syndrome, epidermal necrolysis, rash. Renal and urinary disorders: acute renal failure, interstitial nephritis, haematuria, anuria. Very rare cases of serious skin reactions have been reported. Reporting of suspected adverse reactions. Reporting of suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tachipirina Bambini 10 Suppositories 250 mg\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003ePregnancy: A large amount of data on pregnant women indicate neither malformative nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. Breastfeeding: It is recommended to administer the product only in cases of real need and under the direct supervision of a doctor.\u003c\/span\u003e\u003c\/p\u003e","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":40207823994995,"sku":"012745042","price":6.5,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-tachipirina-bambini-10-supposte-250-mg-farmacia-dottor-tili-1213792739.jpg?v=1767126699"},{"product_id":"gynocanesten-crema-vaginale-30-g-2","title":"Gynocanesten Vaginal Cream 30 g 2%","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eGynocanesten Vaginal Cream 30 g 2%\u003c\/span\u003e \u003cspan\u003eis an antifungal drug indicated for the treatment of vaginal infections caused by fungi, such as vaginal candidiasis. The active ingredient,\u003c\/span\u003e \u003cspan\u003eclotrimazole\u003c\/span\u003e \u003cspan\u003e2%, works by inhibiting the growth of fungi and promoting the recovery of the natural balance of the vaginal flora. The cream is particularly indicated for \u003cstrong\u003equickly relieving the symptoms associated with infections, such as itching, burning, irritation and abnormal vaginal discharge\u003c\/strong\u003e .\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eGynocanesten Vaginal Cream is indicated for:\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e \u003cspan\u003eTreatment of vaginal candidiasis\u003c\/span\u003e \u003cspan\u003eand other fungal infections of the genital area.\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e \u003cspan\u003eRelieve symptoms such as\u003c\/span\u003e \u003cspan\u003eitching, burning\u003c\/span\u003e \u003cspan\u003eand\u003c\/span\u003e \u003cspan\u003eirritation\u003c\/span\u003e \u003cspan\u003ecaused by vaginal infections.\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e \u003cspan\u003eRestoration of natural vaginal flora\u003c\/span\u003e \u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eActive ingredients contained in Gynocanesten Vaginal Cream 30g 2% - What is the active ingredient of Gynocanesten Vaginal Cream 30g 2%?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eGYNO-CANESTEN 2% vaginal cream. 5 g of vaginal cream contain; active ingredient: clotrimazole 100 mg. Excipient with known effect: cetostearyl alcohol and benzyl alcohol. GYNO-CANESTEN 100 mg vaginal tablets. One vaginal tablet contains active ingredient: clotrimazole 100 mg. For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Gynocanesten Vaginal Cream 30g 2% - What does Gynocanesten Vaginal Cream 30g 2% contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eGYNO-CANESTEN 2% vaginal cream: sorbitan stearate, polysorbate 60, cetyl palmitate, cetostearyl alcohol, octyldodecanol, benzyl alcohol, purified water. GYNO-CANESTEN 100 mg vaginal tablets: lactose monohydrate, corn starch, magnesium stearate, colloidal anhydrous silica, calcium lactate pentahydrate, crospovidone, lactic acid, hypromellose, microcrystalline cellulose.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Gynocanesten Vaginal Cream 30g 2% - Why is Gynocanesten Vaginal Cream 30g 2% used? What is it for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eTreatment of localized symptoms such as itching, leucorrhoea, redness and sensation of swelling of the vaginal mucosa and glans, burning when passing urine when these symptoms are due to vulvovaginal infections and balanitis caused by previously diagnosed candida in adults and adolescents over 12 years of age.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eContraindications Gynocanesten Vaginal Cream 30 g 2% - When should Gynocanesten Vaginal Cream 30 g 2% not be used?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Gynocanesten Vaginal Cream 30 g 2% - How to take Gynocanesten Vaginal Cream 30 g 2%?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eApply as deeply as possible into the vagina once a day, preferably in the evening, at bedtime. In case of vulvitis or Candida balanitis, apply a thin layer of Gyno-Canestencrema 2-3 times a day to the entire perineal area (urogenital and anal). In case of balanitis, also apply the cream to the foreskin. Facilitate absorption of the cream applied locally with a light massage. GYNO-CANESTEN 2% vaginal cream: apply as deeply as possible into the vagina once a day, preferably in the evening, at bedtime, for 3 consecutive days. If necessary, the treatment can be continued for another 3 days. Application method: the applicator should be used only once and then discarded in order to avoid possible infections. 1. Remove the piston from the disposable applicator until it stops. 2. Open the tube. Insert the disposable applicator into the latter and hold it firmly. Fill the applicator by carefully pressing on the tube. 3. Once you have assumed the supine position with your legs slightly bent, remove the disposable applicator, insert it as deeply as possible into the vagina and empty it by applying regular and continuous pressure on the piston. 4. Remove the applicator and discard it. GYNO-CANESTEN 100 mg vaginal tablets: apply one tablet as deeply as possible into the vagina once a day, preferably in the evening, at bedtime for six consecutive days or, alternatively, apply 2 for only 3 consecutive days. Method of application: after carefully washing your hands, once you have assumed the supine position with your legs slightly bent, insert the vaginal tablet directly with your finger as deeply as possible into the vagina. In chronic relapsing forms, the daily dosage may be increased to 2 vaginal tablets in the evening, for a period of 6-12 days. It is necessary for the vagina to have an adequate level of humidity to allow Gyno-Canesten vaginal tablets to dissolve completely. Otherwise, undissolved fragments of the tablet may fall out. To avoid this, it is important that the medicine is inserted as deeply as possible into the vagina at bedtime. If, despite this precaution, the tablet does not dissolve completely within one night, the use of vaginal cream should be considered. Duration of treatment: the maximum duration of treatment is 7 days, if symptoms persist, reassess the clinical picture. In case of vulvitis or balanitis, treatment should be continued for 1-2 weeks.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Gynocanesten Vaginal Cream 30g 2% - How to store Gynocanesten Vaginal Cream 30g 2%?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eGYNO-CANESTEN 2% vaginal cream: this medicine does not require any special storage conditions. GYNO-CANESTEN 100 mg vaginal tablets: store at a temperature not exceeding 25 degrees C.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Gynocanesten Vaginal Cream 30g 2% - About Gynocanesten Vaginal Cream 30 g 2% it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIn case of fever, lower abdominal pain, back pain, foul-smelling vaginal discharge, nausea, vaginal bleeding and\/or shoulder pain, the clinical picture should be reassessed. Recurrent infections that recur within 2 months may be secondary to conditions such as diabetes or HIV infection that require thorough clinical examinations. It is preferable to start and finish treatment in the intermenstrual period. Tampons, vaginal douches, spermicides or other vaginal products should not be used during therapy with Gyno-Canesten. Recommend abstinence from vaginal intercourse because the infection could be transmitted to the partner. Furthermore, in order to avoid reinfection, particularly in the presence of Candida vulvitis or balanitis, recommend local treatment of the partner. During pregnancy, use vaginal tablets and insert them without the aid of the applicator. During treatment with Gyno-Canesten, the efficacy and safety of latex-based products, such as condoms and diaphragms, may be reduced. The use, especially if prolonged, of products for topical use may give rise to sensitization phenomena. In this case, it is necessary to interrupt the treatment and adopt appropriate therapeutic measures. Avoid contact with eyes. Do not ingest. Important information on some excipients. Gyno-Canesten cream contains cetostearyl alcohol: may cause local skin reactions (e.g. contact dermatitis). Gyno-Canesten cream contains 20 mg\/g of benzyl alcohol: may cause allergic reactions; may cause mild local irritation.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Gynocanesten Vaginal Cream 30g 2% - Which medicines or foods can modify the effect of Gynocanesten Vaginal Cream 30g 2%?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eConcomitant treatment with vaginal clotrimazole and oral tacrolimus (an immunosuppressant) may result in increased plasma levels of tacrolimus and similarly with sirolimus. Patients should therefore be carefully monitored for symptoms of tacrolimus or sirolimus overdose, if necessary by determination of plasma drug levels.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Gynocanesten Vaginal Cream 30g 2% can cause side effects - What are the side effects of Gynocanesten Vaginal Cream 30g 2%?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe adverse reactions listed below are indicated according to the MedDRA System Organ Class. Since they derive from spontaneous post-marketing reports, their frequency is indicated as not known (the frequency cannot be estimated from the available data). Immune system disorders: anaphylactic reaction, angioedema, hypersensitivity. Vascular disorders: syncope, hypotension. Respiratory, thoracic and mediastinal disorders: dyspnoea. Gastrointestinal disorders: abdominal pain, nausea. Skin and subcutaneous tissue disorders: rash, urticaria. Reproductive system and breast disorders: exfoliation, vaginal discharge, vaginal haemorrhage, discomfort, erythema, burning, pruritus, pain. Systemic disorders and conditions related to the administration site: application site irritation, edema, pain. Reporting of suspected adverse reactions. Reporting of suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Gynocanesten Vaginal Cream 30g 2% Fertility: no studies have been conducted in humans on the effects of clotrimazole on fertility, however animal studies have not shown reproductive toxicity (see section 5.3). Pregnancy: available clinical data on the risk in pregnancy are limited. The administration of Gyno-canesten during pregnancy should be considered only if the expected benefit for the mother outweighs the risk for the fetus or child. Breast-feeding: no data are available on the excretion of clotrimazole in breast milk. However, systemic absorption is minimal after topical administration and is unlikely to lead to systemic effects. Clotrimazole can be used during breast-feeding.\u003c\/span\u003e\u003c\/p\u003e","brand":"BAYER SpA","offers":[{"title":"Default Title","offer_id":40207824060531,"sku":"025833068","price":16.25,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/bayer-spa-gynocanesten-crema-vaginale-30-g-2-farmacia-dottor-tili-1213792742.png?v=1767126671"},{"product_id":"froben-gola-spray-mucosa-orale-15-ml-flurbiprofene-0-25","title":"Froben Throat Oral Mucosa Spray 15 ml Flurbiprofen 0.25%","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eFroben Gola Spray is an over-the-counter drug based on Flurbiprofen indicated for the\u003c\/span\u003e \u003cspan\u003esymptomatic treatment of irritative-inflammatory conditions associated with pain\u003c\/span\u003e \u003cspan\u003ein the oropharyngeal cavity.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eFlurbiprofen belongs to a group of medicines called nonsteroidal anti-inflammatory drugs (NSAIDs), used to relieve pain, redness, heat and swelling in the presence of inflammatory processes. For this reason, Froben Gola Spray is used to\u003c\/span\u003e \u003cspan\u003ereduce burning, redness, pain and inflammation of the mouth and throat\u003c\/span\u003e \u003cspan\u003e, due to\u003c\/span\u003e \u003cspan\u003egingivitis, stomatitis, pharyngitis\u003c\/span\u003e \u003cspan\u003eand as a consequence of\u003c\/span\u003e \u003cspan\u003econservative or extractive dental therapy\u003c\/span\u003e \u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Froben Gola Spray Oral Mucosa 15 ml Flurbiprofen 0.25% - What is the active ingredient of Froben Gola Spray Oral Mucosa 15 ml Flurbiprofen 0.25%?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eFroben Gola 250 mg\/100 ml Mouthwash, 100 ml of solution contain, active ingredient: flurbiprofen 0.25 g. Excipients with known effect: 40-polyoxyethylened hydrogenated castor oil, ethanol, mint essence flavour (containing limonene). Froben Gola 250 mg\/100 ml Oral mucosa spray, 100 ml of solution contain, active ingredient: flurbiprofen 0.25 g. Excipients with known effect: 40-polyoxyethylened hydrogenated castor oil, ethanol, mint essence flavour (containing limonene). For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Froben Throat Spray Oral Mucosa 15 ml Flurbiprofen 0.25% - What does Froben Throat Spray Oral Mucosa 15 ml Flurbiprofen 0.25% contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003ePurified water, ethanol, patent blue V (E131), glycerol, mint essence flavouring (containing limonene), 40-polyoxyethylened hydrogenated castor oil, potassium bicarbonate, sodium saccharinate, sorbitol.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eTherapeutic indications Froben Gola Spray Oral Mucosa 15 ml Flurbiprofen 0.25% - Why is Froben Gola Spray Oral Mucosa 15 ml Flurbiprofen 0.25% used? What is it used for?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eFroben Gola is indicated for the symptomatic treatment of irritative-inflammatory conditions also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Froben Gola Spray Oral Mucosa 15 ml Flurbiprofen 0.25% - When should Froben Gola Spray Oral Mucosa 15 ml Flurbiprofen 0.25% not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eHypersensitivity to flurbiprofen or to any of the excipients listed in section 6.1. Froben Gola is also contraindicated in: patients who have previously shown hypersensitivity reactions (e.g. asthma, urticaria) after taking aspirin or other NSAIDs; patients with a history of gastrointestinal bleeding or perforation related to previous NSAID therapy; patients with active or history of ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal bleeding (defined as two or more distinct episodes of proven ulceration or bleeding); patients with severe cardiac, renal or hepatic insufficiency (see section 4.4). Froben Gola is contraindicated during the third trimester of pregnancy.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Froben Gola Spray Mucosa Orale 15 ml Flurbiprofene 0.25% - How do you take Froben Gola Spray Mucosa Orale 15 ml Flurbiprofene 0.25%?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe lowest effective dose should be used for the shortest duration necessary to relieve symptoms (see section 4.4). It is recommended to use this medicine for a maximum of three days. Dosage. Mouthwash: the recommended dose is two or three rinses or gargles per day with 10 ml of mouthwash. It can be diluted in water. Spray for oral mucosa: the recommended dose is 2 sprays 3 times a day directed directly at the affected area. Paediatric population: there are no adequate data available on the paediatric population; therefore, the use of the medicine is not recommended. Method of administration: the use of Froben Gola is exclusively for local oral use and must not be swallowed.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Froben Throat Spray Oral Mucosa 15 ml Flurbiprofen 0.25% - How is Froben Throat Spray Oral Mucosa 15 ml Flurbiprofen 0.25% stored?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eMouthwash: This medicine should not be stored above 25 degrees C. Oral mucosa spray: This medicine should not be stored above 25 degrees C. Keep the bottle in the outer carton in order to protect from light.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Froben Gola Spray Oral Mucosa 15 ml Flurbiprofen 0.25% - About Froben Gola Spray Oral Mucosa 15 ml Flurbiprofen 0.25% it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eAt the recommended doses, any swallowing of FROBEN GOLA does not cause any harm to the patient as these doses are much lower than those of the single dosage of the product for systemic use. The use of Froben Gola, especially if prolonged, may give rise to phenomena of sensitization or local irritation; in such cases the treatment should be interrupted and, if necessary, appropriate therapy should be instituted. General precautions: flurbiprofen should not be used for prolonged treatments. It is necessary to inform patients to seek medical advice if after short periods of treatment there are no appreciable results. Undesirable effects can be minimised by using the lowest effective dose for the shortest duration of treatment necessary to control symptoms (see section 4.2 and the sections below on gastrointestinal and cardiovascular risks). Use in elderly patients: elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal. Gastrointestinal effects: Flurbiprofen should be administered with caution to patients with a history of peptic ulcer and other gastrointestinal disease as these conditions may be exacerbated. Gastrointestinal bleeding, ulceration or perforation have been reported with all NSAIDs at any time during treatment. These adverse events can be fatal and may occur with or without warning symptoms or with a previous history of serious gastrointestinal events. The risk of gastrointestinal bleeding, ulceration or perforation is higher with increasing flurbiprofen dosage in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation and in the elderly. These patients should start treatment on the lowest available dose. Concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking low dose aspirin or other drugs likely to increase the risk of gastrointestinal events (see section below and section 4.5). Patients with a history of gastrointestinal disease, particularly when elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. When gastrointestinal bleeding or ulceration occurs in patients receiving Froben Gola, the treatment should be withdrawn. Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or anti-platelet agents such as acetylsalicylic acid (see section 4.5). In case of concomitant intake of alcohol, the undesirable effects related to the active substance, particularly those involving the gastrointestinal tract or the central nervous system, may be increased with the use of NSAIDs. Respiratory disorders: cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma. Cardiac, renal and hepatic impairment: Particular caution should be exercised when treating patients with severely impaired renal, cardiac or hepatic function, as the use of NSAIDs may result in deterioration of renal function. In such patients the dosage should be kept as low as possible and renal function should be monitored. Administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation, precipitating renal failure. Patients at highest risk of developing this reaction are those with impaired renal function, cardiac insufficiency and hepatic dysfunction, those taking diuretics and the elderly. Renal function should be monitored in these patients (see also section 4.3). Flurbiprofen should be administered with caution in patients with a history of cardiac insufficiency or hypertension since cases of oedema have been reported in association with flurbiprofen administration. Central nervous system effects: Headache may occur with prolonged use of any analgesic and should not be treated by increasing the dosage of the medicinal product. Cardiovascular and cerebrovascular effects: Appropriate monitoring and advice are necessary in patients with a history of hypertension and\/or mild to moderate congestive heart failure since fluid retention and oedema have been reported in association with flurbiprofen administration and NSAID treatment. Froben Gola should be used with caution in these patients. Clinical trial and epidemiological data suggest that the use of some NSAIDs, particularly at high doses and in long-term treatment, may be associated with a small increased risk of arterial thrombotic events, such as myocardial infarction or stroke. There are insufficient data to exclude a similar risk for flurbiprofen. Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should only be treated with flurbiprofen after careful consideration. Similar consideration should be made before initiating long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking). Skin reactions: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs. Patients appear to be at highest risk early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first month of treatment. Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity. Renal effects: Caution should be exercised when initiating treatment with NSAIDs such as flurbiprofen in patients with considerable dehydration.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Froben Gola Spray Mucosa Orale 15 ml Flurbiprofene 0.25% - Which medicines or foods can modify the effect of Froben Gola Spray Mucosa Orale 15 ml Flurbiprofene 0.25%?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eCaution should be exercised in patients treated with any of the following medicinal products, as interactions have been reported in some patients. Diuretics, ACE inhibitors and angiotensin II antagonists: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. Diuretics may also increase the risk of nephrotoxicity of NSAIDs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking flurbiprofen concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and periodically thereafter. Lithium salts: decreased lithium elimination. Methotrexate: caution is advised when co-administering flurbiprofen and methotrexate since NSAIDs may increase methotrexate levels and thus its toxic effects. Anticoagulants, such as warfarin: increased anticoagulant. Anti-platelet agents: increased risk of gastrointestinal bleeding (see section 4.4). Selective serotonin reuptake inhibitors (SSRIS): increased risk of gastrointestinal bleeding. Acetylsalicylic acid (Aspirin): as with other NSAID-containing medicinal products, concomitant administration of flurbiprofen and aspirin is generally not recommended due to the potential for increased adverse effects (see section 4.4). Cardiac glycosides: NSAIDs may exacerbate cardiac failure, reduce glomerular filtration rate and increase plasma levels of cardiac glycosides. Ciclosporins: Increased risk of nephrotoxicity with NSAIDs. Corticosteroids: Increased risk of gastrointestinal ulceration or haemorrhage with NSAIDs. Cox-2 inhibitors and other NSAIDs: Concomitant use of other NSAIDs, including cyclooxygenase-2 selective inhibitors, should be avoided due to potential additive effects. Mifepristone: NSAIDs should not be taken for 8-12 days after mifepristone administration since NSAIDs may reduce the effects of mifepristone. Quinolone antibiotics: Results from animal studies suggest that NSAIDs may increase the risk of convulsions associated with the use of quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions. Tacrolimus: possible increased risk of nephrotoxicity in case of co-administration with NSAIDs. Zidovudine: increased risk of haematotoxicity in case of co-administration with NSAIDs. There is evidence of an increased risk of haemarthrosis and haematoma in haemophiliac patients affected by HIV in concomitant treatment with Zidovudine and other NSAIDs. The interactions reported above have been reported in particular after the administration of flurbiprofen-based formulations for systemic use. At the recommended doses of Froben Gola no interactions with other medicinal products or other types have been reported. In any case, inform your doctor if you are taking other medicines.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Froben Gola Spray Mucosa Orale 15 ml Flurbiprofene 0.25% can cause side effects - What are the side effects of Froben Gola Spray Mucosa Orale 15 ml Flurbiprofene 0.25%?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe following adverse reactions, reported in particular after administration of systemic formulations, are reported according to the MedDRA classification. Frequency groupings are classified according to the following convention: very common (\u0026gt;= 1\/10), common (\u0026gt;= 1\/100, \u0026lt;1\/10), uncommon (\u0026gt;= 1\/1000, \u0026lt;1\/100), rare (\u0026gt;= 1\/10 000, \u0026lt;1\/1 000), very rare (\u0026lt;1\/10 000) and not known (frequency cannot be estimated from the available data). Blood and lymphatic system disorders: Uncommon: anaemia; very rare: leucopenia, agranulocytosis, aplastic anaemia, neutropenia, thrombocytopenia, haemolytic anaemia. Immune system disorders: Uncommon: hypersensitivity; rare: anaphylactic reaction. Psychiatric disorders: Rare: depression, confusional state; very rare: hallucination. Nervous system disorders. Common: migraine, dizziness; uncommon: paraesthesia; rare: somnolence, insomnia; not known: optic neuritis, cerebrovascular accident, aseptic meningitis, headache. Eye disorders. Uncommon: visual disturbances. Ear and labyrinth disorders. Uncommon: tinnitus, vertigo. Respiratory, thoracic and mediastinal disorders. Uncommon: asthma, dyspnoea; rare: bronchospasm. Gastrointestinal disorders. Common: dyspepsia, diarrhoea, nausea, vomiting, abdominal pain, flatulence, constipation, melaena, haematemesis, gastrointestinal haemorrhage; uncommon: gastritis, duodenal ulcer, gastric ulcer, mouth ulcer, gastrointestinal perforation; very rare: pancreatitis; not known: colitis and Crohn's disease. Hepatobiliary disorders. Very rare: jaundice, cholestatic jaundice, abnormal liver function; not known: hepatitis. Skin and subcutaneous tissue disorders. Uncommon: rash, urticaria, pruritus, purpura, angioedema, photosensitivity reactions; very rare: severe forms of bullous skin reactions (e.g. erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis). Renal and urinary disorders. Rare: nephrotoxicity in various forms. Interstitial nephritis, nephrotic syndrome, renal failure and acute renal failure (see section 4.4); not known: glomerulonephritis. General disorders and administration site conditions. Common: fatigue, malaise, oedema. Cardiac disorders. Uncommon: cardiac failure. Vascular disorders. Uncommon: hypertension. Investigations. Common: liver function test abnormal, prolonged bleeding time. Metabolism and nutrition disorders. Common: fluid retention. Immune system disorders. Hypersensitivity reactions have been reported following treatment with flurbiprofen. These consist of: a) non-specific allergic reactions and anaphylaxis; b) respiratory tract reactions including asthma, including severe asthma, bronchospasm or dyspnoea, or c) various skin disorders, such as rashes of various types, pruritus, urticaria, purpura, angioedema and, very rarely, exfoliative and bullous dermatitis (including toxic epidermal necrolysis and erythema multiforme). Cardiac and vascular disorders: Cases of oedema, hypertension and cardiac failure have been reported in association with treatment with NSAIDs. Clinical trial and epidemiological data suggest that the intake of some NSAIDs (particularly at high doses and in case of long-term treatment) may be associated with an increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). Nervous System Disorders: aseptic meningitis (especially in patients with existing autoimmune disorders such as systemic lupus erythematosus and connective tissue disorders) with symptoms such as stiff neck, headache, nausea, vomiting, fever or disorientation (see section 4.4). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Froben Gola Spray Mucosa Orale 15 ml Flurbiprofen 0.25%\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eFertility: The use of Froben Gola may adversely affect fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of fertility, discontinuation of Froben Gola should be considered. Pregnancy: Inhibition of prostaglandin synthesis may adversely affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increases from less than 1%, up to approximately 1.5%. The risk was believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular, has been reported in animals administered prostaglandin synthesis inhibitors during the organogenetic period. There are no clinical data on the use of Froben Gola during pregnancy. Although systemic exposure is lower than with oral administration, it is not known whether systemic exposure of Froben Gola achieved after topical administration can be harmful to an embryo\/fetus. During the first and second trimester of pregnancy, flurbiprofen should not be administered unless clearly necessary. If administered, the dose should be the lowest possible and the duration of treatment as short as possible. During the third trimester of pregnancy, systemic use of prostaglandin synthetase inhibitors, including Froben Gola, may induce cardiopulmonary and renal toxicity in the fetus. At the end of pregnancy, prolonged bleeding time may occur in both mother and child and labor may take longer. Therefore, Froben Gola is contraindicated during the third trimester of pregnancy (see section 4.3). Breastfeeding: in the few studies available to date, NSAIDs may appear in breast milk in very low concentrations. If possible, NSAIDs should be avoided during breastfeeding. See section 4.4 Special warnings and precautions for use, regarding fertility in women.\u003c\/span\u003e\u003c\/p\u003e","brand":"MYLAN ITALIA Srl","offers":[{"title":"Default Title","offer_id":40207824158835,"sku":"042822027","price":11.44,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/mylan-italia-srl-froben-gola-spray-mucosa-orale-15-ml-flurbiprofene-0-25-farmacia-dottor-tili-1213792740.jpg?v=1767126746"},{"product_id":"rinazina-spray-nasale-decongestionante-15ml-0-1","title":"Rinazina Decongestant Nasal Spray 15ml 0.1%","description":"\u003cp\u003eRinazina Nasal Spray is a nasal decongestant based on Naphazoline. Rinazina Nasal Spray is useful in cases of \u003cstrong\u003eacute catarrhal rhinitis and pharyngitis, allergic rhinitis and acute sinusitis\u003c\/strong\u003e .\u003c\/p\u003e\n\n\u003cp\u003e Rinazina Decongestant Nasal Spray 15ml combats the \u003cstrong\u003esymptoms of seasonal allergies.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Rinazina Decongestant Nasal Spray 15ml 0.1% - What is the active ingredient of Rinazina Decongestant Nasal Spray 15ml 0.1%?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003e1 ml of solution contains, active ingredient: naphazoline nitrate 1 mg. Excipients with known effect: benzalkonium chloride. For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Rinazina Decongestant Nasal Spray 15ml 0.1% - What does Rinazina Decongestant Nasal Spray 15ml 0.1% contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eRinazina 1 mg\/ml nasal drops, solution: sodium chloride, disodium edetate, sodium phosphate monobasic dihydrate, concentrated phosphoric acid, benzalkonium chloride, purified water. Rinazina 1 mg\/ml nasal spray, solution: sodium chloride, disodium edetate, sodium phosphate monobasic dihydrate, concentrated phosphoric acid, benzalkonium chloride, balsamic aroma, purified water.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Rinazina Decongestant Nasal Spray 15ml 0.1% - Why is Rinazina Decongestant Nasal Spray 15ml 0.1% used? What is it for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eNasal decongestant in the course of acute catarrhal rhinitis and pharyngitis, allergic rhinitis, acute sinusitis.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Rinazina Decongestant Nasal Spray 15ml 0.1% - When should Rinazina Decongestant Nasal Spray 15ml 0.1% not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1; severe heart disease and arterial hypertension; glaucoma; hyperthyroidism; the medicinal product is contraindicated in children under 12 years of age. Do not administer during and for two weeks following therapy with antidepressant drugs.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Rinazina Decongestant Nasal Spray 15ml 0.1% - How do you take Rinazina Decongestant Nasal Spray 15ml 0.1%?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eNasal drops; adults: 2-3 drops in each nostril, 2-3 times a day. Nasal spray; adults: 1-2 sprays in each nostril, 2-3 times a day. Paediatric population: the medicine is contraindicated in children under 12 years of age (see section 4.3). Strictly adhere to the recommended doses. A higher dosage of the product even if taken topically and for a short period of time can give rise to serious systemic effects. In the absence of a complete therapeutic response within a few days, consult your doctor; in any case, treatment should not be continued for more than a week.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Rinazina Decongestant Nasal Spray 15ml 0.1% - How is Rinazina Decongestant Nasal Spray 15ml 0.1% stored?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eRinazina 1 mg\/ml nasal spray, solution: This medicine does not require any special storage conditions. Rinazina 1 mg\/ml nasal drops, solution: Store below 25 degrees C. Store upright.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Rinazina Decongestant Nasal Spray 15ml 0.1% - About Rinazina Decongestant Nasal Spray 15ml 0.1% it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eUse with caution in the elderly and in those with prostatic hypertrophy due to the risk of urinary retention. In patients with cardiovascular disease, especially hypertensive patients, the use of nasal decongestants must be subjected to the doctor's judgment from time to time. Prolonged use of vasoconstrictors can alter the normal function of the nasal mucosa and paranasal sinuses, also inducing addiction to the drug. Repeated applications for a long period of time can be harmful. Rinazina nasal drops and nasal spray contain 0.1 mg\/ml of benzalkonium chloride. Benzalkonium chloride (BAC) contained as a preservative in Rinazina nasal drops and nasal spray can cause irritation and swelling of the nasal mucosa, especially if used for long periods. If such a reaction is suspected (persistent nasal congestion), a nasal medicine without BAC should be used, if possible. If such nasal medicinal products without BAC are not available, another pharmaceutical form should be considered. May cause bronchospasm. Use, especially if prolonged, of topical products may give rise to sensitization phenomena; in this case, treatment should be stopped and, if necessary, appropriate therapy should be instituted. Rare cases of posterior reversible encephalopathy\/reversible cerebral vasoconstriction syndrome have been reported with the use of sympathomimetic drugs, to which naphazoline also belongs. Reported symptoms include sudden onset of severe headache, nausea, vomiting and visual disturbances. Most cases improve or resolve within a few days following appropriate treatment. Use of naphazoline should be stopped immediately and a doctor should be consulted if signs and\/or symptoms of posterior reversible encephalopathy\/reversible cerebral vasoconstriction syndrome occur.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Rinazina Decongestant Nasal Spray 15ml 0.1% - Which medicines or foods can modify the effect of Rinazina Decongestant Nasal Spray 15ml 0.1%?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThe drug may interact with antidepressant drugs.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Rinazina Decongestant Nasal Spray 15ml 0.1% can cause side effects - What are the side effects of Rinazina Decongestant Nasal Spray 15ml 0.1%?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe product may locally cause rebound phenomena of sensitization and congestion of the mucous membranes. Due to rapid absorption of naphazoline through inflamed mucous membranes, systemic effects may occur consisting of arterial hypertension, reflex bradycardia, headache, urination disorders. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Rinazina Decongestant Nasal Spray 15ml 0.1%.\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eDuring pregnancy and breastfeeding, Rinazina should be used only after consulting your doctor and evaluating with him the risk\/benefit ratio in your case.\u003c\/span\u003e\u003c\/p\u003e","brand":"GLAXOSMITHKLINE C.HEALTH.SpA","offers":[{"title":"Default Title","offer_id":40207824191603,"sku":"000590051","price":11.59,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/glaxosmithkline-c-health-spa-rinazina-spray-nasale-decongestionante-15ml-0-1-farmacia-dottor-tili-1213792738.webp?v=1767126771"},{"product_id":"proctolyn-crema-rettale-30-g","title":"Proctolyn Rectal Cream 30 g","description":"\u003cp\u003e \u003cstrong\u003eProctolyn Rectal Cream 30 g\u003c\/strong\u003e is a drug indicated for the treatment of anal and perianal conditions such as hemorrhoids, fissures and dermatitis. Its active ingredient, fluocinolone acetonide, belongs to the class of corticosteroids and has a local anti-inflammatory action, reducing inflammation, itching and pain. The cream also contains \u003cstrong\u003ebenzocaine\u003c\/strong\u003e , a local anesthetic that quickly relieves pain and discomfort, providing rapid relief of symptoms.\u003c\/p\u003e\n\n\u003cp\u003e Proctolyn Rectal Cream is indicated for:\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e \n\u003cstrong\u003eSymptomatic treatment of external and internal hemorrhoids\u003c\/strong\u003e .\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eTreatment of anal fissures\u003c\/strong\u003e .\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eDermatitis and itching\u003c\/strong\u003e in the anal and perianal area.\u003c\/li\u003e\n\n\u003cli\u003e Reduction of inflammation and pain associated with rectal conditions.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Proctolyn Rectal Cream 30 g - What is the active ingredient of Proctolyn Rectal Cream 30 g?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eFluocinolone acetonide and ketocaine hydrochloride.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Proctolyn Rectal Cream 30 g - What does Proctolyn Rectal Cream 30 g contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eRectal cream: citric acid, menthol methyl parahydroxybenzoate, propyl parahydroxybenzoate, propylene glycol, stearyl alcohol, cetyl alcohol, vaseline oil, sorbitan monostearate, polysorbate 60, purified water. Suppositories: citric acid, menthol, propylene glycol, polysorbate 60, sorbitan monostearate, colloidal silica, semi-synthetic glycerides.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n \u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Proctolyn Rectal Cream 30 g - Why is Proctolyn Rectal Cream 30 g used? What is it used for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eInternal and external hemorrhoids; anal and perianal eczema and erythema; anal fissures; anal and perianal itching and burning; pre- and post-operative treatment in ano-rectal surgery.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Proctolyn Rectal Cream 30 g - When should Proctolyn Rectal Cream 30 g not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eHypersensitivity to the active substances or to any of the excipients. Tbc, mycosis, Herpes Symplex, viral diseases with cutaneous localization.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Proctolyn Rectal Cream 30 g - How to take Proctolyn Rectal Cream 30 g?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eRectal cream: enough to cover the affected area, massaging lightly and repeating the application 2-3 times a day. For internal application, use the special cannula inserted into the tube. Suppositories: 1 suppository in the morning and 1 in the evening. Rectal cream and suppositories can be used for combined treatments. The use of the drug is not recommended in children under 12 years of age, due to the lack of data on safety and efficacy.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Proctolyn Rectal Cream 30 g - How to store Proctolyn Rectal Cream 30 g?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThis medicinal product does not require any special storage conditions.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Proctolyn Rectal Cream 30 g - About Proctolyn Rectal Cream 30 g it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eTopical application of corticosteroids in excessive doses and for prolonged periods may cause systemic absorption. Use, especially if prolonged, of topical products may give rise to sensitization phenomena. In the presence of a skin infection, appropriate cover therapy should be instituted. Visual disturbances may be reported with the use of systemic and topical corticosteroids. If a patient presents with symptoms such as blurred vision or other visual disturbances, it is necessary to consider referral to an ophthalmologist for evaluation of possible causes which may include cataracts, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR), which have been reported after the use of systemic and topical corticosteroids. The rectal cream contains methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions; stearyl alcohol and cetyl alcohol which may cause localized skin reactions.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n \u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Proctolyn Rectal Cream 30 g - Which medicines or foods can modify the effect of Proctolyn Rectal Cream 30 g?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eConcomitant treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side effects, in which case patients should be monitored for systemic corticosteroid side effects.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Proctolyn Rectal Cream 30 g can cause side effects - What are the side effects of Proctolyn Rectal Cream 30 g?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eDuring topical cortisone therapy, especially for intense and prolonged treatments, the following side effects may occur: burning sensation, itching, irritation. Blurred vision may occur, with an unknown frequency.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Proctolyn Rectal Cream 30 g.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThe medicine should be used during pregnancy only if necessary, after evaluating the expected benefit for the mother in relation to the possible risk for the fetus. Topical corticosteroids should be used with caution during breastfeeding.\u003c\/span\u003e\u003c\/p\u003e","brand":"RECORDATI SpA","offers":[{"title":"Default Title","offer_id":40207824289907,"sku":"021925060","price":12.74,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/recordati-spa-proctolyn-crema-rettale-30-g-farmacia-dottor-tili-1213792737.jpg?v=1767126730"},{"product_id":"imodium-12-capsule-2-mg","title":"Imodium 12 Capsules 2mg","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eImodium 12 Capsules 2 mg is an antidiarrheal drug indicated for the treatment of\u003c\/span\u003e \u003cspan\u003eacute and chronic diarrhea\u003c\/span\u003e \u003cspan\u003e. Each capsule contains 2 mg of loperamide hydrochloride, the active ingredient that works by slowing down intestinal movements, thus promoting\u003c\/span\u003e \u003cspan\u003egreater absorption of liquids and reducing the frequency of bowel movements\u003c\/span\u003e \u003cspan\u003e. Imodium is indicated for adults and children aged 12 years and over, and is effective in\u003c\/span\u003e \u003cspan\u003erapidly reducing the symptoms of diarrhea\u003c\/span\u003e \u003cspan\u003e, improving stool consistency and reducing fluid loss.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eImodium is indicated for:\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e \u003cspan\u003eSymptomatic treatment of acute diarrhoea in adults and children over 12 years.\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e \u003cspan\u003eTreatment of chronic diarrhea associated with specific pathological conditions.\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e \u003cspan\u003eRegulation of stool consistency in patients with ileostomy.\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eActive ingredients contained in Imodium 12 Capsules 2 mg - What is the active ingredient in Imodium 12 Capsules 2 mg?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eOne hard capsule contains the active substance: loperamide hydrochloride 2 mg. One orodispersible tablet contains the active substance: loperamide hydrochloride 2 mg. One soft capsule contains the active substance: loperamide hydrochloride 2 mg. Excipients with known effect. Imodium 2 mg hard capsules: lactose 127 mg. Imodium 2 mg orodispersible tablets: each tablet contains 750 micrograms of aspartame; the mint flavour contains traces of sulphites. Imodium 2 mg soft capsules: each soft capsule contains 115.31 mg of propylene glycol. For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Imodium 12 Capsules 2 mg - What does Imodium 12 Capsules 2 mg contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eImodium mg hard capsules: lactose, corn starch, talc, magnesium stearate. A green-grey hard capsule consists of: erythrosine (E 127); indigo carmine (E 132); yellow iron oxide (E 172); black iron oxide (E 172); titanium dioxide and gelatin. Imodium 2 mg orodispersible tablets: gelatin, mannitol, aspartame, mint flavour, sodium bicarbonate. Imodium 2 mg soft capsules: propylene glycol monocaprylate, propylene glycol, distilled water. A capsule consists of: gelatin, glycerol 99%, propylene glycol, FD\u0026amp;C blue n.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Imodium 12 Capsules 2 mg - Why is Imodium 12 Capsules 2 mg used? What is it used for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eImodium is indicated for the symptomatic treatment of acute diarrhea.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Imodium 12 Capsules 2 mg - When should Imodium 12 Capsules 2 mg not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eHypersensitivity to the active substance or to any of the excipients listed in section 6.1; children under 6 years of age; Pregnancy and lactation (see section 4.6 \"Pregnancy and lactation\"). Imodium should not be used as primary therapy: in acute dysentery characterised by blood in the stool and high fever; in patients with acute ulcerative colitis or pseudomembranous colitis due to the use of broad-spectrum antibiotics; in patients with bacterial enterocolitis caused by invasive organisms including Salmonella, Shigella and Campylobacter. In general, the use of loperamide HCl is contraindicated in all cases where inhibition of peristalsis is to be initiated because of the possible risk of significant sequelae such as ileus, megacolon and toxic megacolon.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Imodium 12 Capsules 2 mg - How to take Imodium 12 Capsules 2 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eDosage. Adults: the initial dose is 2 hard capsules or 2 soft capsules or 2 orodispersible tablets (4 mg). Continue treatment with 1 capsule or 1 tablet (2 mg), after each subsequent evacuation of loose (soft) stools. The maximum daily dose is 8 capsules or tablets per day (16 mg). Special populations. Children aged 6 to 17 years (see section 4.3): the initial dose is 1 hard capsule or 1 soft capsule or 1 orodispersible tablet (2 mg). Continue treatment with 1 capsule or 1 tablet (2 mg), after each subsequent evacuation of loose (soft) stools. The maximum daily dose in children must be established according to body weight (3 capsules or tablets\/20 kg), but must not exceed the maximum of 8 capsules or tablets per day (16 mg). There are limited data available on the use of loperamide HCl in children under 12 years of age (see section 4.8 \"Undesirable effects\"). Elderly: No dose adjustment is necessary in the elderly. Renal impairment: No dose adjustment is necessary in patients with renal impairment. Hepatic impairment: Although no data are available in patients with hepatic impairment, loperamide HCl should be used with caution in these patients due to reduced first-pass metabolism (see section 4.4 \"Special warnings and precautions for use\"). Method of administration. Imodium 2 mg hard capsules\/2 mg soft capsules: take by mouth with a little water. Imodium 2 mg orodispersible tablets: leave the tablet to dissolve on the tongue for a few seconds; the tablet will dissolve rapidly in saliva. No water is required. Caution: do not use for more than 2 days. In any case, discontinue treatment when stools return to normal, or if you have not had bowel movements for 12 hours, or if constipation occurs. In episodes of acute diarrhea, loperamide HCl is generally able to stop the symptoms within 48 hours. If this period elapses without appreciable results, discontinue treatment and consult your doctor.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Imodium 12 Capsules 2 mg - How is Imodium 12 Capsules 2 mg stored?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eStore the medicine at a temperature not exceeding 25 degrees C.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Imodium 12 Capsules 2 mg - About Imodium 12 Capsules 2 mg it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eTreatment of diarrhea with loperamide HCl is only symptomatic. Therefore, where possible, it is also advisable to treat the causes of the disorder. In acute diarrhea, loperamide HCl is usually able to arrest the symptoms within 48 hours; if this period elapses without appreciable results, treatment should be stopped and the patient should be advised to consult a doctor. Patients with diarrhea, especially children, may experience significant fluid and electrolyte loss. In such cases, appropriate fluid and electrolyte replacement may be very important. Although no pharmacokinetic data are available in patients with hepatic dysfunction, loperamide HCl should be used with caution in these patients due to extensive first-pass metabolism. The drug should be used with caution in patients with hepatic insufficiency as it may lead to relative overdose with CNS toxicity. AIDS patients treated with loperamide HCl for diarrhea should discontinue therapy at the first signs of abdominal distension. In these patients with infectious colitis of bacterial or viral origin, treated with loperamide HCl, isolated cases of intestinal obstruction with an increased risk of toxic megacolon have been observed. If constipation or abdominal or ileal distension occurs, treatment should be discontinued immediately. Cases of abuse and misuse of loperamide, used as an opioid substitute, in individuals with opioid dependence have been reported (see section 4.9). Cardiac events including QT and QRS prolongation and torsade de pointes have been reported in association with overdose. Some cases have had a fatal outcome (see section 4.9). Overdose may unmask the presence of Brugada syndrome. Patients should not exceed the recommended dose and\/or prolong the duration of therapy. Paediatric population: In children between 6 and 12 years of age, Imodium should be used only under medical supervision. There are limited data available on the use of loperamide HCl in children under 12 years of age (see section 4.8 \"Undesirable effects\"). Important information about some of the excipients: Imodium 2 mg hard capsules contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Imodium 2 mg orodispersible tablets contain: traces of sulphites. Sulphites may rarely cause severe hypersensitivity reactions and bronchospasm; 0.750 mg of aspartame per single dose which is equivalent to 0.011 mg\/kg for a 70 kg adult and 0.038 mg\/kg for a 20 kg child. Aspartame is hydrolysed in the gastrointestinal tract when taken orally. One of the major products of its hydrolysis is phenylalanine. There are no clinical or non-clinical data available to evaluate the use of aspartame in infants less than 12 weeks of age; less than 1 mmol (23 mg) sodium per single dose. It can therefore be considered essentially sodium-free; 0.00066 mg benzyl alcohol per single tablet. Benzyl alcohol may cause allergic reactions. It is possible that accumulation of large amounts of benzyl alcohol may cause metabolic acidosis; use with caution and only if necessary, especially in patients with hepatic or renal insufficiency; 0.00003 mg alcohol (ethanol) in each tablet. The amount of ethanol in this medicinal product is equivalent to less than 0.00000075 ml of beer or 0.0000003 of wine. This medicinal product contains enough ethanol to produce no relevant effects. Imodium 2 mg soft capsules contain: 115.31 mg propylene glycol. 115.31 mg propylene glycol per single dose, equivalent to 1.65 mg\/kg for a 70 kg adult and 5.77 mg\/kg for a 20 kg child; less than 1 mmol (23 mg) sodium per single dose. It can therefore be considered essentially sodium-free.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Imodium 12 Capsules 2 mg - Which medicines or foods can modify the effect of Imodium 12 Capsules 2 mg?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eNon-clinical data have shown that loperamide is a substrate of P-glycoprotein. Co-administration of loperamide (single dose of 16 mg) with quinidine or ritonavir (both inhibitors of P-glycoprotein) has been shown to increase the plasma levels of loperamide by 2 to 3-fold. The clinical relevance of this pharmacokinetic interaction with P-glycoprotein inhibitors when loperamide is administered at the recommended doses (2 to a maximum of 16 mg daily) is unknown. Co-administration of loperamide (single dose of 4 mg) with itraconazole, an inhibitor of CYP3A4, and P-glycoprotein, has been shown to increase the plasma levels of loperamide by 34-fold. In the same study, gemfibrozil, an inhibitor of CYP2C8, has been shown to increase the plasma levels of loperamide by 2-fold. The combination of itraconazole and gemfibrozil showed a 4-fold increase in peak plasma levels of loperamide and a 13-fold increase in total plasma exposure. These increases were not associated with central nervous system (CNS) effects as measured by psychomotor tests (e.g. subjective dizziness and Digit Symbol Substitution Test). Concomitant administration of loperamide (single dose of 16 mg) and ketoconazole, an inhibitor of CYP3A4, and P-glycoprotein, showed a 5-fold increase in plasma levels of loperamide. This increase was not associated with an increase in pharmacodynamic effects as measured by pupillometry. Concomitant treatment with oral desmopressin resulted in a 3-fold increase in plasma desmopressin concentrations, presumably due to slowed gastrointestinal motility. Concomitant use of CYP450 inhibitors is not recommended. Substances that accelerate gastrointestinal transit may decrease Imodium. Drugs with pharmacological properties similar to those of loperamide or drugs that can slow intestinal peristalsis (e.g. anticholinergics) may increase Imodium.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Imodium 12 Capsules 2 mg can cause side effects - What are the side effects of Imodium 12 Capsules 2 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eAdults and children aged ≥12 years Adverse reactions reported in clinical trials with loperamide HCl The safety of Loperamide HCl has been evaluated in 3076 adult and child subjects aged ≥12 years who participated in 31 controlled and uncontrolled clinical trials with loperamide HCl used for the treatment of diarrhoea. Of these, 26 trials were for acute diarrhoea (N=2755) and 5 for chronic diarrhoea (N=321). The most commonly reported adverse drug reactions (ADRs) (i.e. with an incidence of ≥1%) in clinical trials with Loperamide HCl for the treatment of acute diarrhoea were: constipation (2.7%), flatulence (1.7%), headache (1.2%) and nausea (1.1%). In clinical trials for the treatment of chronic diarrhoea, the most commonly reported ADRs (i.e. \u0026gt;=1% incidence) were: flatulence (2.8%), constipation (2.2%), nausea (1.2%) and dizziness (1.2%). The following list shows the ADRs that have been reported with the use of loperamide HCl in clinical trials (in acute or chronic diarrhoea) in adults and children aged ≥12 years. The frequency of adverse reactions presented below is defined using the following convention: very common (\u0026gt;=1\/10); common (\u0026gt;=1\/100 to \u0026lt;1\/10); uncommon (\u0026gt;=1\/1,000 to \u0026lt;1\/100); rare (\u0026gt;=1\/10,000 to \u0026lt;1\/1,000); very rare (\u0026lt;1\/10,000); not known (cannot be estimated from the available data). Adverse reactions reported with the use of loperamide HCl in clinical trials in adults and children aged ≥ 12 years. Nervous system disorders. Headache. Acute diarrhoea: common; chronic diarrhoea: uncommon. Dizziness. Acute diarrhoea: uncommon; chronic diarrhoea: common. Gastrointestinal disorders. Constipation, nausea, flatulence. Acute diarrhoea: common; chronic diarrhoea: common. Abdominal pain, abdominal discomfort, dry mouth. Acute diarrhoea: uncommon; chronic diarrhoea: uncommon. Upper abdominal pain, vomiting. Acute diarrhoea: uncommon. Dyspepsia. Chronic diarrhoea: uncommon. Abdominal distension. Acute diarrhoea: rare. Skin and subcutaneous tissue disorders. Rash. Acute diarrhoea: uncommon. Adverse reactions reported in post-marketing experience with loperamide HCl: The determination of adverse reactions via post-marketing experience for loperamide HCl does not distinguish between the indications acute and chronic diarrhoea or the populations adults and children; the data collected therefore represent the combination of the indications (acute and chronic diarrhoea) and the populations in question (adults and children). Adverse reactions observed during post-marketing experience for loperamide HCl are listed below by System Organ Class, using MedDRA terminology. Adverse reactions reported with the use of loperamide HCl in post-marketing experience in adults and children. Immune system disorders: hypersensitivity reaction, anaphylactic reaction (including anaphylactic shock), anaphylactic reaction. Nervous system disorders: somnolence, loss of consciousness, drowsiness, depressed level of consciousness, hypertonia, coordination disorders. Eye disorders: miosis. Gastrointestinal disorders: ileus (including paralytic ileus), megacolon (including toxic megacolon), glossodynia, acute pancreatitis (frequency not known). Skin and subcutaneous tissue disorders: bullous eruption (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme), angioedema, urticaria, pruritus. Renal and urinary disorders: urinary retention. General disorders and administration site conditions: fatigue. Paediatric population: the safety of loperamide HCl has been evaluated in 607 patients aged 10 days to 13 years, who participated in 13 controlled and uncontrolled clinical trials with loperamide HCl used for the treatment of acute diarrhoea. In general, the ADR profile in this patient population was similar to that observed in clinical trials with loperamide HCl used in adults and children aged 12 years and above. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at http:\/\/www.agenziafarmaco.gov.it\/content\/come-segnalare-unasospe tta-reazione-avversa.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Imodium 12 Capsules 2 mg.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThe administration of Imodium is contraindicated during pregnancy and breastfeeding. Pregnant or breastfeeding women should therefore be advised to consult their doctor for the most appropriate treatment.\u003c\/span\u003e\u003c\/p\u003e","brand":"JOHNSON \u0026 JOHNSON SpA","offers":[{"title":"Default Title","offer_id":40207824355443,"sku":"023673128","price":12.92,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/johnson-johnson-spa-imodium-12-capsule-2-mg-farmacia-dottor-tili-1213792735.jpg?v=1767126790"},{"product_id":"fluibron-aerosol-20-fiale-15-mg-2-ml","title":"Fluibron Aerosol 20 vials 15mg\/2ml","description":"\u003cp dir=\"ltr\"\u003e \u003cspan\u003eFluibron Aerosol 20 Vials is a\u003c\/span\u003e \u003cspan\u003enebulizing solution for inhalation use\u003c\/span\u003e \u003cspan\u003efor adults and children. Indicated for the treatment of\u003c\/span\u003e \u003cspan\u003esecretion disorders\u003c\/span\u003e \u003cspan\u003ein\u003c\/span\u003e \u003cspan\u003eacute and chronic bronchopulmonary diseases\u003c\/span\u003e \u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe active ingredient contained in Fluibron 20 Vials is\u003c\/span\u003e \u003cspan\u003eambroxol\u003c\/span\u003e \u003cspan\u003e, an active ingredient from the mucolytic family, which\u003c\/span\u003e \u003cspan\u003eacts quickly and effectively against the dense and viscous consistency of mucus\u003c\/span\u003e \u003cspan\u003e, making it more fluid and easier to expectorate.\u003c\/span\u003e\u003cspan\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003e\u003cbr\u003e\u003c\/span\u003e \u003cspan\u003eFluibron vials can be used effectively in case of:\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e \u003cspan\u003eChesty cough\u003c\/span\u003e \u003cspan\u003e: Fluibron Aerosol 20 Vials contains ambroxol which\u003c\/span\u003e \u003cspan\u003emakes the mucus less dense, viscous and\u003c\/span\u003e\u003cspan\u003e \u003c\/span\u003e\u003cspan\u003eeasier to eliminate\u003c\/span\u003e \u003cspan\u003e.\u003c\/span\u003e\u003cspan\u003e\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e \u003cspan\u003eAcute and chronic sinusitis\u003c\/span\u003e \u003cspan\u003e. Sinusitis is an inflammation of the mucosa of the paranasal cavities. It often occurs due to an accumulation of mucus in the sinuses. Fluibron Aerosol 20 Vials promotes the elimination of mucus and reduces the symptoms of sinusitis.\u003c\/span\u003e\u003cspan\u003e\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e \u003cspan\u003eBronchitis\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eActive ingredients contained in Fluibron Aerosol 20 Vials 15 mg\/2 ml - What is the active ingredient of Fluibron Aerosol 20 Vials 15 mg\/2 ml?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003e100 ml of sterile solution contains: ambroxol hydrochloride 750 mg. A single-dose container contains 15 mg of ambroxol hydrochloride.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Fluibron Aerosol 20 Vials 15 mg\/2 ml - What does Fluibron Aerosol 20 Vials 15 mg\/2 ml contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eSodium chloride, water for injections.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Fluibron Aerosol 20 Vials 15 mg\/2 ml - Why is Fluibron Aerosol 20 Vials 15 mg\/2 ml used? What is it used for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eTreatment of secretion disorders in acute and chronic bronchopulmonary diseases.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Fluibron Aerosol 20 Vials 15 mg\/2 ml - When should Fluibron Aerosol 20 Vials 15 mg\/2 ml not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eHypersensitivity to the active substance or to any of the excipients. Severe hepatic and\/or renal alterations. First three months of pregnancy. Paediatric population: the medicinal product is contraindicated in children under 2 years of age.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Fluibron Aerosol 20 Vials 15 mg\/2 ml - How do you take Fluibron Aerosol 20 Vials 15 mg\/2 ml?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eDosage. Paediatric population. This medicine should not be used in children under 2 years of age due to safety concerns. Adults and children over 5 years of age: one single-dose container, 2 times a day. Children aged 2 to 5 years: half a container or one single-dose container, 1-2 times a day. Do not exceed the recommended doses. Do not use for prolonged treatments. After a short period of treatment without appreciable results, consult your doctor. Method of administration: the solution can be administered using normal aerosol therapy devices. It can also be diluted in distilled water in a 1:1 ratio. To use, perform the following operations: bend the single-dose container in both directions. Detach the single-dose container from the strip first at the top and then in the centre. Open the single-dose container by rotating the flap in the direction indicated by the arrow. By exerting moderate pressure on the walls of the single-dose container, release the prescribed amount of medicine and put it into the nebuliser bulb. If half a dose is used, the container can be closed as indicated in the package leaflet. The closed container must be stored at a temperature between 2 degrees C and 8 degrees C (in the refrigerator) and the remaining quantity must be used within 12 hours of first opening.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Fluibron Aerosol 20 Vials 15 mg\/2 ml - How is Fluibron Aerosol 20 Vials 15 mg\/2 ml stored?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eSingle-dose containers must be stored in the protective bag, away from light. If using half a dose, the closed container must be stored at a temperature between 2 degrees and 8 degrees C (in the refrigerator) and used within 12 hours.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Fluibron Aerosol 20 Vials 15 mg\/2 ml - About Fluibron Aerosol 20 Vials 15 mg\/2 ml it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003ePaediatric population. Mucolytics may induce bronchial obstruction in children under 2 years of age. In fact, the capacity for bronchial mucus drainage is limited in this age group, due to the physiological characteristics of the airways. They should therefore not be used in children under 2 years of age. Since excessively deep inhalation of aerosols may cause irritation coughing, one should try to inhale and exhale normally during inhalation. In particularly sensitive patients, pre-warming of the inhaled product to body temperature may be recommended. For patients with bronchial asthma, it is advisable to use a bronchial spasmolytic before inhalation. This drug should be administered with caution to patients with peptic ulcer. Cases of serious skin reactions such as erythema multiforme, Stevens-Johnson syndrome (SJS)\/toxic epidermal necrolysis (TEN) and acute generalized exanthematous pustulosis (AGEP) have been reported in association with the administration of ambroxol. If symptoms or signs of progressive skin rash (sometimes associated with blistering or mucosal lesions) are present, treatment with ambroxol should be stopped immediately and a doctor should be consulted. Most of these cases can be explained by the severity of the patient's underlying disease and\/or concomitant therapy. Furthermore, during the initial phase of Stevens-Johnson syndrome or TEN, patients may experience non-specific flu-like prodromes such as fever, muscle aches, rhinitis, cough and sore throat. Due to these misleading non-specific flu-like prodromes, symptomatic treatment with cough and cold medicines may be initiated. Therefore, if new skin or mucosal lesions appear, it is necessary to consult a doctor immediately and discontinue treatment with ambroxol hydrochloride as a precaution. In the presence of mild or moderate renal insufficiency, this medicine should be used only after consulting a doctor. As with any medicine with hepatic metabolism followed by renal elimination, in case of severe renal insufficiency, accumulation of ambroxol metabolites generated in the liver may occur.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Fluibron Aerosol 20 Vials 15 mg\/2 ml - Which medicines or foods can modify the effect of Fluibron Aerosol 20 Vials 15 mg\/2 ml?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eFollowing the administration of ambroxol, the concentrations of antibiotics (amoxicillin, cefuroxime, erythromycin) in bronchopulmonary secretions and saliva are increased. No interactions with other medicinal products have been observed.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Fluibron Aerosol 20 Vials 15 mg\/2 ml can cause side effects - What are the side effects of Fluibron Aerosol 20 Vials 15 mg\/2 ml?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eAt the recommended doses the medicine is usually well tolerated. During therapy with ambroxol hydrochloride the following undesirable effects have been observed, with the frequencies: very common \u0026gt;=1\/10, common \u0026gt;=1\/100 and \u0026lt;1\/10, uncommon \u0026gt;=1\/1,000 and \u0026lt;1\/100, rare \u0026gt;=1\/10,000 and \u0026lt;1\/1,000, very rare \u0026lt;1\/10,000, not known not known (frequency cannot be estimated from the available data). Immune system disorders. Rare: hypersensitivity reactions; not known: anaphylactic reactions, including anaphylactic shock, angioedema and pruritus. Nervous system disorders. Common: dysgeusia (e.g. altered sense of taste); rare: headache. Respiratory, thoracic and mediastinal disorders. Common: hypoaesthesia of the oral cavity and pharynx; not known: bronchial obstruction. Gastrointestinal disorders. Common: nausea; uncommon: vomiting, diarrhoea, dyspepsia and abdominal pain, dry mouth; not known: dry throat. Skin and subcutaneous tissue disorders. Rare: rash, urticaria; not known: serious skin adverse reactions (including erythema multiforme, Stevens-Johnson syndrome\/toxic epidermal necrolysis and acute generalised exanthematous pustulosis). Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at http:\/\/www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetta-reazione-avversa\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Fluibron Aerosol 20 Vials 15 mg\/2 ml.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eAmbroxol hydrochloride crosses the placental barrier. Animal studies have not shown any direct or indirect harmful effects on pregnancy, embryonic\/foetal development, parturition or postnatal development. Clinical studies and extensive clinical experience after the twenty-eighth week of pregnancy have not shown any evidence of harmful effects on the foetus. However, it is recommended to observe the usual precautions regarding the use of medicinal products during pregnancy. In particular during the first trimester, the use of this drug is not recommended. Ambroxol hydrochloride is secreted in breast milk. Although no undesirable effects on infants are expected, the use of this drug is not recommended in nursing mothers.\u003c\/span\u003e\u003c\/p\u003e","brand":"CHIESI FARMACEUTICI SpA","offers":[{"title":"Default Title","offer_id":40207824420979,"sku":"024596153","price":16.15,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/chiesi-farmaceutici-spa-fluibron-aerosol-20-fiale-15-mg-2-ml-farmacia-dottor-tili-1213792734.webp?v=1767126819"},{"product_id":"verolax-ad-rettale-6-clismi-6-75g","title":"Verolax AD Rectal 6 Enemas 6.75g","description":"\u003cp\u003e\u003cstrong\u003eVerolax AD\u003c\/strong\u003e is a drug used to treat occasional constipation. Thanks to its \u003cstrong\u003eglycerol\u003c\/strong\u003e -based formulation, Verolax works by softening the stool and facilitating its expulsion. This rectal enema is indicated for a rapid and delicate action, with local effects that help stimulate intestinal transit without causing irritation or cramps. The package contains \u003cstrong\u003e6 ready-to-use enemas\u003c\/strong\u003e , 6.75g, for rapid and safe relief.\u003c\/p\u003e\n\n\u003cp\u003e Verolax AD is indicated for the treatment of \u003cstrong\u003eoccasional constipation\u003c\/strong\u003e in adults. It is particularly useful in situations where rapid evacuation is necessary, such as before medical or surgical examinations. It can also be used in case of temporary constipation caused by changes in diet, stress or a sedentary lifestyle.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eActive ingredients contained in Verolax AD Rettale 6 Clismi 6 - What is the active ingredient of Verolax AD Rettale 6 Clismi 6?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eAdults Rectal Solution. 6 single-dose containers 9G: glycerin 6.75 g. Children Rectal Solution. 6 Single-dose Containers 3 G: glycerin 2.25 g. Adults Suppositories: glycerin 2.25 g. Children Suppositories: glycerin 1.375 g. Infants Suppositories: glycerin 0.675 g.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Verolax AD Rectal 6 Enemas 6 - What does Verolax AD Rectal 6 Enemas 6 contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eRectal solution. Adults and Children: mallow fluid extract; chamomile fluid extract; wheat starch; purified water. Suppositories Adults, Children, Infants: sodium stearate, sodium carbonate.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Verolax AD Rectal 6 Enemas 6 - Why is Verolax AD Rectal 6 Enemas 6 used? What is it for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eConstipation.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eContraindications Verolax AD Rectal 6 Enemas 6 - When should Verolax AD Rectal 6 Enemas 6 not be used?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eKnown individual hypersensitivity to the product. Anorectal affections, hemorrhagic rectocolitis and inflammation of hemorrhoids.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Verolax AD Rectal 6 Enemas 6 - How do you take Verolax AD Rectal 6 Enemas 6?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eRectal solution: 1 or 2 single-dose containers in 24 hours. In case of obstinate constipation, no more than 2 doses can be introduced into the rectum at the same time. Suppositories: 1 suppository as needed. Do not exceed the recommended doses.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Verolax AD Rectal 6 Enemas 6 - How do you store Verolax AD Rectal 6 Enemas 6?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eNo special storage precautions.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eWarnings Verolax AD Rectal 6 Enemas 6 - About Verolax AD Rectal 6 Enemas 6 it is important to know that:\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eContinuous use of laxatives can cause addiction or harm of various kinds. Do not use laxatives if you have abdominal pain, nausea and vomiting. If constipation is persistent, consult your doctor.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Verolax AD Rettale 6 Clismi 6 - Which medicines or foods can modify the effect of Verolax AD Rettale 6 Clismi 6?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eNo interactions with other drugs have been found.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Verolax AD Rettale 6 Clismi 6 can cause side effects - What are the side effects of Verolax AD Rettale 6 Clismi 6?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThe only effects that may be encountered are of an irritative nature, at the level of the rectal area. These are usually mild forms, which do not require medical intervention.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n \u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Verolax AD Rettale 6 Clismi 6\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eBased on its chemical-physical properties, rectal glycerin can be usefully used during pregnancy or the puerperium.\u003c\/span\u003e\u003c\/p\u003e","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":40207824453747,"sku":"026525055","price":5.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-verolax-ad-rettale-6-clismi-6-75g-farmacia-dottor-tili-1213792736.jpg?v=1767126868"},{"product_id":"benactiv-gola-arancia-16-pastiglie","title":"Benactiv Throat Orange 16 Lozenges","description":"\u003cp dir=\"\"\u003e\u003cspan\u003eBenactiv Gola Arancia is an\u003c\/span\u003e \u003cspan\u003eover-the-counter analgesic medicine\u003c\/span\u003e \u003cspan\u003ebased on \u003cstrong\u003eflurbiprofen\u003c\/strong\u003e indicated to\u003c\/span\u003e \u003cspan\u003e\u003cstrong\u003erelieve sore throat and associated cough\u003c\/strong\u003e ,\u003c\/span\u003e \u003cspan\u003eproviding long-lasting relief for up to 6 hours.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"\"\u003e \u003cspan\u003eBenactiv Gola Arancia combines flurbiprofen, an active \u003cstrong\u003eanalgesic\u003c\/strong\u003e and \u003cstrong\u003eanti-inflammatory\u003c\/strong\u003e ingredient, with the emollient action of a lozenge. It penetrates from the surface to the deepest layers of the throat tissue and\u003c\/span\u003e \u003cspan\u003e\u003cstrong\u003efights irritative-inflammatory conditions of the oropharyngeal cavity\u003c\/strong\u003e , also associated with \u003cstrong\u003epain\u003c\/strong\u003e , such as \u003cstrong\u003egingivitis\u003c\/strong\u003e , \u003cstrong\u003epharyngitis\u003c\/strong\u003e and \u003cstrong\u003estomatitis\u003c\/strong\u003e .\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"\"\u003e \u003cspan\u003eBenactiv Gola Arancia does not contain gluten and can also be taken by celiac subjects.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"\"\u003e\u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"\"\u003e\u003cspan\u003eActive ingredients contained in Benactiv Gola Arancia 16 Pastiglie - What is the active ingredient in Benactiv Gola Arancia 16 Pastiglie?\u003c\/span\u003e\u003c\/h3\u003e\n\n \u003cp dir=\"\"\u003e\u003cspan\u003eBenactiv Gola Mouthwash. 100 ml of mouthwash contain the active ingredient: flurbiprofen 250 mg. Excipients with known effects: hydrogenated castor oil-40-polyoxyethylene, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene). Benactiv Gola Spray for oral mucosa. 100 ml of solution contain the active ingredient: flurbiprofen 250 mg. Excipients with known effects: hydrogenated castor oil-40-polyoxyethylene, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene). Benactiv Gola Lemon and Honey flavour lozenges. One lozenge contains the active ingredient: flurbiprofen 8.75 mg. Excipients with known effects: liquid glucose (containing sulphites and wheat starch), liquid sucrose, honey, lemon flavouring and levomenthol (containing butylated hydroxyanisole, citral, citronellol, d-limonene, farnesol, geraniol, linalool). Benactiv Gola Sugar Free Lozenges Orange flavour. One lozenge contains the active ingredient: flurbiprofen 8.75mg. Excipients with known effects: liquid maltitol (E965), isomalt (E953), orange flavouring and levomenthol (containing citral, citronellol, d-limonene, geraniol, linalool). Benactiv Gola Sugar Free Lozenges Eucalyptus and Manuka Honey flavour. One lozenge contains the active ingredient: flurbiprofen 8.75mg. Excipients with known effect: liquid maltitol (E965), isomalt (E953), eucalyptus flavour and Manuka honey (containing anisilicate alcohol, benzyl alcohol, benzyl benzoate, benzyl cinnamate, benzyl salicylate, cinnamal, cinnamyl alcohol, citral, geraniol, d-limonene, linalool). For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"\"\u003e \u003cspan\u003eComposition of Benactiv Gola Arancia 16 Pastilles - What does Benactiv Gola Arancia 16 Pastilles contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"\"\u003e\u003cspan\u003eBenactiv Gola Mouthwash: glycerol, ethanol (96 percent), sorbitol 70, hydrogenated castor oil-40-polyoxyethylene, sodium hydroxide, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene), patent blue V (E131), purified water. Benactiv Gola Spray for oral mucosa: glycerol, ethanol (96 percent), sorbitol 70, hydrogenated castor oil-40-polyoxyethylene, sodium hydroxide, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene), patent blue V (E131), purified water. Benactiv Gola Lemon and Honey Flavour Pastilles: liquid sucrose, liquid glucose (containing sulphites and wheat starch), macrogol 300, potassium hydroxide, lemon flavouring and levomenthol (containing butylated hydroxyanisole, citral, citronellol, d-limonene, farnesol, geraniol, linalool), honey. Benactiv Gola Sugar Free Pastilles Orange Flavour: macrogol 300, potassium hydroxide, orange flavouring and levomenthol (containing citral, citronellol, d-limonene, geraniol, linalool), acesulfame potassium (E950), liquid maltitol (E965), isomalt (E953). Benactiv Gola Sugar Free Lozenges Eucalyptus and Manuka Honey Flavour: macrogol 300, potassium hydroxide, ammonia caramel (E150c), curcumin (E100), eucalyptus and Manuka honey flavouring (containing anisyl alcohol, benzyl alcohol, benzyl benzoate, benzyl cinnamate, benzyl salicylate, cinnamal, cinnamyl alcohol, citral, geraniol, d-limonene, linalool), acesulfame potassium (E950), liquid maltitol (E965), isomalt (E953).\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"\"\u003e \u003cspan\u003eTherapeutic indications Benactiv Gola Arancia 16 Pastiglie - Why is Benactiv Gola Arancia 16 Pastiglie used? What is it for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"\"\u003e \u003cspan\u003eBenactiv Gola Mouthwash; Benactiv Gola Spray for oral mucosa: symptomatic treatment of irritative-inflammatory conditions also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy. Benactiv Gola Lemon and Honey flavour lozenges; Benactiv Gola Sugar-Free Lozenges Orange flavour; Benactiv Gola Sugar-Free Lozenges Eucalyptus and Manuka Honey flavour: symptomatic treatment of irritative-inflammatory conditions also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"\"\u003e \u003cspan\u003eContraindications Benactiv Gola Arancia 16 Pastilles - When should Benactiv Gola Arancia 16 Pastilles not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"\"\u003e\u003cspan\u003eDo not use the medicinal product in children under 12 years of age. Flurbiprofen is contraindicated in patients with known hypersensitivity to flurbiprofen or to any of the excipients listed in section 6.1. Patients who have previously shown hypersensitivity reactions (e.g. asthma, urticaria, allergy, rhinitis, angioedema, bronchospasm) to ibuprofen, acetylsalicylic acid (aspirin) or other nonsteroidal anti-inflammatory drugs (NSAIDs). Flurbiprofen is also contraindicated in patients with a history of gastrointestinal bleeding or perforation related to previous NSAID treatment. Flurbiprofen should not be taken by patients with active or history of ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal bleeding (defined as two or more distinct episodes of proven ulceration or bleeding). Flurbiprofen is contraindicated in patients with severe heart failure, severe hepatic failure and renal failure (see section 4.4). Third trimester of pregnancy.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"\"\u003e \u003cspan\u003eQuantity and method of taking Benactiv Gola Arancia 16 Pastiglie - How to take Benactiv Gola Arancia 16 Pastiglie?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"\"\u003e\u003cspan\u003eThe lowest effective dose should be used for the shortest duration necessary to relieve symptoms (see section 4.4). Benactiv Gola Mouthwash. Dosage. Adults: 2-3 rinses or gargles per day with 10 ml (1 measuring spoon) of mouthwash. Paediatric population. Children over 12 years of age: as for adults. Children under 12 years of age: do not administer to children under 12 years of age (see section 4.3). Special populations. Elderly: the clinical data currently available are limited, therefore no recommendation on posology can be made. The elderly are at increased risk of serious consequences in case of adverse reactions (see section 4.4). Patients with hepatic insufficiency: a dosage reduction is not necessary in patients with mild to moderate hepatic insufficiency. Flurbiprofen is contraindicated in patients with severe hepatic insufficiency (see section 4.3). Patients with renal insufficiency: no dosage reduction is necessary in patients with mild to moderate renal insufficiency. Flurbiprofen is contraindicated in patients with severe hepatic insufficiency (see section 4.3). Method of administration: for oropharyngeal use. Rinse or hold in the mouth during gargling for up to 1 minute. Do not swallow. The mouthwash can be used pure or diluted in half a glass of water. Benactiv Gola Spray for oral mucosa. Dosage. Adults: apply one dose (2 sprays) 3 times a day, directed directly at the affected area. Each spray delivers 0.2 ml of solution, equivalent to 0.5 mg of active ingredient. Paediatric population. Children Over 12 years of age: as for adults. Children under 12 years of age: do not administer to children under 12 years of age (see section 4.3). Special populations. Elderly: The clinical data currently available are limited, therefore no recommendation on dosage can be made. Elderly people are at increased risk of serious consequences in case of adverse reactions (see section 4.4). Patients with hepatic impairment: no dosage reduction is necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). Patients with renal impairment: no dosage reduction is necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). Method of administration: for oropharyngeal use. Aim the dispenser towards the back of the throat and spray on the affected area. Benactiv Gola Lemon and Honey flavoured Lozenges; Benactiv Gola Sugar Free Lozenges Orange flavoured; Benactiv Gola Sugar Free Lozenges Eucalyptus and Manuka Honey flavoured. Dosage. Adults: 1 lozenge every 3-6 hours, as needed. Do not exceed 8 lozenges in 24 hours. Paediatric population. Children over 12 years of age: as for adults. Children under 12 years of age: do not administer to children under 12 years of age (see section 4.3). Special populations. Elderly: Currently available clinical data are limited, therefore no recommendation on posology can be made. Elderly are at increased risk of serious consequences in case of adverse reactions (see section 4.4). Patients with hepatic impairment: no dosage reduction is necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). Patients with renal impairment: no dosage reduction is necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). Method of administration: For oropharyngeal use. Dissolve slowly in the mouth. As with all lozenges, flurbiprofen lozenges should be moved around the mouth during administration to avoid local irritation. If mouth irritation occurs, treatment should be discontinued.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"\"\u003e \u003cspan\u003eStorage Benactiv Gola Arancia 16 Pastilles - How do you store Benactiv Gola Arancia 16 Pastilles?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"\"\u003e \u003cspan\u003eBenactiv Gola Sugar-Free Lozenges Orange Flavour\/Lemon and Honey Flavour Lozenges\/Sugar-Free Lozenges Eucalyptus and Manuka Honey Flavour: store below 25 degrees C.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"\"\u003e \u003cspan\u003eWarnings Benactiv Gola Arancia 16 Pastiglie - About Benactiv Gola Arancia 16 Pastiglie it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"\"\u003e\u003cspan\u003eAt the recommended doses, when using the medicinal product in its various pharmaceutical forms, any swallowing does not cause any harm to the patient, as the dose of flurbiprofen is much lower than that commonly used in systemic treatments. Elderly: elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal. Respiratory disorders: cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma or allergies. Flurbiprofen should be used with caution in these patients. Other NSAIDs: it is advisable not to combine the medicinal product with other NSAIDs (see section 4.5). Systemic lupus erythematosus (SLE) and mixed connective tissue disease: Patients with systemic lupus erythematosus and mixed connective tissue disease may be at increased risk of aseptic meningitis (see section 4.8), however, this effect is not usually seen with products intended for limited and short-term use such as flurbiprofen. Cardiac, hepatic and renal impairment: The medicinal product should be used with caution in patients with cardiac, renal or hepatic insufficiency. NSAIDs have been reported to cause various forms of nephrotoxicity, including interstitial nephritis, nephrotic syndrome and renal failure. Administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and precipitate renal failure. Patients at greatest risk of developing this reaction are those with impaired renal function, cardiac impairment, hepatic dysfunction, those on diuretic therapy and the elderly; however, this effect is not usually seen with products intended for limited and short-term use such as flurbiprofen. Cardiovascular and cerebrovascular effects: Caution is advised before initiating treatment in patients with a history of hypertension and\/or heart failure (discuss with your doctor or pharmacist), since fluid retention, hypertension and oedema have been reported in association with NSAID treatment. Clinical trial and epidemiological data suggest that use of some NSAIDs, particularly at high doses and in long-term treatment, may be associated with a small increased risk of arterial thrombotic events such as myocardial infarction or stroke. There are insufficient data to exclude a similar risk for flurbiprofen. Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should only be treated with flurbiprofen after careful consideration. Similar consideration should be made before initiating long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking). Central nervous system effects: Analgesic-induced headache. Headache may occur with prolonged or inappropriate use of analgesics, which should not be treated by increasing the dose of the medicinal product. Gastrointestinal effects: Flurbiprofen should be administered with caution to patients with a history of peptic ulcer and other gastrointestinal diseases as these conditions may be exacerbated. The risk of gastrointestinal bleeding, ulceration or perforation is higher with increasing flurbiprofen dosage in patients with a history of ulcer, particularly if complicated with haemorrhage and perforation and in the elderly. These patients should start treatment on the lowest available dose. Gastrointestinal bleeding, ulceration or perforation have been reported with all NSAIDs at any time during treatment. These adverse reactions can be fatal and may occur with or without warning symptoms or in case of a previous history of serious gastrointestinal reactions. Patients with a history of gastrointestinal disease, particularly when elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the early stages of treatment. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.2). Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or anti-platelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients receiving flurbiprofen, the treatment should be withdrawn. Dermatological effects: Use of the medicinal product, especially if prolonged, may give rise to sensitisation or local irritation phenomena. In such cases, treatment should be discontinued and a doctor should be consulted to institute, if necessary, an appropriate therapy. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity. Infections: Since isolated cases of exacerbation of infection-related inflammation (e.g. development of necrotising fasciitis) have been described in temporal association with the systematic use of NSAIDs, patients are advised to seek medical advice immediately if signs of bacterial infection appear or worsen during flurbiprofen therapy. The possibility of initiating antibiotic therapy should be considered. If mouth irritation develops, treatment should be discontinued. Masking of symptoms of underlying infections: Epidemiological studies suggest that systemic nonsteroidal anti-inflammatory drugs (NSAIDs) may mask the symptoms of infection, which may lead to delays in initiating appropriate treatment and thus worsen the outcome of the infection. This has been observed in community-acquired bacterial pneumonia and in bacterial complications of chickenpox.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"\"\u003e \u003cspan\u003eInteractions Benactiv Gola Arancia 16 Pastiglie - Which medicines or foods can modify the effect of Benactiv Gola Arancia 16 Pastiglie?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"\"\u003e\u003cspan\u003eCaution should be exercised in patients treated with any of the following medicinal products, as interactions have been reported in some patients. Inform your doctor if you are taking other medicinal products. Flurbiprofen should be avoided in combination with aspirin: unless low dose aspirin (not exceeding 100 mg\/day or local prophylactic doses for cardiovascular protection) has been recommended by your doctor; as with other NSAID-containing medicinal products, concomitant administration of flurbiprofen and aspirin is generally not recommended due to the potential for increased adverse effects (see section 4.4). Cox-2 inhibitors and other NSAIDs: Concomitant use of other NSAIDs, including cyclooxygenase-2 selective inhibitors, should be avoided due to the potential for additive effects and an increased risk of adverse reactions (see section 4.4). Flurbiprofen should be used with caution in combination with anticoagulants: NSAIDs may enhance the effects of anticoagulants such as warfarin (see section 4.4). Antiplatelet agents: increased risk of gastrointestinal bleeding. Selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding. Antihypertensives (diuretics, ACE inhibitors and angiotensin II antagonists): NSAIDs may reduce the effect of diuretics. Other antihypertensive drugs may enhance nephrotoxicity caused by inhibition of cyclooxygenase, especially in patients with impaired renal function (these patients must be adequately hydrated). Alcohol: may increase the risk of adverse reactions, especially bleeding in the gastrointestinal tract. Cardiac glycosides: NSAIDs may exacerbate cardiac failure, reduce GFR (glomerular filtration rate) and increase plasma glycoside levels. Ciclosporin: Increased risk of nephrotoxicity. Corticosteroids: Increased risk of gastrointestinal ulceration or haemorrhage with NSAIDs (see section 4.4). Lithium: There is evidence of a possible increase in lithium plasma levels. Methotrexate: There may be an increase in methotrexate plasma levels. Mifepristone: NSAIDs should not be used for 8-12 days after mifepristone administration, as NSAIDs may reduce the effect of mifepristone. Quinolone antibiotics: Animal data indicate that NSAIDs may increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions. Tacrolimus: Possible increased risk of nephrotoxicity when NSAIDs are administered with tacrolimus. Zidovudine: Increased risk of haematological toxicity when NSAIDs are administered with zidovudine.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"\"\u003e \u003cspan\u003eLike all medicines, Benactiv Gola Arancia 16 Pastiglie can cause side effects - What are the side effects of Benactiv Gola Arancia 16 Pastiglie?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"\"\u003e\u003cspan\u003eHypersensitivity reactions to NSAIDs have been reported and may consist of: (a) non-specific allergic reactions and anaphylaxis; (b) respiratory tract reactivity, e.g. asthma, aggravated asthma, bronchospasm, dyspnoea; (c) various skin disorders, including e.g. rashes of various types, pruritus, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatoses (including epidermal necrolysis and erythema multiforme). The most commonly observed adverse reactions are gastrointestinal in nature. Local use of the medicinal product, especially if prolonged, may give rise to sensitization or local irritation phenomena. Dissolution of the medicinal product in the oral cavity in tablet form may be accompanied by sensations of heat or tingling in the oropharynx. In such cases, treatment should be discontinued and, if necessary, appropriate therapy instituted. The following undesirable effects have been reported, particularly after administration of systemic formulations. They refer to those observed with the use of flurbiprofen used short-term and at doses compatible with the classification of over-the-counter medicines. In case of treatment of chronic conditions and for long periods of time, additional undesirable effects may occur. The undesirable effects associated with the use of flurbiprofen are divided below according to the system organ class and frequency. The frequency is defined as: very common (\u0026gt;= 1\/10), common (\u0026gt;=1\/100, \u0026lt;1\/10), uncommon (\u0026gt;=1\/1,000, \u0026lt;1\/100), rare (\u0026gt;=1\/10,000, \u0026lt;1\/1,000), very rare (\u0026lt;1\/10,000) and not known (the frequency cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Blood and lymphatic system disorders. Not known: anaemia, thrombocytopenia, aplastic anaemia and agranulocytosis. Nervous system disorders. Common: dizziness, headache, paraesthesia; uncommon: somnolence; not known: cerebrovascular accident, optic neuritis, migraine, confusional states, vertigo. Immune system disorders. Rare: anaphylactic reaction; not known: angioedema, hypersensitivity. Eye disorders. Not known: visual impairment. Ear and labyrinth disorders. Not known: tinnitus. Cardiac disorders. Not known: cardiac failure, oedema. Vascular disorders. Not known: hypertension. Respiratory, thoracic and mediastinal disorders. Common: throat irritation; uncommon: asthma, bronchospasm and dyspnoea, oropharyngeal vesicular eruption, oropharyngeal hypoaesthesia. Gastrointestinal disorders. Common: diarrhoea, mouth ulceration, nausea, oral pain, oral paraesthesia, oropharyngeal pain, oral discomfort (warm or burning sensation, tingling of the mouth); uncommon: abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, glossodynia, dysgeusia, oral dysaesthesia, vomiting; not known: melaena, haematemesis, gastrointestinal haemorrhage, colitis, exacerbation of Crohn's disease, gastritis, peptic ulcer, gastric perforation, ulcer haemorrhage. Skin and subcutaneous tissue disorders. Uncommon: rash, pruritus; not known: urticaria, purpura, bullous dermatitis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme). Renal and urinary disorders. Not known: toxic nephropathy, tubulointerstitial nephritis and nephrotic syndrome, renal failure (as with other NSAIDs). General disorders and administration site conditions. Uncommon: pyrexia, pain; not known: discomfort, fatigue. Hepatobiliary disorders. Not known: hepatitis. Psychiatric disorders. Uncommon: insomnia; not known: depression, hallucination. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Benactiv Gola Arancia 16 Pastiglie.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"\"\u003e\u003cspan\u003ePregnancy: There are no clinical data on the use of Benactiv Gola during pregnancy. Although systemic exposure is lower than with oral administration, it is not known whether the systemic exposure of Benactiv Gola reached after topical administration can be harmful to an embryo\/fetus. During the first and second trimester of pregnancy Benactiv Gola should not be administered unless strictly necessary. If administered, the dose should be the lowest possible and the duration of treatment as short as possible. During the third trimester of pregnancy, systemic use of prostaglandin synthase inhibitors, including Benactiv Gola, may induce cardiopulmonary and renal toxicity in the fetus. At the end of pregnancy, prolonged bleeding time may occur in both the mother and the child and labor may take longer. Therefore, Benactiv Gola is contraindicated during the last trimester of pregnancy (see section 4.3). Breastfeeding: In a limited number of studies, flurbiprofen appears in breast milk at very low concentrations and is unlikely to have any adverse effects on the breast-fed infant. However, administration of flurbiprofen is not recommended in nursing mothers. Fertility: There is evidence that cyclooxygenase\/prostaglandin synthesis inhibitors may cause impairment of female fertility by an effect on ovulation. This is reversible upon discontinuation of treatment.\u003c\/span\u003e\u003c\/p\u003e","brand":"RECKITT BENCKISER H.(IT.) SpA","offers":[{"title":"Default Title","offer_id":40207824552051,"sku":"033262078","price":12.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/reckitt-benckiser-h-it-spa-benactiv-gola-arancia-16-pastiglie-farmacia-dottor-tili-1213792732.webp?v=1767126886"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/collections\/promo-promozioni-sconti-cartellino-scaffale-supermercato-offerte-AdobeStock_271933823.jpg?v=1703155512","url":"https:\/\/www.dottortili.com\/en-eu\/collections\/all-supplements-cosmetics-and-medical-devices-subject-to-points-collection.oembed?page=110","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}